<?xml version="1.0" encoding="utf-8"?>
<XML>
<JOURNAL>
<YEAR>1399</YEAR>
<VOL>30</VOL>
<NO>193</NO>
<MOSALSAL>0</MOSALSAL>
<PAGE_NO>211</PAGE_NO>


<ARTICLES>

	<ARTICLE> 
		<TitleF>سخن سردبیر ویژه نامه میکروبیوتا</TitleF>
		<TitleE>Editorial for Special Issue of Microbiota</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>جمعیت عظیم میکروارگانیسم&#8207;های ساکن در مناطق مختلف بدن انسان شامل دهان، مجرای گوارشی، مجاری تنفسی و پوست، اکوسیستمی پویا و فعال به نام میکروبیوتای بدن انسان را تشکیل می&#8207;دهند. مجموعه ژنوم این میکروارگانیسم&#8207;ها میکروبیوم نامیده می&#8207;شود که بیش از 100 برابر ژنوم انسانی می&#8207;باشد. میکروبیوتا با ترشح متابولیت&#8207;های مختلف در تنظیم متابولیسم بدن، عملکرد غدد درون ریز، سیستم ایمنی و سیستم عصبی مرکزی، نقش دارد. نتایج مطالعات دو دهه اخیر نشان داده&#8207;اند که اختلال در تنوع و ترکیب میکروبیوتای روده با بیماری&#8207;های غیرواگیر متعددی از جمله اختلالات غدد درون-ریز شامل دیابت، چاقی و پوکی استخوان، بیماری&#8207;های گوارشی مانند بیماری&#8207;های التهابی روده، کبد چرب، اختلالات کلیوی، بیماری&#8204;های قلبی-عروقی و همچنین بیماری&#8207;های شناختی از جمله دمانس، اوتیسم، پارکینسون و آلزایمر در ارتباط است.
در اپیدمی اخیر نیز دنیا در واقع با چندهمه&#8204;گیری کووید19 و بیماری&#8207;های غیرواگیر مواجه است. این ویروس در کنش متقابل با بیماری&#8204;های زمینه&#172;ای فرد مبتلا مثل دیابت، سرطان، مشکلات قلبی و پرفشاری خون، نظام بهداشتی را با چالش&#8207;های بسیاری روبرو کرده است. مطالعات نشان داده است که شدت بیماری کووید19 و عوارض ناشی از آن در افراد مبتلا به بیماری&#8207;های غیرواگیر بیشتر است و نشان دهنده مکانیسم&#8207;های زمینه&#8207;ای مشترک میان این دو دسته از بیماری&#8207;هاست. دیس بیوزیس روده یا اختلال در ترکیب میکروبیوتا از جمله این عوامل مطرح شده است. به عنوان مثال چاقی خطر مرگ و میر را در بیماران مبتلا به کووید19 افزایش می&#8207;دهد و از طرف دیگر چاقی عامل خطر بسیاری از بیماری&#8207;های غیرواگیر محسوب می&#172;شود. مطالعات نیز نقش میکروبیوتای روده را در اتیولوژی چاقی به خوبی نشان داده&#8207;اند. به نظر می&#8207;رسد اختلال در ترکیب و عملکرد میکروبیوتای روده می&#8207;تواند عامل ارتباط دهنده بسیاری از بیماری&#8207;ها باشد.&#160; 
شناسایی دقیق عوامل تأثیرگذار بر میکروبیوتا و مطالعه تغییرات ترکیب و عملکرد میکروبیوتا در بیماری&#8207;های مختلف، راه را برای رسیدن به روش&#8207;های درمانی جدید از طریق تعدیل ترکیب میکروبیوتا باز می&#8207;کند که در این میان بررسی ترکیب میکروبیوتای افراد با نژادها و قومیت&#8207;های متعدد در کشورهای مختلف در راستای رسیدن به اهداف پزشکی شخصی و ارائه خدمات پزشکی موثر، ضروری است.&#160; 
میکروبیوم به عنوان علمی نوین و بین رشته&#8207;ای، توانایی کاربردی کردن نتایج تحقیقات علوم پایه را بر بالین بیمار داشته و در پیشگیری و درمان بسیاری از اختلالات موثر خواهد بود. در راستای اعتلای دانش و توسعه پژوهش&#8207;های حوزه میکروبیوم، شماره ویژه میکروبیوتا با تمرکز بر رویکرد جامع از تحقیقات علوم پایه تا کاربردهای بالینی در این حوزه در جهت بالا بردن توان علمی کشور و ارتقای همکاری&#8207;های مشترک در این زمینه گرداوری شده است. ضمن تشکر از کلیه همکاران محترم مجله وزین دانشگاه علوم پزشکی مازندران، امیدوارم شاهد توسعه دانش میکروبیوم در کشور باشیم.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Editorial for Special Issue of Microbiota
Bagher Larijani
Professor, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>1</FPAGE>
			<TPAGE>1</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/1
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/11/13
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/29
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/11/10
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>باقر</Name>
				<MidName></MidName>
				<Family>لاریجانی</Family>
				<NameE>Bagher</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Larijani</FamilyE>
				<Organizations>
				<Organization>استاد غدد درون ریز و متابولیسم، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Editorial for Special Issue of Microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سخن سردبیر ویژه نامه میکروبیوتا</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>Editorial for Special Issue of Microbiota## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>اثر مهاری پروبیوتیک E. coli Nissle1917 روی رشد سویه های بالینی جدا شده از بیمار و سویه استاندارد سودوموناس آئروژینوزا</TitleF>
		<TitleE>Inhibitory Effect of E. coli Nissle 1917 on Clinical and Standard Strains of Pseudomonas aeruginosa</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: سودوموناس آئروژینوزا یک عامل بیماری&#8204;زای پراهمیت است که می&#8204;تواند منجر به عفونت&#8204;های جدی شود. به دلیل وجود مقاومت&#8204;های آنتی&#8204;بیوتیکی که در میان باکتری&#8204;ها رایج می&#8204;باشد، یافت یک عامل درمانی جدید می&#8204;تواند ما را قادر به غلبه بر این مشکل نماید. براساس مطالعات قبلی، فرض ما بر این است که سویه&#8204;های پروبیوتیک باید دارای اثرات حفاظتی علیه باکتری&#8204;های پاتوژن و یا فرصت طلب از طریق مکانیسم&#8204;های مختلف باشند. هدف اصلی از مطالعه حاضر ارزیابی اثر E. coli Nissle1917 به عنوان یک پروبیوتیک بر روی سویه&#8204;های سودوموناس آئروژینوزا است.
مواد و روش&#8204;ها: در مطالعه تجربی حاضر، به&#8204;منظور ارزیابی اثر E. coli Nissle197 بر روی سویه&#8204;های بالینی سودوموناس آئروژینوزا از تکنیک&#8204;های MIC و دیسک دیفیوژن استفاده شد و اثر فعالیت میکروبی سویه پروبیوتیک پس از 24 ساعت در دمای 37 درجه سانتی&#8204;گراد مورد ارزیابی قرار گرفت.
یافته&#8204;ها: نتایج مطالعه نشان داد که بالاترین غلظت از سویه E. coli Nissle1917 دارای بهترین فعالیت ضد میکروبی بر علیه سویه&#8204;های بالینی و استاندارد سودوموناس آئروژینوزا را پس از 24 ساعت دارا می&#8204;باشد.
استنتاج: استفاده از باکتری&#8204;های پروبیوتیک دارای اثرات مثبتی در جنبه&#8204;های پزشکی است، به&#8204;خصوص به علت بروز مسیرهای مقاومت&#8204;های آنتی&#8204;بیوتیکی بیشماری که باکتری&#8204;ها به آن دستیابی پیدا می&#8204;کنند. بنابراین، با توجه به فقدان آنتی&#8204;بیوتیک مناسب برای بسیاری از عفونت&#8204;ها، پروبیوتیک&#8204;ها می&#8204;توانند جهت کنترل عفونت&#8204;ها کمک&#8204;کننده باشند. غلظت&#8204;های مختلف از یک پروبیوتیک می&#8204;تواند مهارکننده رشد باکتری پاتوژن باشد</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Pseudomonas aeruginosa is an indispensable pathogenic agent that can lead to serious infections. Antibiotic resistance is really common among bacteria, so, new therapeutic agents could be of great help in overcoming this problem. Based on previous studies, probiotic strains have a protective effect against pathogenic or Image result for opportunist bacteria opportunistic bacteria thorough various mechanisms. The main purpose of the present study was to evaluate the influence of E. coli Nissle 1917 as a probiotic strain on Pseudomonas aeruginosa&#160;strains.
Materials and methods: In this experimental study, MIC and Disk Diffusion techniques were used to investigate the effect of E. coli Nissle 1917 on Pseudomonas aeruginosa&#160;strains. Effect of antibacterial activity of the probiotic strain was evaluated after 24h at 37&#176;C.
Results: The highest concentration of E. coli Nissle 1917 showed the most effective antibacterial activity against clinical and standard Pseudomonas aeruginosa&#160;strains after 24h.
Conclusion: Probiotic bacteria can have a positive effect on medical aspects, especially because of having access to numerous antibiotic resistance pathways. Therefore, due to lack of suitable antibiotics for several infections, probiotics could be highly helpful. Various concentrations of probiotic bacteria can also inhibit the pathogenic strain.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>2</FPAGE>
			<TPAGE>11</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/31
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/8/10
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/6
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/16
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>شیدا</Name>
				<MidName></MidName>
				<Family>داموغ</Family>
				<NameE>Sheyda</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Damoogh</FamilyE>
				<Organizations>
				<Organization>. کارشناسی ارشد میکروب شناسی، گروه میکروبیولوژی، دانشگده علوم و فن آوری های نوین- واحد علوم پزشکی تهران، دانشگاه آزاد اسلامی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>sheyda.damoogh@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مهراد</Name>
				<MidName></MidName>
				<Family>وثوق</Family>
				<NameE>Mehrad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Vosough</FamilyE>
				<Organizations>
				<Organization>کارشناسی ارشد میکروب شناسی، گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mehrdad.vo@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سروناز</Name>
				<MidName></MidName>
				<Family>فلسفی</Family>
				<NameE>Sarvenaz</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Falsafi</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه میکروبیولوژی، دانشگده علوم و فن آوری های نوین، واحد علوم پزشکی تهران، دانشگاه آزاد اسلامی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>sarvenaz_falsafi@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>آوا</Name>
				<MidName></MidName>
				<Family>بهروزی</Family>
				<NameE>Ava</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Behrouzi</FamilyE>
				<Organizations>
				<Organization>. دکترای میکروبیولوژی، گروه سل و تحقیقات ریوی، انستیتو پاستور ایران، تهران، ایران . گروه میکروبیولوژی، دانشگده علوم و فن آوری های نوین، واحد علوم پزشکی تهران، دانشگاه آزاد اسلامی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>ava.behrouzi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>MIC</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>E. coli Nissle1917</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Pseudomonas aeruginosa</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>E. coli Nissle1917</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>MIC</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سودوموناس آئروژینوزا</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Mielko KA, Jabłoński SJ, Milczewska J, Sands D, Łukaszewicz M, Młynarz P. Metabolomic studies of Pseudomonas aeruginosa. World Journal of Microbiology &#38; Biotechnology 2019; 35(11): 178.##2.	Mielko KA, Jabłoński SJ, Milczewska J, Sands D, Łukaszewicz M, Młynarz P. Metabolomic studies of Pseudomonas aeruginosa. World Journal of Microbiology and Biotechnology 2019; 35(11): 178.##3.	Martin SJ, Yost RJ. Infectious diseases in the critically ill patients. Journal of Pharmacy Practice 2011; 24(1): 35-43.##4.	Markou P, Apidianakis Y. Pathogenesis of intestinal Pseudomonas aeruginosa infection in patients with cancer. Front Cell Infect Microbiol 2014; 3: 115.##5.	Chuang CH, Wang YH, Chang HJ, Chen HL, Huang YC, Lin TY, et al. Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease. Gut 2014; 63(5): 736-743.##6.	Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology E-Book: Elsevier Health Sciences; 2020.##7.	Foulkes DM, McLean K, Haneef AS, Fernig DG, Winstanley C, Berry N, et al. Pseudomonas aeruginosa Toxin ExoU as a Therapeutic Target in the Treatment of Bacterial Infections. Microorganisms 2019; 7(12): 707.##8.	Behzadi E, Mahmoodzadeh Hosseini H, Imani Fooladi AA. The inhibitory impacts ##of Lactobacillus rhamnosus GG-derived extracellular vesicles on the growth of hepatic cancer cells. Microbial Pathogenesis 2017; 110: 1-6.##9.	Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occupational Medicine (Oxford, England) 2007; 57(8): 552-556.##10.	Dudek-Wicher R, Junka A, Paleczny J, Bartoszewicz M. Clinical Trials of Probiotic Strains in Selected Disease Entities. International Journal of Microbiology 2020; 2020: 8854119.##11.	Liu Y, Tran DQ, Rhoads JM. Probiotics in Disease Prevention and Treatment. Journal of Clinical Pharmacology 2018; 58 Suppl 10(Suppl 10): S164-S179.##12.	Erreni M, Mantovani A, Allavena P. Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenvironment: official Journal of the International Cancer Microenvironment Society 2011; 4(2): 141-154.##13.	Rhodes JM. The role of Escherichia coli in inflammatory bowel disease. Gut 2007; 56(5): 610-612.##14.	Arribas B, Rodríguez-Cabezas ME, Camuesco D, Comalada M, Bailón E, Utrilla P, et al. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide- induced sepsis in mice. British Journal of Pharmacology 2009; 157(6): 1024-1033.##15.	Rastegar Lari A, Bahrami H, Alaghehbandan R. Pseudomonas aeroginosa infection in Tohid center, Iran Burns: Journal of the International Society for Burn Injuries 1998; 24(7): 637-641.##16.	Jiang X, Zhang Z, Li M, Zhou D, Ruan F, Lu Y. Detection of extended-spectrum beta-lactamases in clinical isolates of Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 2006; 50(9): 2990-2995.##17.	Selvin J, Maity D, Sajayan A, Kiran GS. Revealing antibiotic resistance in therapeutic and dietary probiotic supplements. Journal of Global Antimicrobial Resistance 2020; 22: 202-205.##18.	Joint F. WHO working group report on drafting guidelines for the evaluation of probiotics in food. London, Ontario, Canada. 2002; 30.##19.	Bierbaum G, Sahl H-G. Lantibiotics: mode of action, biosynthesis and bioengineering. Current Pharmaceutical Biotechnology 2009; 10(1): 2-18.##20.	Rybalchenko OV, Bondarenko VM, Orlova OG, Markov AG, Amasheh S. Inhibitory effects of Lactobacillus fermentum on microbial growth and biofilm formation. Archives of Microbiology 2015; 197(8): 1027-1032.##21.	Rasamiravaka T, Labtani Q, Duez P, El Jaziri M. The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms. BioMed Research International 2015; 2015.##22.	Chatterjee M, Anju C, Biswas L, Kumar VA, Mohan CG, Biswas R. Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. International Journal of Medical Microbiology 2016; 306(1): 48-58.##23.	Gutiérrez S, Martínez-Blanco H, Rodríguez-Aparicio LB, Ferrero MA. Effect of fermented broth from lactic acid bacteria on pathogenic bacteria proliferation. Journal of Dairy Science 2016; 99(4): 2654-2665.##24.	Drago L, Gismondo MR, Lombardi A, De Haën C, Gozzini L. Inhibition of in vitro growth of enteropathogens by new Lactobacillus isolates of human intestinal origin. FEMS Microbiology Letters 1997; 153(2): 455-463.##25.	Stavropoulou E, Bezirtzoglou E. Probiotics in Medicine: A Long Debate. Front Immunol 2020; 11.##26.	López-Brea M, Alarcón T, Domingo D, Díaz-Regañón J. Inhibitory effect of Gram-negative and Gram-positive microorganisms against Helicobacter pylori clinical isolates. Journal of Antimicrobial Chemotherapy 2008; 61(1): 139-142.##27.	Yang E, Fan L, Jiang Y, Doucette C, Fillmore S. Antimicrobial activity of bacteriocin-producing lactic acid bacteria isolated from cheeses and yogurts. Amb Express 2012; 2(1): 48.##28.	Deng Z, Luo XM, Liu J, Wang H. Quorum Sensing, Biofilm, and Intestinal Mucosal Barrier: Involvement the Role of Probiotic. Front Cell Infect Microbiol 2020; 10: 538077.##29.	Chapman C, Gibson GR, Rowland I. In vitro evaluation of single-and multi-strain probiotics: Inter-species inhibition between probiotic strains, and inhibition of pathogens. Anaerobe 2012; 18(4): 405-413.##30.	Gutiérrez S, Martínez-Blanco H, Rodríguez-Aparicio L, Ferrero M. Effect of fermented broth from lactic acid bacteria on pathogenic bacteria proliferation. Journal of Dairy Science 2016; 99(4): 2654-2665.##31.	Chen CC, Lai CC, Huang HL, Huang WY, Toh HS, Weng TC, et al. Antimicrobial Activity of Lactobacillus Species Against Carbapenem-Resistant Enterobacteriaceae. Front Microbiol 2019; 10: 789.##32.	Chapman C, Gibson G, Rowland I. Effects of single-and multi-strain probiotics on biofilm formation and in vitro adhesion to bladder cells by urinary tract pathogens. Anaerobe 2014; 27: 71-76.##33.	Stavropoulou E, Bezirtzoglou E. Probiotics in Medicine: A Long Debate. Frontiers in Immunology 2020; 11: 2192.##34.	Olaimat AN, Aolymat I, Al-Holy M, Ayyash M, Abu Ghoush M, Al-Nabulsi AA, et al. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. NPJ Sci Food 2020; 4: 17.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>ترکیب میکروبیوتای روده در بزرگسالان ایرانی چاق و با وزن نرمال</TitleF>
		<TitleE>Gut Microbiota Composition in Obese and Normal 
Weight Adults in Iran</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>سابقه و هدف: شیوع فزاینده چاقی طی دهه&#8204;های اخیر، آن را به چالش بزرگ سلامت عمومی جهان تبدیل کرده است. شواهد اخیر نشان داده است که میکروبیوتای روده می&#8204;تواند در کنترل وزن موثر باشد. در این مطالعه مورد شاهدی فراوانی باکتری&#8204;های مختلف دستگاه گوارش افراد ایرانی چاق و با وزن نرمال مورد مقایسه قرار گرفت.
مواد و روش&#8204;ها: 30 بزرگسال با وزن نرمال (نمایه توده بدنی در محدوده kg/m25/18 تا kg/m225( و 27 بزرگسال چاق (نمایه توده بدنی مساوی و بالاتر از kg/m230) وارد این مطالعه مورد- شاهدی شدند. بررسی دریافت غذایی (پرسشنامه FFQ)، اندازه&#8204;گیری&#8204;های تن&#8204;سنجی و جمع&#8204;آوری نمونه&#8204;های خون و مدفوع برای آن&#8204;ها انجام گرفت. سپس ترکیب میکروبیوتای روده به روش quantitative real time PCR مورد سنجش قرار گرفت.
یافته&#8204;ها: میانگین سنی شرکت&#8204;کنندگان و غلظت قندخون، انسولین ناشتا، شاخص مقاومت انسولینی، غلظت&#8204; تری&#8204;گلیسرید و hsCRP در گروه چاق بالاتر از گروه نرمال بود (05/0P&#60;). فراوانی Akkermansia در افراد با وزن نرمال به&#8204;طور معنی&#8204;داری بالاتر از افراد چاق بود (003/0 P=). در مقابل، فراوانی جنس&#8204;های Prevotella و Lactobacillus در افراد چاق بالاتر بود، ولی این تفاوت&#8204;ها از لحاظ آماری به سطح معنی&#8204;داری نرسید (05/0P&#62;).
استنتاج: در این مطالعه فراوانی برخی از جنس&#8204;های باکتریایی میکروبیوتای روده میان دو گروه افراد چاق و با وزن نرمال تفاوت معنی&#8204;داری داشت. این مساله لزوم بررسی&#8204;های جمعیتی را برای تایید مشاهدات این مطالعه نشان می&#8204;دهد. به علاوه، در راستای رسیدن به اهداف پزشکی فردمحور، اطلاعات در مورد ترکیب میکروبیوتای روده می&#8204;تواند کمک&#8204;کننده باشد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background and purpose: Increasing prevalence of obesity over the past few decades constitutes a global health challenge. Recent evidence suggests that gut microbiota may contribute to weight control. So, the present study aimed at comparing the frequency of different bacteria in gut microbiota between obese and normal weight people in Iran.
Materials and methods: Thirty normal weight (BMI of 18.5- 25 kg/m&#178;) and 27 obese adults (BMI of 30 kg/m&#178; or higher) were included in this case-control study. Dietary intake was assessed using food frequency questionnaire (FFQ). Anthropometric measurements and collection of blood and faecal samples were also done. Then, gut microbiota composition was assessed using quantitative real-time PCR.
Results: The mean age of participants and concentrations of fasting blood glucose and insulin, insulin resistance index, triglyceride concentration and hsCRP were higher in obese group than the normal group (P&#60;0.05). The frequency of Akkermansia was significantly higher in individuals with normal weight than obese individuals (P=0.003). On the other hand, the frequencies of Prevotella and Lactobacillus genera were higher in obese individuals (P&#62;0.05).
Conclusion: In this study, the frequencies of some bacterial genera of intestinal microbiota were significantly different between obese and normal weight individuals. Therefore, population-based studies are needed to confirm current findings. Moreover, in order to achieve personalized medicine goals, information on gut microbiota composition could be helpful.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>12</FPAGE>
			<TPAGE>20</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/15
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/8/25
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/6
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/16
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>هانیه سادات</Name>
				<MidName></MidName>
				<Family>اجتهد</Family>
				<NameE>Hanieh-Sadat</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ejtahed</FamilyE>
				<Organizations>
				<Organization>. استادیار، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران . مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haniejtahed@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>زهرا</Name>
				<MidName></MidName>
				<Family>حسینی توسل</Family>
				<NameE>Zahra</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hoseini Tavassol</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکترای بیوتکنولوژی پزشکی، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران . گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>zhtavassol@Gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>شیرین</Name>
				<MidName></MidName>
				<Family>حسنی رنجبر</Family>
				<NameE>Shirin</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hasani-Ranjbar</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>shirinhasanir@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>احمدرضا</Name>
				<MidName></MidName>
				<Family>سروش</Family>
				<NameE>Ahmad-Reza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Soroush</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Soroush1344@gmail.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سید داور</Name>
				<MidName></MidName>
				<Family>سیادت</Family>
				<NameE>Seyed Davar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Siadat</FamilyE>
				<Organizations>
				<Organization>استاد، گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی، انستیتو پاستور ایران، تهران، ایران.مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>d.siadat@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>باقر</Name>
				<MidName></MidName>
				<Family>لاریجانی</Family>
				<NameE>Bagher</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Larijani</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Larijanib@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>gut microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiome</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>obesity</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>normal weight</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتای روده</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوم</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>چاقی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>وزن نرمال</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Collaboration NRF. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 2016; 387(10026): 1377-1396.##2.	Franks PW, McCarthy MI. Exposing the exposures responsible for type 2 diabetes and obesity. Science 2016; 354(6308): 69-73.##3.	Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444(7122): 1027-1031.##4.	Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol 2014; 28(8): 1221-1238.##5.	Ejtahed HS, Soroush AR, Angoorani P, Larijani B, Hasani-Ranjbar S. Gut Microbiota as a Target in the Pathogenesis of Metabolic Disorders:  A New Approach to Novel Therapeutic Agents. Horm Metab Res 2016; 48(6): 349-358.##6.	Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010; 18(1): 190-195.##7.	Armougom F, Henry M, Vialettes B, Raccah D, Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PloS one 2009; 4(9): e7125.##8.	Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, et al. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. Int J Obes (Lond) 2013; 37(11): 1460-1466##9.	Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TM, Comelli EM. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr Diabetes 2014; 4(6): e121.##10.	Rad SS, Nikkhah A, Orvatinia M, Ejtahed HS, Sarhangi N, Jamaldini SH, Khodayari N, Meybodi HR, Hasanzad M. Gut microbiota: a perspective of precision medicine in endocrine disorders. J Diabetes Metab Disord 2020: 1-8.##11.	Ejtahed HS, Hasani-Ranjbar S, Larijani B. Human Microbiome as an approach to personalized medicine. Altern Ther Health Med 2017; 23(6): 8-9.##12.	Momenan AA, Delshad M, Sarbazi N, Rezaei Ghaleh N, Ghanbarian A, Azizi F. Reliability and validity of the Modifiable Activity Questionnaire (MAQ) in an Iranian urban adult population. Arch Iran Med 2012; 15(5): 279-282.##13.	Esfahani FH, Asghari G, Mirmiran P, Azizi F. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the Tehran Lipid and Glucose Study. J Epidemiol 2010; 20(2): 150-158.##14.	Kanno T, Matsuki T, Oka M, Utsunomiya H, Inada K, Magari H, et al. Gastric acid reduction leads to an alteration in lower intestinal microflora. Biochem Biophys Res Commun 2009; 381(4): 666-670.##15.	Rinttila T, Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 2004; 97(6): 1166-1177.##16.	Schneeberger M, Everard A, Gomez-Valades AG, Matamoros S, Ramirez S, Delzenne NM, et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep 2015; 5: 16643.##17.	Gregory KE, LaPlante RD, Shan G, Kumar DV, Gregas M. Mode of Birth Influences Preterm Infant Intestinal Colonization With Bacteroides Over the Early Neonatal Period. Advances in neonatal care: official Journal of the National Association of Neonatal Nurses 2015; 15(6): 386-393.##18.	Fitzgerald CB, Shkoporov AN, Sutton TDS, Chaplin AV, Velayudhan V, Ross RP, et al. Comparative analysis of Faecalibacterium prausnitzii genomes shows a high level of genome plasticity and warrants separation into new species-level taxa. BMC Genomics 2018; 19(1): 931.##19.	Bartosch S, Fite A, Macfarlane GT, McMurdo ME. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Appl Environ Microbiol 2004; 70(6): 3575-3581.##20.	Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PloS one 2010; 5(2):e9085.##21.	Yassour M, Lim MY, Yun HS, Tickle TL, Sung J, Song YM, et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes. Genome Med 2016; 8(1): 17.##22.	Haro C, Garcia-Carpintero S, Alcala-Diaz JF, Gomez-Delgado F, Delgado-Lista J, Perez-Martinez P, et al. The gut microbial community in metabolic syndrome patients is modified by diet. J Nutr Biochem 2016; 27: 27-31.##23.	Moran-Ramos S, Lopez-Contreras BE, Canizales-Quinteros S. Gut Microbiota in Obesity and Metabolic Abnormalities: A Matter of Composition or Functionality? Arch Med Res 2017; 48(8): 735-753.##24.	Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell 2016; 167(5): 1339-1353.##25.	Radilla-Vazquez RB, Parra-Rojas I, Martinez-Hernandez NE, Marquez-Sandoval YF, Illades-Aguiar B, Castro-Alarcon N. Gut Microbiota and Metabolic Endotoxemia in Young Obese Mexican Subjects. Obes Facts 2016; 9(1): 1-11.##26.	Ejtahed HS, Angoorani P, Soroush AR, Atlasi R, Hasani-Ranjbar S, Mortazavian AM, et al. Probiotics supplementation for the obesity management; A systematic review of animal studies and clinical trials. J Funct Foods 2019; 52: 228-242.##27.	Mai V, McCrary QM, Sinha R, Glei M. Associations between dietary habits and body mass index with gut microbiota composition and fecal water genotoxicity: an observational study in African American and Caucasian American volunteers. Nutr J 2009; 8: 49.##28.	Feng J, Tang H, Li M, Pang X, Wang L, Zhang M, et al. The abundance of fecal Faecalibacterium prausnitzii in relation to obesity and gender in Chinese adults. Arch Microbiol 2014; 196(1): 73-77.##29.	Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 2017; 23(7): 859-868.##30.	Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science 2016; 352(6285): 560-564.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>میکروبیوم در پزشکی فرد محور: رویکردی نوین در درمان سرطان</TitleF>
		<TitleE>The Microbiome in Precision Medicine: A New Approach to Cancer Treatment</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>پزشکی فرد محور یک رویکرد جدید در علم پزشکی با هدف فردی&#8207;سازی درمان، کاهش عوارض جانبی دارو و هزینه&#8207;های مراقبت سلامت است. پزشکی فرد محور همچنین قادر به حفظ سلامتی افراد با تنظیم ترکیب میکروارگانیسم&#8207;های (میکروبیوتای) بدن هر فرد با روش&#8204;های اختصاصی است. به کل گونه&#8207;های میکروبی موجود در بخش&#8207;های مختلف بدن یک فرد میکروبیوتا و مجموعه ژن&#8207;های آن&#8207;ها میکروبیوم گفته می&#8207;شود. ترکیب میکروبیوتا اختصاصی هر فرد است و به فاکتورهای ژنتیکی و محیطی از جمله سبک زندگی و مصرف برخی از انواع داروها ارتباط دارد. روده انسان به شدت تحت تأثیر جوامع باکتریایی است. شواهد نشان می&#8207;دهد که میکروبیوتای روده در ایجاد سرطان&#8207;ها دخیل است بنابراین میکروبیوتا نقش مهمی در حفظ سلامت انسان&#8204;ها و کاهش خطر بیماری در محیط&#8207;های ناپایدار و هنگام تغییر شرایط ایفا می&#8207;کند. به&#8207;طور کلی میکروبیوم به&#8207;عنوان بخشی جدایی ناپذیر از رویکرد پزشکی فرد محور در حال ظهور است زیرا نه تنها به تنوع بین فردی در تمام جنبه&#8207;های بیماری کمک می&#8207;کند بلکه نمایانگر یک فاکتور قابل تغییر است که می&#8207;تواند به طور فزاینده&#8207;ای به عنوان یک هدف درمانی مورد توجه قرار گیرد، نتیجه بسیاری از بیماری&#8207;های مختلف را تغییر دهد و پاسخ&#8207;ها و تحمل داروها را افزایش دهد.
در این مطالعه، اهمیت نقش میکروبیوتا و میکروبیوم در سرطان و عملکرد آن&#8207;ها به&#8207;عنوان نشانگرهای زیستی در رویکرد پزشکی فرد محور را مورد بررسی قرار دادیم.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Precision medicine is a new approach in medical sciences aimed at individualizing treatment, reducing adverse drug reactions (ADRs), and decreasing health care costs. Precision medicine is also able to maintain the health of individuals by regulating their composition of microorganisms (microbiota) using specific methods. Microbiota is the total stock of microbial species in different organs of a human body and their set of genes are called microbiome. The composition of microbiota is unique in each individual and is directly associated with genetic and&#160;invironmental facors, including lifestyle, and certain medications. The human gut is strongly influenced by bacterial communities. Evidence suggests that gut microbiota is involved in oncological diseases. Therefore, microbiota plays a key role in maintaining human health and reducing the risk of diseases in unstable environments. Generally, the microbiome appears to be a vital part of the precision medicine approach, since it leads to interpersonal diversity in all facets of a disease and also represents a changeable component that could increasingly be considered as a therapeutic target and improve drug resistance and responses. In this review, we highlight the importance of the gut microbiota and microbiome in cancer and their functions as therapeutic biomarkers in precision medicine approach.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>21</FPAGE>
			<TPAGE>37</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/26
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/9/6
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/10
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/10/21
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>سلمان</Name>
				<MidName></MidName>
				<Family>شیروانی راد</Family>
				<NameE>Salman</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shirvanirad</FamilyE>
				<Organizations>
				<Organization>. دانشجوی پزشکی، مرکز تحقیقات ژنومیک پزشکی، علوم پزشکی تهران، دانشگاه آزاد اسلامی، تهران، ایران . مرکز تحقیقات پزشکی فردی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>salamonca@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>امیر عباس</Name>
				<MidName></MidName>
				<Family>نیک خواه</Family>
				<NameE>Amirabbas</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Nikkhah</FamilyE>
				<Organizations>
				<Organization>دانشجوی پزشکی، دانشکده پزشکی، دانشگاه علوم پزشکی تهران، تهران ، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>amirabbas.nikkhah@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمد مهدی</Name>
				<MidName></MidName>
				<Family>عروتی نیا</Family>
				<NameE>Mohammad Mahdi</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Orvatinia</FamilyE>
				<Organizations>
				<Organization>دانشجوی پزشکی، دانشکده پزشکی، دانشگاه علوم پزشکی تهران، تهران ، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mehdiorvatinia@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>هانیه السادات</Name>
				<MidName></MidName>
				<Family>اجتهد</Family>
				<NameE>Hanieh-Sadat</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ejtahed</FamilyE>
				<Organizations>
				<Organization>. استادیار، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haniejtahed@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>نگار</Name>
				<MidName></MidName>
				<Family>سرهنگی</Family>
				<NameE>Negar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sarhangi</FamilyE>
				<Organizations>
				<Organization>کارشناسی ارشد علوم سلولی و مولکولی، مرکز تحقیقات پزشکی فردی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>nsarhangi198@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>حمید رضا</Name>
				<MidName></MidName>
				<Family>آقایی میبدی</Family>
				<NameE>Hamid Reza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Aghaei Meybodi</FamilyE>
				<Organizations>
				<Organization>. دانشیار، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران.مرکز تحقیقات پزشکی فردی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>dr_aghai@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>ماندانا</Name>
				<MidName></MidName>
				<Family>حسن زاد</Family>
				<NameE>Mandana</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hasanzad</FamilyE>
				<Organizations>
				<Organization>دانشیار، مرکز تحقیقات ژنومیک پزشکی، علوم پزشکی تهران، دانشگاه آزاد اسلامی، تهران، ایران.مرکز تحقیقات پزشکی فردی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mandanahasanzad@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>precision medicine</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiome</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>cancer</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پزشکی فرد محور</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوم</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سرطان</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Kuntz TM, Gilbert JA. Introducing the Microbiome into Precision Medicine. Trends Pharmacol Sci 2017;38(1):81-91.##2.	Lavelle A, Hill C. Gut microbiome in health and disease: emerging diagnostic opportunities. Gastroenterol Clin North Am 2019; 48(2): 221-235.##3.	Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril 2018; 109(6): 952-963.##4.	Riscuta G, Xi D, Pierre Victor D, Starke Reed P, Khalsa J, Duffy L. Diet, microbiome, and epigenetics in the era of precision medicine. Methods Mol Biol 2018; 1856: 141-156.##5.	Kosyakovsky LB. The emerging role of the microbiome in precision medicine: An overview. UBC Medical Journal 2017; 9(1): 10-12.##6.	Petrosino JF. The microbiome in precision medicine: the way forward. Genome Med 2018; 10(1): 12.##7.	Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 2020; 19(1): 55-71.##8.	Hasani-Ranjbar S, Larijani B. Human Microbiome as an approach to personalized medicine. Alternative Therapies in Health and Medicine 2017; 23(6): 8-9.##9.	Eloe-Fadrosh EA, Rasko DA. The Human Microbiome: From Symbiosis to Pathogenesis. Annu Rev Med 2013; 64(1): 145-163.##10.	Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012; 336(6086): 1268-1273.##11.	Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. The application of ecological theory toward an understanding of the human microbiome. Science 2012; 336(6086): 1255-1262.##12.	Mallick H, Ma S, Franzosa EA, Vatanen T, Morgan XC, Huttenhower C. Experimental design and quantitative analysis of microbial community multiomics. Genome Biol 2017; 18(1): 228.##13.	Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. Science 2009; 324(5931): 1190-1192.##14.	Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307(5717): 1915-1920.##15.	Balato A, Cacciapuoti S, Di Caprio R, Marasca C, Masarà A, Raimondo A, et al. Human microbiome: composition and role in inflammatory skin diseases. Arch Immunol Ther Exp 2019; 67(1): 1-18.##16.	Kashyap PC, Chia N, Nelson H, Segal E, Elinav E, editors. Microbiome at the frontier of personalized medicine. Mayo Clin Proc 2017; 92(12): 1855-1864.##17.	Zitvogel L, Daillere R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol 2017; 15(8): 465-478.##18.	World Health Organization (WHO). Cardiovascular diseases (CVDs). https://wwwwhoint/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).##19.	World Health Organization (WHO). Cancer. https://www.who.int/cancer/country-profiles/Global_Cancer_Profile_2020.##20.	Mattiuzzi C, Lippi G. Current Cancer Epidemiology. J Epidemiol Glob Health 2019; 9(4): 217-222.##21.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1): 7-30.##22.	Joukar F, Mavaddati S, Mansour-Ghanaei F, Samadani AA. Gut microbiota as a positive potential therapeutic factor in carcinogenesis: an overview of microbiota-targeted therapy. J Gastrointest Cancer 2020; 51(2): 363-378.##23.	de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020; 8(2): e180-e190.##24.	Xavier JB, Young VB, Skufca J, Ginty F, Testerman T, Pearson AT, et al. The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends Cancer 2020; 6(3): 192-204.##25.	Behrouzi A, Nafari AH, Siadat SD. The significance of microbiome in personalized medicine. Clin Transl Med 2019; 8(1): 16.##26.	Doestzada M, Vila AV, Zhernakova A, Koonen DP, Weersma RK, Touw DJ, et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell 2018; 9(5): 432-445.##27.	International Cancer Control Partnership (ICCP). WHO-Cancer Country Profiles Iran 2020. https://www.who.int/cancer/country-profiles/IRN_2020.##28.	Ejtahed HS, Angoorani P, Soroush AR, Siadat SD, Shirzad N, Hasani Ranjbar S, et al. Our Little Friends with Big Roles: Alterations of the Gut Microbiota in Thyroid Disorders. Endocr Metab Immune Disord Drug Targets 2020; 20(3): 344-350.##29.	Gonçalves CF, De Freitas ML, Ferreira AC. Flavonoids, thyroid iodide uptake and thyroid cancer—a review. Int J Mol Sci 2017; 18(6): 1247.##30.	Zhang J, Zhang F, Zhao C, Xu Q, Liang C, Yang Y, et al. Dysbiosis of the gut microbiome is associated with thyroid cancer and thyroid nodules and correlated with clinical index of thyroid function. Endocrine 2019; 64(3): 564-574.##31.	Feng J, Zhao F, Sun J, Lin B, Zhao L, Liu Y, et al. Alterations in the gut microbiota and metabolite profiles of thyroid carcinoma patients. Int J Cancer 2019; 144(11): 2728-2745.##32.	Knezevic J, Starchl C, Tmava Berisha A, Amrein K. Thyroid-Gut-Axis: How Does the Microbiota Influence Thyroid Function? Nutrients 2020; 12(6): 1769.##33.	Tumino D, Grani G, Di Stefano M, Di Mauro M, Scutari M, Rago T, et al. Nodular thyroid disease in the era of precision medicine. Front Endocrinol 2020; 10: 907.##34.	Zhang J, Xia Y, Sun J. Breast and gut microbiome in health and cancer. Genes &#38; Diseases 2020.##35.	Eslami SZ, Majidzadeh AK, Halvaei S, Babapirali F, Esmaeili R. Microbiome and Breast Cancer: New Role for an Ancient Population. Front Oncol 2020; 10: 120.##36.	Chen J, Douglass J, Prasath V, Neace M, Atrchian S, Manjili MH, et al. The microbiome and breast cancer: a review. Breast Cancer Res Treat 2019: 493-496.##37.	Bodai BI, Nakata TE. Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship. Perm J 2020; 24: 19. 129.##38.	Bodai BI, Nakata TE, Wong WT, Clark DR, Lawenda S, Tsou C, et al. Lifestyle medicine: A brief review of its dramatic impact on health and survival. Perm J 2018; 22: 17-025.##39.	Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH, et al. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med 2012; 10(1): 253.##40.	Barroso-Sousa R, Teles LT. Gut Microbiome and Breast Cancer in the Era of Cancer Immunotherapy. Curr Breast Cancer Rep 2019; 11(4): 272-276.##41.	Parida S,Sharma D. The Microbiome–Estrogen Connection and Breast Cancer Risk. Cells 2019; 8(12): 1642.##42.	Schulz C, Schütte K, Mayerle J, Malfertheiner P. The role of the gastric bacterial microbiome in gastric cancer: Helicobacter pylori and beyond. Therap Adv Gastroenterol 2019; 12: 1756284819894062.##43.	Brawner KM, Morrow CD, Smith PD. Gastric microbiome and gastric cancer. Cancer J 2014; 20(3): 211-216.##44.	Arora N, Majumder K, Gupta A. Gastric cancer and the microbiome. Asian Pac J Trop Dis 2015; 5(5): 353-357.##45.	Engstrand L, Graham DY. Microbiome and Gastric Cancer. Dig Dis Sci 2020; 65: 865-873.##46.	Zhang H, Sun L. When human cells meet bacteria: precision medicine for cancers using the microbiota. Am J Cancer Res 2018; 8(7): 1157-1175.##47.	Hou L, El Omar E, Chen J, Grillo P, Rabkin C, Baccarelli A, et al. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis 2007; 28(1): 118-123.##48.	Hwang JW, Baek Y-M, Yang KE, Yoo H-S, Cho C-K, Lee Y-W, et al. Lactobacillus casei extract induces apoptosis in gastric cancer by inhibiting NF-κB and mTOR-mediated signaling. Integr Cancer Ther 2013; 12(2): 165-173.##49.	Dahmus JD, Kotler DL, Kastenberg DM, Kistler CA. The gut microbiome and colorectal cancer: a review of bacterial pathogenesis. J Gastrointest Oncol 2018; 9(4): 769-777.##50.	Sánchez-Alcoholado L, Ramos-Molina B, Otero A, Laborda-Illanes A, Ordóñez R, Medina JA, et al. The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response. Cancers 2020; 12(6): 1406.##51.	Saus E, Iraola Guzmán S, Willis JR, Brunet Vega A, Gabaldón T. Microbiome and colorectal cancer: roles in carcinogenesis and clinical potential. Mol Aspects Med 2019; 69: 93-106.##52.	Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol 2019; 16(11): 690-704.##53.	Goodwin AC, Shields CED, Wu S, Huso DL, Wu X, Murray-Stewart TR, et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci U S A 2011; 108(37): 15354-15359.##54.	Magalhães B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: systematic review and meta-analysis. Eur J Cancer Prev 2012; 21(1): 15-23.##55.	Attene-Ramos MS, Wagner ED, Plewa MJ, Gaskins HR. Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res 2006; 4(1): 9-14.##56.	Deplancke B, Gaskins HR. Hydrogen sulfide induces serum independent cell cycle entry in nontransformed rat intestinal epithelial cells. FASEB J 2003; 17(10): 1310-1312.##57.	Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016; 65(12): 1973-1980.##58.	Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 2014; 33(8): 1381-1390.##59.	Ramírez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, et al. The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy. Trends Cancer 2020; 6(2): 86-97.##60.	Sommariva M, Le Noci V, Bianchi F, Camelliti S, Balsari A, Tagliabue E, et al. The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. Cell Mol Life Sci 2020; 77(14): 2739-2749.##61.	Ordóñez-Mena JM, Schöttker B, Mons U, Jenab M, Freisling H, Bueno-de-Mesquita B, et al. Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium. BMC Medicine 2016; 14(1): 1-15.##62.	Pattaroni C, Watzenboeck ML, Schneidegger S, Kieser S, Wong NC, Bernasconi E, et al. Early-life formation of the microbial and immunological environment of the human airways. Cell Host Microbe 2018; 24(6): 857-865. e4.##63.	Ocáriz-Díez M, Cruellas M, Gascón M, Lastra R, Martínez-Lostao L, Ramírez-Labrada A, et al. Microbiota and lung cancer. Opportunities and challenges for improving immunotherapy efficacy. Front Oncol 2020; 10: 568939.##64.	Goto T. Airway Microbiota as a Modulator of Lung Cancer. Int J Mol Sci 2020; 21(9): 3044.##65.	Yan X, Yang M, Liu J, Gao R, Hu J, Li J, et al. Discovery and validation of potential bacterial biomarkers for lung cancer. Am J Cancer Res 2015; 5(10): 3111-3122.##66.	Brooks AW. How could ethnicity-associated microbiomes contribute to personalized therapies? Future Microbiol 2019; 14(6): 451-455.##67.	Di Paolo A, Sarkozy F, Ryll B, Siebert U. Personalized medicine in Europe: not yet personal enough? BMC Health Serv Res 2017; 17(1): 289.##68.	König IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine? Eur Respir J 2017; 50(4): 1700391.##69.	Žitnik IP, Černe D, Mancini I, Simi L, Pazzagli M, Di Resta C, et al. Personalized laboratory medicine: a patient-centered future approach. Clin Chem Lab Med 2018; 56(12): 1981-1991.##70.	Rasool M, Malik A, Naseer MI, Manan A, Ansari SA, Begum I, et al. The role of epigenetics in personalized medicine: challenges and opportunities. BMC Med Genomics 2015; 8(S1): S5.##71.	Chen R, Snyder M. Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med 2013; 5(1): 73-82.##72.	Feero WG, Guttmacher AE. Genomics, personalized medicine, and pediatrics. Acad Pediatr 2014; 14(1): 14-22.##73.	Nie P, Li Z, Wang Y, Zhang Y, Zhao M, Luo J, et al. Gut microbiome interventions in human health and diseases. Med Res Rev 2019; 39(6): 2286-2313.##74.	Vázquez Baeza Y, Callewaert C, Debelius J, Hyde E, Marotz C, Morton JT, et al. Impacts of the human gut microbiome on therapeutics. Annu Rev Pharmacol Toxicol 2018; 58: 253-270.##75.	Ottman N, Smidt H, De Vos WM, Belzer C. The function of our microbiota: who is out there and what do they do? Front Cell Infect Microbiol 2012; 2: 104.##76.	Klingbeil E, de La Serre CB. Microbiota modulation by eating patterns and diet composition: impact on food intake. Am J Physiol Regul Integr Comp Physiol 2018; 315(6): R1254-R1260.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>اهمیت میکروبیوتای دستگاه گوارش و تغییرات اپی‌ژنتیکی در حفظ سلامت و بروز بیماری</TitleF>
		<TitleE>Importance of Gut Microbiota and Epigenetic Modifications in Maintaining Health or Diseases</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>برخی از ارگانیسم&#8204;ها ممکن است با ایجاد اختلال یا القای چندین مسیر سیگنالینگ در بدن انسان، حفظ سلامتی یا بروز اختلالات را تعدیل کنند. طبق نتایج پژوهش&#8204;های انجام شده طی سال&#8204;های اخیر، اختلالات متابولیکی متعددی مانند دیابت، چاقی، بیماری&#8204;های قلبی-عروقی، اختلالات روانی و سرطان&#8204;ها، نتیجه تعامل و یا تداخل مثبت و منفی باکتریایی با میزبان است. گونه&#8204;های مختلفی از سلول&#8204;های باکتریایی تحت عنوان میکروبیوتای کامنسال(commensal microbiota )در بدن انسان ساکن هستند که عملکردهای حیاتی مختلفی را به عهده دارند. یکی از جالب&#8204;ترین این مکانیسم&#8204;ها، القای تغییرات اپی&#8204;ژنتیکی(epigenetic) در سلول&#8204;های میزبان است که در حفظ هموستاز یا القای بیماری بسیار حائز اهمیت است. به طور کلی، عوامل مختلفی ممکن است باعث القای تغییرات اپی&#8204;ژنتیکی شوند. به عنوان مثال، رژیم غذایی و اثر آن در جمعیت میکروبیوتای دستگاه گوارش ممکن است از نظر اپی&#8204;ژنتیکی، بر بیان ژن&#8204;هایی خاص اهمیت داشته باشد. چنین تغییراتی ممکن است حتی خطرناک بوده و به نسل&#8204;های بعدی هم منتقل شوند. مقاله حاضرسعی در ارائه کامل تغییرات اپی&#8204;ژنتیکی القا شده در انسان توسط میکروبیوتا و تعامل با ماشین اپی&#8204;ژنوم میزبان در دو حالت سلامت و بیماری دارد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>&#160;Some organisms may modulate a healthy state or cause disorders by disruption or induction of several signaling pathways in human body. According to recent evaluations, numerous metabolic disorders such as diabetes, obesity, cardiovascular diseases, mental disorders, and cancers are as the result of bacterial interactions with the host. Various species of the bacteria, called commensal microbiota, live in normal human body which modulate some of the host critical functions by different mechanisms. Induction of epigenetic modifications in host cells that are important in the maintenance of homeostasis or induction of disorders is amongst these mechanisms. Indeed, different factors may induce epigenetic modifications. For example, diet and its effect on microbiota community may epigenetically change the expression of some specific genes. Such modifications may also be dangerous and inherited to next generations. The current review tried to explain the inter-talk between gut microbiota and epigenetic modifications in health and disorders.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>38</FPAGE>
			<TPAGE>46</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/31
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/8/10
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/6
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/16
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>سمیرا</Name>
				<MidName></MidName>
				<Family>تراشی</Family>
				<NameE>Samira</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Tarashi</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری باکتری‌شناسی پزشکی، مرکز تحقیقات میکروبیولوژی، بخش سل و تحقیقات ریوی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>tarashisamira@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>میرداود</Name>
				<MidName></MidName>
				<Family>عمرانی</Family>
				<NameE>Mir Davood</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Omrani</FamilyE>
				<Organizations>
				<Organization>استاد، گروه ژنتیک پزشکی، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>davood_omrani@yahoo.co.uk</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>ارفع</Name>
				<MidName></MidName>
				<Family>مشیری</Family>
				<NameE>Arfa</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Moshiri</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه پزشکی مولکولی، مرکز تحقیقات میکروبیولوژی، انستیتو پاستور ایران، تهران، ایران   پژوهشکده بیماری‌های گوارش و کبد، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران   آزمایشگاه پزشکی مولکولی، انستیتو IRCCS جنوآ، ایتالیا</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>arfa.moshiri@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سید داور</Name>
				<MidName></MidName>
				<Family>سیادت</Family>
				<NameE>Seyed Davar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Siadat</FamilyE>
				<Organizations>
				<Organization>استاد، گروه میکروب‌شناسی پزشکی، مرکز تحقیقات میکروبیولوژی، بخش سل و تحقیقات ریوی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>d.siadat@gmail.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>gut microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>epigenetics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>DNA methylation</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>histone modification</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>miRNA</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتای دستگاه گوارش</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>اپی‌ژنتیک</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>متیلاسیون DNA</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>هیستون</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>miRNA</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Kumar H, Lund R, Laiho A, Lundelin K, Ley RE, Isolauri E, et al. Gut microbiota as an epigenetic regulator: pilot study based on whole-genome methylation analysis. MBio 2014; 5(6): e02113-e02114.##2.	Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017; 474(11): 1823-1836.##3.	Tarashi S, Siadat SD, Ahmadi Badi S, Zali M, Biassoni R, Ponzoni M, et al. Gut Bacteria and their Metabolites: Which One ##Is the Defendant for Colorectal Cancer? Microorganisms 2019; 7(11): 561.##4.	Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007; 128(4): 669-681.##5.	Waddington CH. The epigenotype. Int J Epidemiol 2012; 41(1): 10-13.##6.	Kim J, Samaranayake M, Pradhan S. Epigenetic mechanisms in mammals. Cellular and Molecular Life Sciences 2009; 66(4): 596.##7.	Bártová E, Krejčí J, Harničarová A, Galiová G, Kozubek S. Histone modifications and nuclear architecture: a review. Journal of Histochemistry &#38; Cytochemistry 2008; 56(8): 711-721.##8.	Chen Z, Zhang Y. Role of mammalian DNA methyltransferases in development. Annual Review of Biochemistry 2019; 89: 135-158.##9.	Yao Q, Chen Y, Zhou X. The roles of microRNAs in epigenetic regulation. Current Opinion in Chemical Biology 2019; 51: 11-17.##10.	Bierne H, Hamon M, Cossart P. Epigenetics and bacterial infections. Cold Spring Harbor Perspectives in Medicine 2012; 2(12): a010272.##11.	Miro Blanch J, Yanes O. Epigenetic regulation at the interplay between gut microbiota and host metabolism. Front Genet 2019; 10: 638.##12.	Tarashi S, Badi SA, MoshiriA, Nasehi M, Fateh A, Vaziri F, et al. The human microbiota in pulmonary tuberculosis: Not so innocent bystanders. Tuberculosis 2018; 113: 215-221.##13.	Macpherson AJ, de Agüero MG, Ganal-Vonarburg SC. How nutrition and the maternal microbiota shape the neonatal immune system. Nature Reviews Immunology 2017; 17(8): 508-517.##14.	Cuevas-Sierra A, Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Martinez JA. Diet, gut microbiota, and obesity: links with host genetics and epigenetics and potential applications. Advances in Nutrition 2019; 10(suppl_1): S17-S30.##15.	Ansari I, Raddatz G, Gutekunst J, Ridnik M, Cohen D, Abu-Remaileh M, et al. The microbiota programs DNA methylation to control intestinal homeostasis and inflammation. Nature Microbiology 2020; 5(4): 610-619.##16.	LouisP, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environmental Microbiology 2017; 19(1): 29-41.##17.	Watson MM, Søreide K. The Gut Microbiota Influence on Human Epigenetics, Health, and Disease.  Handbook of Epigenetics: Elsevier; 2017: 495-510.##18.	Obata Y, Furusawa Y, Hase K. Epigenetic modifications of the immune system in health and disease. Immunology and Cell Biology 2015; 93(3): 226-232.##19.	Lee Y-S, Kim T-Y, Kim Y, Lee S-H, Kim S, Kang SW, etal. Microbiota-derived lactate accelerates intestinal stem-cell-mediated epithelial development. Cell Host &#38; Microbe 2018; 24(6): 833-846. e6.##20.	Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nature Reviews Genetics 2012; 13(4): 260-270.##21.	Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cellular Microbiology 2014; 16(7): 1024-1033.##22.	Aleksandrova K, Romero Mosquera B, Hernandez V. Diet, gut microbiome and epigenetics: emerging links with inflammatory bowel diseases and prospects for management and prevention. Nutrients 2017; 9(9): 962.##23.	Paul B, Barnes S, Demark Wahnefried W, Morrow C, Salvador C, Skibola C, et al. Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clinical Epigenetics 2015; 7(1): 112.##24.	Sharma M, Li Y, Stoll ML, Tollefsbol TO. The epigenetic connection between the gut microbiome in obesity and diabetes. Front Genet 2019; 10: 1329.##25.	Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gutmicrobes associated with obesity. Nature 2006; 444(7122): 1022-1023.##26.	Nieuwdorp M, Gilijamse PW, Pai N, Kaplan LM. Role of the microbiome in energy regulation and metabolism. Gastroenterology 2014; 146(6): 1525-1533.##27.	Remely M, Aumueller E, Merold C, Dworzak S, Hippe B, Zanner J, etal. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene 2014; 537(1): 85-92.##28.	Noureldein MH, Bitar S, Youssef N, Azar S, Eid AA. Butyrate modulates diabetes-linked gut dysbiosis: epigenetic and mechanistic modifications. Journal of Molecular Endocrinology 2020; 64(1): 29-42.##29.	Canani RB, Di Costanzo M, Leone L. The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. Clinical Epigenetics 2012; 4(1): 1-7.##30.	Meijer K, de Vos P, Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Current Opinion in Clinical Nutrition &#38; Metabolic Care 2010; 13(6): 715-721.##31.	AunanJ, Watson M, Hagland H, Søreide K. Molecular and biological hallmarks of ageing. British Journal of Surgery 2016; 103(2): e29-e46.##32.	Collins D, Hogan AM, Winter DC. Microbial and viral pathogens in colorectal cancer. The Lancet Oncology 2011; 12(5): 504-512.##33.	Bultman SJ. Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer. Molecular Nutrition &#38; Food Research 2017; 61(1): 1500902.##34.	Irrazábal T, Belcheva A, Girardin SE, Martin A, Philpott DJ. The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell 2014; 54(2): 309-320.##35.	Hullar MA, Fu BC. Diet, the gut microbiome, and epigenetics. Cancer J 2014; 20(3): 170-175.##36.	Sebastián C, Mostoslavsky R. Untangling the fiber yarn: butyrate feeds Warburg to suppress colorectal cancer. Cancer Discovery 2014; 4(12): 1368-1370.##37.	Donohoe DR, Holley D, Collins LB, Montgomery SA, Whitmore AC, Hillhouse A, et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov 2014; 4(12): 1387-1397.##38.	Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet 2019; 20(2): 109-127.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>مروری بر نقش پروبیوتیک ها در کنترل دیابت</TitleF>
		<TitleE>The Role of Probiotics on Controlling Diabetes Mellitus: An Umbrella Review</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>&#160;سابقه و هدف: با وجود مطالعات متعدد در خصوص اثر پروبیوتیک&#8207;ها در کنترل انواع مختلف دیابت، به نظر می&#8207;رسد جمع&#8207;بندی شواهد موجود می&#8207;تواند به روشن شدن میزان اثر این دست از مکمل&#8207;های غذایی به کنترل دیابت کمک کند. لذا هدف از مطالعه حاضر، بررسی نقش پروبیوتیک&#8207;ها بر کنترل شاخص وضعیت گلیسمی و سایر عوامل بیوشیمیایی در بیماران مبتلا به دیابت می&#8207;باشد.
مواد و روش&#8204;ها: مطالعه حاضر یک مطالعه مروری چتری (Umbrella review) است که در آن مطالعات مرور سیستماتیک، متاآنالیز، مطالعات مرور سیستماتیک و متاآنالیزی که اثرات پروبیوتیک&#8207;ها را در انواع دیابت مورد بررسی قرار داده بودند، به زبان انگلیسی و فارسی در دو پایگاه الکترونیکی Pubmed و Scopus تا انتهای سپتامبر 2020 جمع&#8207;آوری شدند.
یافته&#8204;ها: در نهایت31 مطالعه واجد شرایط شناسایی شدند. در این مطالعات تاثیر مصرف مکمل یا مواد غذایی غنی شده با پروبیوتیک بر شاخص&#8207;های متابولیسم قند (18 مطالعه)، پروفایل لیپیدی (12 مطالعه)، عوامل التهابی و استرس اکسیداتیو (11 مطالعه)، فشار خون (4 مطالعه) و BMI (2 مطالعه) در بیماران دیابت نوع 2 و دیابت بارداری مورد بررسی قرار گرفته بود.
استنتاج: نتایج مطالعه حاضر حاکی از اثرات مثبت مکمل&#8207;یاری با پروبیوتیک بر وضعیت گلیسمی، لیپیدی، فشارخون، وضعیت استرس اکسیداتیو و التهابی در بیماران مبتلا به دیابت نوع 2 و دیابت بارداری می&#8207;باشد. اما به دلیل هتروژنیتی بالا در برخی از شاخص&#8207;های بررسی شده، انجام مطالعات کارآزمایی بالینی دوسوکور با کیفیت متدولوژی بالا می&#8207;تواند به روشن شدن اثربخشی کمک کند.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>&#160;Background and purpose: There are some evidences about the effects of probiotics on controlling different types of diabetes and reviewing these studies could be of great help in clarifying the efficacy of these dietary supplements in management of diabetes. Thus, we aimed to review the role of probiotics on glycemic control and other biochemical parameters in patients with diabetes.
Materials and methods: An umbrella review of systematic reviews, meta-analyses, systematic reviews and meta-analysis in English and Persian were performed by thorough search in PubMed and Scopus. Eligible studies on the effects of probiotics in patients with diabetes published up to 30 September 2020 were selected.
Results: Thirty one eligible papers were identified. In these studies, the effects of probiotic supplements or probiotic food products on glycemic status (n=18), lipid profile (n=12), inflammatory and oxidative stress factors (n=11), blood pressure (n=4), and Body Mass Index (n=2) in patients with type 2 diabetes and gestational diabetes were investigated.
Conclusion: Findings revealed positive effects of probiotic supplements on glycemic status, lipid profile, blood pressure, oxidative stress and inflammation in patients with type 2 diabetes, and gestational diabetes. However, due to high heterogeneity in some parameters, further high quality double-blind clinical trials can shed light on the effectiveness of these supplements.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>47</FPAGE>
			<TPAGE>58</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/29
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/8/8
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/6
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/16
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>نازلی</Name>
				<MidName></MidName>
				<Family>نمازی</Family>
				<NameE>Nazli</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Namazi</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات دیابت، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>nazli.namazi@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>زهره</Name>
				<MidName></MidName>
				<Family>سجادی هزاوه</Family>
				<NameE>Zohreh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sajjadi Hazaveh</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکترای تغذیه، مرکز تحقیقات سرطان، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>zohre_sjd@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>الهام</Name>
				<MidName></MidName>
				<Family>اختری</Family>
				<NameE>Elham</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Akhtari</FamilyE>
				<Organizations>
				<Organization>استادیار، دانشکده طب ایرانی، دانشگاه علوم پزشکی ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>eli.akhtari@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمدحسین</Name>
				<MidName></MidName>
				<Family>آیتی</Family>
				<NameE>Mohammad Hossein</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ayati</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mh-ayati@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>باقر</Name>
				<MidName></MidName>
				<Family>لاریجانی</Family>
				<NameE>Bagher</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Larijani</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>larijanib@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>probiotics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>diabetes mellitus</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>oxidative stress</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>inflammation</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>lipid profile</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پروبیوتیک</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>دیابت</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>استرس اکسیداتیو</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>التهاب</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>لیپید</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Ho J, Nicolucci AC, Virtanen H, Schick A, Meddings J, Reimer RA, et al. Effect of Prebiotic on Microbiota, Intestinal Permeability, and Glycemic Control in Children With Type 1 Diabetes. J Clin Endocrinol Metab 2019; 104(10): 4427-4440.##2.	Brugman S, Klatter F, Visser J, Wildeboer-Veloo A, Harmsen H, Rozing J, et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 2006; 49(9): 2105-2108.##3.	Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013; 34(1): 39-58.##4.	Saad MJA, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology 2016; 31(4): 283-293##5.	Li X, Watanabe K, Kimura I. Gut microbiota dysbiosis drives and implies novel therapeutic strategies for diabetes mellitus and related metabolic diseases. Front Immunol 2017; 8: 1882.##6.	Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50(11): 2374-2383.##7.	Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58(8): 1091-1103.##8.	Mujico JR, Baccan GC, Gheorghe A, Díaz LE, Marcos A. Changes in gut microbiota due to supplemented fatty acids in diet-induced obese mice. Br J Nutr 2013; 110(4): 711-720.##9.	Sergeev IN, Aljutaily T, Walton G, Huarte E. Effects of synbiotic supplement on human gut microbiota, body composition and weight loss in obesity. Nutrients 2020; 12(1): 222.##10.	Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes 2014; 5(1): 3-17.##11.	Dehghan P, Gargari BP, Jafar-Abadi MA. Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition 2014; 30(4): 418-423.##12.	LeBlanc JG, Chain F, Martín R, Bermúdez-Humarán LG, Courau S, Langella P. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb Cell Fact 2017; 16(1): 79.##13.	Akbari V, Hendijani F. Effects of probiotic supplementation in patients with type 2 diabetes: systematic review and meta-analysis. Nutr Rev 2016; 74(12): 774-784.##14.	Zhang J, Ma S, Wu S, Guo C, Long S, Tan H. Effects of Probiotic Supplement in Pregnant Women with Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Diabetes Res 2019; 2019: 5364730.##15.	Kasińska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a meta-analysis. Pol Arch Med Wewn 2015; 125(11): 803-813.##16.	Yao K, Zeng L, He Q, Wang W, Lei J, Zou X. Effect of probiotics on glucose and lipid metabolism in type 2 diabetes mellitus: a meta-analysis of 12 randomized controlled trials. Med Sci Monit 2017; 23: 3044-3053.##17.	Nikbakht E, Khalesi S, Singh I, Williams LT, West NP, Colson N. Effect of probiotics and synbiotics on blood glucose: a systematic review and meta-analysis of controlled trials. Eur J Nutr 2018; 57(1): 95-106.##18.	Kazemi A, Soltani S, Ghorabi S, Keshtkar A, Daneshzad E, Nasri F, et al. Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. Clin Nutr 2020; 39(3): 789-819.##19.	Bezerra AN, Carvalho NS, Viana ACC, Morais SR. Effect of probiotics supplementation in diabetes mellitus: A systematic review. Revista HUPE 2016; 15(2): 129-139.##20.	Koczarski M. The Effect of Probiotic Supplementation on Glycemic Control in Women With Gestational Diabetes Mellitus: A Systematic Review. Top Clin Nutr 2020; 35(3): 270-276.##21.	Razmpoosh E, Javadi M, Ejtahed HS, Mirmiran P. Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review. Diabetes Metab Res Rev 2016; 32(2): 143-168.##22.	Vlachou E, Ntikoudi A, Govina O, Lavdaniti M, Kotsalas N, Tsartsalis A, et al. Effects of Probiotics on Diabetic Nephropathy: A Systematic Review. Curr Clin Pharmacol 2020; 15(3): 234-242.##23.	Ardeshirlarijani E, Tabatabaei-Malazy O, Mohseni S, Qorbani M, Larijani B, Jalili RB. Effect of probiotics supplementation on glucose and oxidative stress in type 2 diabetes mellitus: A meta-analysis of randomized trials. DARU J Pharm Sci 2019: 27: 827-837.##24.	Chen Y, Yue R, Zhang B, Li Z, Shui J, Huang X. Effects of probiotics on blood glucose, biomarkers of inflammation and oxidative stress in pregnant women with gestationaldiabetes mellitus: A meta-analysis of randomized controlled trials. Med Clin 2020; 154(6): 199-206.##25.	He J, Zhang F, Han Y. Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: a meta-analysis of RCTs. Medicine 2017; 96(51): e9166.##26.	Hu YM, Zhou F, Yuan Y, Xu YC. Effects of probiotics supplement in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. Medicina Clínica 2017; 148(8): 362-370.##27.	Jafar-Abadi MA, Dehghani A, Khalili L, Barzegar A, Mesrizad M, Hassanalilou T. A meta-analysis of randomized controlled trials of the effect of probiotic food or supplement on glycemic response and body mass index in patients with type 2 diabetes, updating the evidence. Curr Diabetes Rev 2020. Online ahead of print.##28.	Kocsis T, Molnár B, Németh D, Hegyi P, Szakács Z, Bálint A, et al. Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. Sci Rep 2020; 10(1): 11787.##29.	Li C, Li X, Han H, Cui H, Peng M, Wang G, et al. Effect of probiotics on metabolic profiles in type 2 diabetes mellitus: A meta-analysis of randomized, controlled trials. Medicine 2016; 95(26): e 4088.##30.	Liang T, Wu L, Xi Y, Li Y, Xie X, Fan C, et al. Probiotics supplementation improves hyperglycemia, hypercholesterolemia, and hypertension in type 2 diabetes mellitus: An update of meta-analysis. Crit Rev Food Sci Nutr 2020: 1-19.##31.	Tao YW, Gu YL, Mao XQ, Zhang L, Pei YF. Effects of probiotics on type II diabetes mellitus: a meta-analysis. J Transl Med 2020; 18(1): 30.##32.	AbdelQadir YH, Hamdallah A, Sibaey EA, Hussein AS, Abdelaziz M, AbdelAzim A, et al. Efficacy of probiotic supplementation in patientswith diabetic nephropathy: A systematic review and meta-analysis. Clin Nutr ESPEN 2020; 40: 57-56.##33.	Companys J, Pla-Pagà L, Calderón-Pérez L, Llauradó E, Solà R, Pedret A, et al. Fermented Dairy Products, Probiotic Supplementation, and Cardiometabolic Diseases: A Systematic Review and Meta-analysis. Adv Nutr 2020; 11(4): 834-863.##34.	Hendijani F, Akbari V. Probiotic supplementation for management of cardiovascular risk factors in adults with type II diabetes: A systematic review and meta-analysis. Clin Nutr 2018; 37(2): 532-541.##35.	Jin S, Sha L, Dong J, Yi J, Liu Y, Guo Z, et al. Effects of Nutritional Strategies on Glucose Homeostasis in Gestational Diabetes Mellitus: A Systematic Review and Network Meta-Analysis. J Diabetes Res 2020; 2020: 6062478.##36.	Koutnikova H, Genser B, Monteiro-Sepulveda M, Faurie JM, Rizkalla S, Schrezenmeir J, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2019; 9(3): e017995.##37.	Pan J, Pan Q, Chen Y, Zhang H, Zheng X. Efficacy of probiotic supplement for gestational diabetes mellitus: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2019; 32(2): 317-323.##38.	Samah S, Ramasamy K, Lim SM, Neoh CF. Probiotics for the management of type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract 2016; 118:172-182.##39.	Tabrizi R, Ostadmohammadi V, Lankarani KB, Akbari M, Akbari H, Vakili S, et al. The effects of probiotic and synbiotic supplementation on inflammatory markers among patients with diabetes: A systematic review and meta-analysis of randomized controlled trials. Eur J Pharmacol 2019; 852: 254-264.##40.	Taylor BL, Woodfall GE, Sheedy KE, O'Riley ML, Rainbow KA, Bramwell EL, et al. Effect of Probiotics on Metabolic Outcomes in Pregnant Women with Gestational Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2017; 9(5): 461.##41.	Wang X, Juan QF, He YW, Zhuang L, Fang YY, Wang YH. Multiple effects of probiotics on different types of diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Pediatr Endocrinol Metab 2017; 30(6): 611-622.##42.	Zheng HJ, Guo J, Jia Q, Huang YS, Huang WJ, Zhang W, et al. The effect of probiotic and synbiotic supplementation on biomarkers of inflammation and oxidative stress in diabetic patients: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2019; 142: 303-313.##43.	Mafi A, Namazi G, Soleimani A, Bahmani F, Aghadavod E, Asemi Z. Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. Food Funct 2018; 9(9): 4763-4770.##44.	Dallanora S, Medeiros de Souza Y, Deon RG, Tracey CA, Freitas-Vilela AA, Wurdig Roesch LF, et al. Do probiotics effectively ameliorate glycemic control during gestational diabetes? A systematic review. Arch Gynecol Obstet 2018; 298(3): 477-485.##45.	Okesene-Gafa KA, Moore AE, Jordan V, McCowan L, Crowther CA. Probiotic treatment for women with gestational diabetes to improve maternal and infant health and well-being. Cochrane Database Syst Rev 2020; 6(6): Cd012970.##46.	Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49(5): 821-830.##47.	Badehnoosh B, Karamali M, ZarratiM, Jamilian M, Bahmani F, Tajabadi-Ebrahimi M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med 2018; 31(9): 1128-1136.##48.	Tonucci LB, Dos Santos KMO, de Oliveira LL, Ribeiro SMR, Martino HSD. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin Nutr 2017; 36(1): 85-92.##49.	Kim HI, Kim J-K, Kim J-Y, Jang S-E, Han MJ, Kim D-H. Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 simultaneously alleviate high-fat diet-induced colitis, endotoxemia, liver steatosis, and obesity in mice. Nutr Res 2019; 67: 78-89.##50.	Arora T, Singh S, Sharma RK. Probiotics: interaction with gut microbiome and antiobesity potential. Nutrition 2013; 29(4): 591-596.##51.	An HM, Park SY, Lee DK, Kim JR, Cha MK, Lee SW, et al. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fatdiet-induced obese rats. Lipids Health Dis 2011; 10(1): 116.##52.	Rather SA, Pothuraju R, Sharma RK, De S, Mir NA, Jangra S. Anti obesity effect ##of feeding probiotic dahi containing Lactobacillus casei NCDC 19 in high fat diet induced obese mice. Int J Dairy Technol 2014; 67(4): 504-509.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>نقش پروبیوتیک ها در کنترل زخم عفونی پای دیابتی</TitleF>
		<TitleE>The Role of Probiotics in Management of Infected Diabetic Foot Ulcers</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>&#160;زخم عفونی پای دیابتی یکی از عوامل شایع بروز آمپوتاسیون غیرتروماتیک اندام تحتانی است ،که برای درمان نیاز به تشخیص مناسب، گرفتن نمونه&#8204;های مناسب برای کشت، انتخاب دقیق آنتی&#8204;بیوتیک، درمان عفونت مبتنی بر شرایط بیماری، تعیین سریع نیاز بیمار به مداخله جراحی و انجام دیگر انواع مراقبت زخم دارد. با توجه به مشکل مقاومت آنتی&#8204;بیوتیکی در درمان زخم عفونی پای دیابتی، استفاده از پروبیوتیک&#8204;ها به&#8204;عنوان میکروارگانیسم&#8204;های غیربیماری&#8204;زایی که می&#8204;تواند در کمک به درمان زخم&#8204;های عفونی کاربرد داشته باشند، مطرح می&#8204;شود. تاثیر پروبیوتیک&#8204;ها بر عملکرد ایمنی بدن، بیماری&#8204;های پوسـتی و دیابـت مورد بررسی قرار گرفته است و شواهد اخیر نشان&#8204;دهنده تاثیر آن&#8204;ها بر زخم&#8204;های عفونی پای دیابتی از طریق مکانیسم&#8204;های احتمالی کمک به کنترل مناسب قندخون، بهبود عملکرد سیستم ایمنی و تعدیل میکروبیوتای بدن می&#8204;باشد. در مقاله مروری حاضر به بررسی نقش پروبیوتیک&#8204;ها در درمان زخم&#8204;های مزمن عفونی پای دیابتی از چند منظر نقش میکروبیوتا در کنترل قندخون و اثر پروبیوتیک&#8204;ها بر روی سیستم ایمنی، مارکرهای التهابی، تسریع بهبود زخم و کنترل عفونت می&#8204;پردازیم. به نظر می&#8204;رسد کاربرد موضعی و خوراکی پروبیوتیک&#8204;ها به ویژه هنگامی که به&#8204;عنوان درمان کمکی با آنتی&#8204;بیوتیک&#8204;ها همراه شود، کاهش عفونت&#8204;های زخم پای دیابتی را در پی&#8204;داشته باشد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>&#160;Diabetic foot ulcer (DFU) is one of the common reasons for non-traumatic amputation of the lower limbs, which requires proper diagnosis, proper collection of specimens, careful selection of antibiotics, treatment of infection based on the disease condition, quick decision about whether or not surgery is necessary and other types of wound care. Probiotics are suggested as non-pathogenic microorganisms due to antibiotic resistance in the treatment of DFU. The effects of probiotics on immune function, skin diseases, and diabetes have been studied and recent evidence suggests their effect on DFU through controlling hyperglycemia, improving immune function, and modulating the microbiota as possible mechanisms. In this review article, we discuss the role of probiotics in healing chronic infected wounds of the diabetic foot from several perspectives including the role of microbiota in glycemic control, the effect of probiotics on the immune system, inflammatory markers, wound healing acceleration, and infection control. Topical application and oral intake of probiotics, especially when used as adjunctive therapies with antibiotics, seems to facilitate the healing process of infected diabetic foot ulcers.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>59</FPAGE>
			<TPAGE>70</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/24
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/9/4
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/6
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/16
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>محمدرضا</Name>
				<MidName></MidName>
				<Family>امینی</Family>
				<NameE>Mohammad Reza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Amini</FamilyE>
				<Organizations>
				<Organization>دکتری پلاسما پزشکی، مرکز تحقیقات دیابت، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>amini80@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مریم</Name>
				<MidName></MidName>
				<Family>اعلاء</Family>
				<NameE>Maryam</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Aalaa</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری آموزش پزشکی، مرکز تحقیقات پزشکی مبتنی بر شواهد، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>aalaamaryam@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>مهناز</Name>
				<MidName></MidName>
				<Family>سنجری</Family>
				<NameE>Mahnaz</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sanjari</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات استئوپروز، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mahnaz.sanjari@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>ندا</Name>
				<MidName></MidName>
				<Family>مهرداد</Family>
				<NameE>Neda</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mehrdad</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات سلامت سالمندان، پژوهشکده علوم جمعیتی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>nmehrdad@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمدرضا</Name>
				<MidName></MidName>
				<Family>مهاجری تهرانی</Family>
				<NameE>Mohammad Reza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mohajeri Tehrani</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mmohajeri@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>هانیه السادات</Name>
				<MidName></MidName>
				<Family>اجتهد</Family>
				<NameE>Hanieh-Sadat</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ejtahed</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران   مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haniejtahed@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>diabetic foot ulcer</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>infection</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>probiotics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>زخم پای دیابتی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>عفونت</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پروبیوتیک</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers in the diabetic patient, prevention and treatment. Vasc Health Risk Manag 2007; 3(1): 65-76.##2.	Fallah F, Eslami G, Khoshnevis J, Goudarzi H, Habibi M, Azargashb E. Isolation of anaerobic, aerobic bacteria and mycobacterium. Research in Medicine 2006; 30(4): 0 (Persian).##3.	Raspovic KM, Wukich DK. Self-reported quality of life and diabetic foot infections. The Journal of Foot and Ankle Surgery 2014; 53(6): 716-719.##4.	Apelqvist J, Bakker K, Houtum Wv, Nabuurs-Franssen M, Shaper N. International Consensus and practical quidelines on the management and the prevention of the diabetic foot. Internacional Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2000; 16(suppl 1): s84-s92.##5.	Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis 2007; 44(4): 562-565.##6.	Saseedharan S, Sahu M, Chaddha R, Pathrose E, Bal A, Bhalekar P, Sekar P, Krishnan P. Epidemiology of diabetic foot infections in a reference tertiary hospital in India. Braz J Microbiol 2018; 49(2): 401-406.##7.	Jneid J, Cassir N, Schuldiner S, Jourdan N, Sotto A, Lavigne JP, La Scola B. Exploring the microbiota of diabetic foot infections with culturomics. Front Cell Infect Microbiol 2018; 8: 282.##8.	Fuchs-Tarlovsky V, Marquez-Barba MF, Sriram K. Probiotics in dermatologic practice. Nutrition 2016; 32(3): 289-295.##9.	Talebi Taher M , Abasi M , Barati M1. The study of diabetic foot infection: bacteriology, antimicrobial resistance pattern, treatment and outcome in inpatient cases in Rasoul-Akram and Firoozgar hospitals, 2005-2006. Scientific Research Journal of Ardabil University of Medical Sciences 2010; 10(3): 232-240 (Persian).##10.	Edmonds ME, Foster AV, Thompson S. Managing the diabetic foot: Wiley Online Library; 2014.##11.	Paisley AN, Kalavalapalli S, Subudhi CP, Chadwick PR, Chadwick PJ, Young B. Real time presence of a microbiologist in a multidisciplinary diabetes foot clinic. Diabetes Res Clin Pract 2012; 96(1): e1-e3.##12.	Sotto A, Lina G, Richard J-L, Combescure C, Bourg G, Vidal L, et al. Virulence potential of Staphylococcus aureus strains isolated from diabetic foot ulcers: a new paradigm. Diabetes Care 2008; 31(12): 2318-2324.##13.	Tobalem M, Uçkay I. Images in clinical medicine. Evolution of a diabetic foot infection. New Engl J Med 2013; 369(23): 2252.##14.	Abbas M, Uckay I, Lipsky BA. In diabetic foot infections antibiotics are to treat infection, not to heal wounds. Expert Opin Pharmacother 2015; 16(6): 821-832.##15.	Gardner SE, Hillis SL, Frantz RA. Clinical signs of infection in diabetic foot ulcers with high microbial load. Biological Research For Nursing 2009; 11(2): 119-128.##16.	Kallstrom G. Are quantitative bacterial wound cultures useful? J Clin Microbiol 2014; 52(8): 2753-2756.##17.	Lipsky B, Peters E, Senneville E, Berendt A, Embil J, Lavery L, et al. Expert opinion on the management of infections in the diabetic foot. Diabetes/Metabolism Research and Reviews 2012; 28(s1): 163-178.##18.	Schaper N. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev 2004; 20(S1): S90-S95.##19.	Cutting KF, White R. Defined and refined: criteria for identifying wound infection revisited. Br J Community Nurs 2004; 9(3): S6-S15.##20.	Volmer Thole M, Lobmann R. Neuropathy and Diabetic Foot Syndrome. Int J Mol Sci 2016; 17(6): 917.##21.	Aragón Sánchez J. Seminar review: a review of the basis of surgical treatment of diabetic foot infections. Int J Low Extrem Wounds 2011; 10(1): 33-65.##22.	Jneid J, Lavigne JP, La Scola B, Cassir N. The diabetic foot microbiota: a review. Human Microbiome Journal 2017; 5-6: 1-6.##23.	Adamczyk K, Garncarczyk A, Antończak P, Wcisło‐Dziadecka D. The foot microbiome. Journal of Cosmetic Dermatology 2020; 19(5): 1039-1043.##24.	Kong HH, Segre JA. Skin microbiome: looking back to move forward. J Invest Dermatol 2012; 132(3 pt 2): 933-939.##25.	Hannigan GD, Grice EA. Microbial ecology of the skin in the era of metagenomics and molecular microbiology. Cold Spring Harb Perspect Med 2013; 3(12): a015362.##26.	Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science 2009; 326(5960): 1694-1697.##27.	Nakatsuji T, Chiang H-I, Jiang SB, Nagarajan H, Zengler K, Gallo RL. The microbiome extends to subepidermal compartments of normal skin. Nature Communications 2013; 4(1): 1-8.##28.	Jneid J, Lavigne J, La Scola B, Cassir N. The diabetic foot microbiota: a review. Human Microbiome Journal 2017; 5-6: 1-6.##29.	Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature reviews Gastroenterology &#38; Hepatology 2014; 11(8): 506-514.##30.	Ziaeifar E, Goodarzi A, Saki N. The role of microbiota, probiotics and prebiotics in dermatology. Journal of Dermatology and Cosmetic 2019; 10(1): 44-51 (Persian).##31.	Grice EA, Segre JA. The skin microbiome. Nature Reviews Microbiology 2011; 9(4): 244-253.##32.	Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489(7415): 242-249.##33.	Brahe LK, Le Chatelier E, Prifti E, Pons N, Kennedy S, Hansen T, et al. Specific gut microbiota features and metabolic markers in postmenopausal women with obesity. Nutr Diabetes 2015; 5(6): e159.##34.	Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328(5975): 228-231.##35.	Sjögren K, Engdahl C, Henning P, Lerner UH, Tremaroli V, Lagerquist MK, et al. The gut microbiota regulates bone mass in mice. J Bone Mineral Res 2012; 27(6): 1357-1367.##36.	Larsen N, Vogensen FK, Van Den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PloS One 2010; 5(2): e9085.##37.	Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015; 519(7541): 92-96.##38.	Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 2014; 514(7521): 181-186.##39.	Ejtahed HS, Mohtadi Nia J, Homayouni Rad A, Niafar M, Asghari Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 2012; 28(5): 539-543.##40.	Ejtahed H, Mohtadi Nia J, Homayouni Rad A, Niafar M, Asghari Jafarabadi M, Mofid V, et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci 2011; 94(7): 3288-3294.##41.	Prasad J, Gill H, Smart J, Gopal PK. Selection and characterisation of Lactobacillus and Bifidobacterium strains for use as probiotics. International Dairy Journal 1998; 8(12): 993-1002.##42.	Shoelson S, Lee J, Goldfine AB. Inflammation and insulin resistance J Clin Invest 2006; 116: 1793-1801.##43.	Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27(3): 813-823.##44.	Razmpoosh E, Javadi M, Ejtahed HS, Mirmiran P. Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review. Diabetes Metab Res Rev 2016; 32(2): 143-168.##45.	Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, etal. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50(11): 2374-2383.##46.	Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011; 60(11): 2775-2286.##47.	Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation ##in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58(8): 1091-1103.##48.	Watters C, Yuan TT, Rumbaugh KP. Beneficial and deleterious bacterial-host interactions in chronic wound pathophysiology. University of Texas at Austin Austin United States 2015.##49.	Sekhar MS, Unnikrishnan M, Vijayanarayana K, Rodrigues GS, Mukhopadhyay C. Topical application/formulation of probiotics: will it be a novel treatment approach for diabetic foot ulcer? Med Hypotheses 2014; 82(1): 86-88.##50.	Peral M, Rachid M, Gobbato N, Martinez MH, Valdez J. Interleukin-8 production by polymorphonuclear leukocytes from patients with chronic infected leg ulcers treated with Lactobacillus plantarum. Clin Microbiol Infec 2010; 16(3): 281-286.##51.	Liévin-Le Moal V, Servin AL. Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clinical Microbiology Reviews 2014; 27(2): 167-199.##52.	Moubareck C, Gavini F, Vaugien L, Butel M, Doucet-Populaire F. Antimicrobial susceptibility of bifidobacteria. Journal of Antimicrobial Chemotherapy 2005; 55(1): 38-44.##53.	Usami M, Miyoshi M, Kanbara Y, Aoyama M, Sakaki H, Shuno K, et al. Effects of perioperative synbiotic treatment on infectious complications, intestinal integrity, and fecal flora and organic acids in hepatic surgery with or without cirrhosis. J Parenter Enteral Nutr 2011; 35(3): 317-328.##54.	Rehman A, Heinsen F-A, Koenen ME, Venema K, Knecht H, Hellmig S, et al. Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine. BMC Microbiology 2012; 12(1): 47.##55.	Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, et al. Compartmentalized control of skin immunity by resident commensals. Science 2012; 337(6098): 1115-1119.##56.	Spichler A, Hurwitz BL, Armstrong DG, Lipsky BA. Microbiology of diabetic foot infections: from Louis Pasteur to ‘crime scene investigation’. BMC Medicine 2015; 13(1): 2.##57.	Strugeon E, Tilloy V, Ploy MC, Da Re S. The stringent response promotes antibiotic resistance dissemination by regulating integron integrase expression in biofilms. MBio 2016; 7(4).##58.	Santos R, Veiga AS, Tavares L, Castanho M, Oliveira M. Bacterial biofilms in diabetic foot ulcers: potential alternative therapeutics. Microbial Biofilms–Importance and Applications. 2016: 251-269.##59.	Fijan S, Frauwallner A, Langerholc T, Krebs B, ter Haar née Younes JA, Heschl A, et al. Efficacy of using probiotics with antagonistic activity against pathogens of wound infections: An integrative review of literature. BioMed Res Int 2019; 2019: 7585486.##60.	Ringel Y, Quigley EM, Lin HC. Using probiotics in gastrointestinal disorders. American Journal of Gastroenterology Supplements 2012; 1(1): 34-40.##61.	Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109(10): 1547-1561.##62.	Zheng HJ, Guo J, Jia Q, Huang YS, Huang W-J, Zhang W, et al. The effect of probiotic and synbiotic supplementation on biomarkers of inflammation and oxidative stress in diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2019; 142: 303-313.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>مقایسه ی اثر Akkermansia muciniphila زنده و پاستوریزه
در کنترل چاقی و دیابت</TitleF>
		<TitleE>Comparing the Effects of Live and Pasteurized Akkermansia muciniphila on Management of Obesity and Diabetes</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>&#160;سابقه و هدف: دیابت و چاقی از جمله مهم&#8204;ترین بیماری&#8204;های متابولیک است که همواره نگرانی&#8204;هایی را در سطح جهانی به همراه دارد. امروزه نقش کلیدی تنوع و ترکیب میکروبیوتای روده در بروز و کنترل بیماری&#8204;های متابولیک از طریق تنظیم متابولیسم و پاسخ&#8204;&#8204;های ایمنی میزبان، به اثبات رسیده است. در مطالعات پیشین ارتباط میان باکتری Akkermansia muciniphila، باکتری موجود در میکروبیوتای روده با چاقی و دیابت مورد توجه قرار گرفته است. مطالعات انسانی و حیوانی نشان داده اند که این باکتری تجزیه&#8204;کننده موسین از طریق کاهش نفوذپذیری دیواره روده و پیشگیری از بروز اندوتوکسمی متابولیک و التهاب، همچنین تعدیل متابولیسم انرژی و چربی، در پیشگیری از چاقی و دیابت موثر است. شواهد جدید نشان داده&#8204;اند علاوه بر باکتری زنده Akkermansia muciniphila، فرم پاستوریزه آن نیز قابلیت کنترل بیماری را دارد. با توجه به دشواری&#8204;های زنده&#8204;مانی و کشت این باکتری غیرهوازی و در راستای کمک به استفاده&#8204;ی بهینه از باکتری Akkermansia muciniphila در درمان&#8204;های بالینی بیماری&#8204;های متابولیک، این مطالعه مروری با هدف مقایسه اثر Akkermansia muciniphila زنده و پاستوریزه به بررسی اثرات این باکتری به عنوان پروبیوتیک&#8204; نسل جدید در کنترل بیماری&#8204;های چاقی و دیابت پرداخته است.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>&#160;Diabetes and obesity are among the most important metabolic disorders which are of worldwide concern. Today, it has been proven that the diversity and composition of the intestinal microbiota play a key role in the incidence and control of metabolic diseases via regulating the metabolism and immune responses of the host. Previous studies reported links between Akkermansia muciniphila, a commensal bacterium in the gut microbiota, and obesity and diabetes. Human and animal studies have shown that this mucin-degrading bacterium is effective in preventing obesity and diabetes by reducing intestinal wall permeability and preventing metabolic endotoxemia and inflammation, as well as modulating energy and fat metabolism. New evidence shows that both forms of the A. muciniphila (live bacterium or its pasteurized form) can control the disease. Considering the difficulties of the survival and cultivation of this anaerobic bacterium and in order to help optimal use of A. muciniphila in clinical treatments of metabolic diseases, in this study we compared the effect of live and pasteurized A. muciniphila. Besides, we investigated the effects of this bacterium as the next generation of probiotics on obesity and management of diabetes.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>71</FPAGE>
			<TPAGE>83</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/242020/11/21
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/9/1
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/62020/12/9
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/19
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>عارفه</Name>
				<MidName></MidName>
				<Family>شهریاری</Family>
				<NameE>Arefeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shahriary</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد میکروبیولوژی، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران   گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی، انستیتو پاستور ایران، تهران، ایران.</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>a.sh.shaparak@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>زهرا</Name>
				<MidName></MidName>
				<Family>حسینی توسل</Family>
				<NameE>Zahra</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hoseini-Tavassol</FamilyE>
				<Organizations>
				<Organization>گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی، انستیتو پاستور ایران، تهران، ایران.   دانشجوی دکترای بیوتکنولوژی پزشکی، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>zhtavassol@Gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>احمدرضا</Name>
				<MidName></MidName>
				<Family>سروش</Family>
				<NameE>Ahmad-Reza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Soroush</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Soroush1344@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>هانیه السادات</Name>
				<MidName></MidName>
				<Family>اجتهد</Family>
				<NameE>Hanieh-Sadat</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ejtahed</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران    مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران.</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haniejtahed@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>باقر</Name>
				<MidName></MidName>
				<Family>لاریجانی</Family>
				<NameE>Bagher</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Larijani</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Larijanib@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Akkermansia muciniphila</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>obesity</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>diabetes</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>pasteurization</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>probiotics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>باکتری Akkermansia muciniphila</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>چاقی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>دیابت</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پاستوریزاسیون</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پروبیوتیک نسل جدید</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89(6): 2595-2600.##2.	Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008; 93(11 suppl 1): S9-S30.##3.	Romaní-Pérez M, Agusti A, Sanz Y. Innovation in microbiome-based strategies for promoting metabolic health. Curr Opin Clin Nutr Metab Care 2017; 20(6): 484-491.##4.	Ejtahed HS, Soroush AR, Angoorani P, Larijani B, HasaniRanjbar S. Gut microbiota as a target in the pathogenesis of metabolic disorders: a new approach to novel therapeutic agents. Horm Metab Res 2016; 48(06): 349-358.##5.	Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut 2014; 63(9): 1513-1521.##6.	Ejtahed H-S, Hoseini-Tavassol Z, Khatami S, Zangeneh M, Behrouzi A, Badi SA, et al. Main gut bacterial composition differs between patients with type 1 and type 2 diabetes and non-diabetic adults. J Diabetes Metab Disord 2020: 265-271.##7.	Ashrafian F, Behrouzi A. Comparative study of effect of Akkermansia muciniphila and its extracellular vesicles on toll-like receptors and tight junction. Gastroenterology and Hepatology from Bed to Bench 2019; 12(2): 163.##8.	Munro N. Gut microbiota: its role in diabetes and obesity. Diabetes &#38; Primary Care 2016; 18(4): 1-6.##9.	Ursell LK, Clemente JC, Rideout JR, Gevers D, Caporaso JG, Knight R. The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. J Allergy Clin Immunol 2012; 129(5): 1204-1208.##10.	Ho JT, Chan GC, Li JC. Systemic effects of gut microbiota and its relationship with disease and modulation. BMC Immunol 2015; 16: 21##11.	Xu X, Wang Z, Zhang X. The human microbiota associated with overall health. Crit Rev Biotechnol 2015; 35(1): 129-140.##12.	Hur KY, Lee MS. Gut microbiota and metabolic disorders. Diabetes Metab J 2015; 39(3): 198-203.##13.	Cani PD, Geurts L, Matamoros S, Plovier H, Duparc T. Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond. Diabetes Metab2014; 40(4): 246-257.##14.	Kamneva OK, Knight SJ, Liberles DA, Ward NL. Analysis of genome content evolution in PVC bacterial super-phylum: assessment of candidate genes associated with cellular organization and lifestyle. Genome Biol Evol 2012; 4(12): 1375-1390.##15.	Everard A, Cani PD. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 2013; 27(1): 73-83.##16.	Dehghanbanadaki H, Aazami H, Raftar SKA, Ashrafian F, Ejtahed H-S, Hashemi E, et al. Global Scientific Output Trend for Akkermansia muciniphila Research: A Bibliometric and Scientometric Analysis. BMC Med Inform Decis Mak 2020; 20(1): 291.##17.	Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 2013; 110(22): 9066-9071.##18.	Shin NR, Lee JC, Lee H-Y, Kim MS, Whon TW, Lee M-S, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 2014; 63(5): 727-735.##19.	Org E, Parks BW, Joo JWJ, Emert B, Schwartzman W, Kang EY, et al. Genetic and environmental control of host-gut microbiota interactions. Genome Res 2015; 25(10): 1558-1569.##20.	Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe−/− mice. Circulation 2016; 133(24): 2434-2446.##21.	Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 2019; 25(7): 1096-1103.##22.	Depommier C, Van Hul M, Everard A, Delzenne NM, De Vos WM, Cani PD. Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice. Gut Microbes 2020: 11(5): 1231-1245.##23.	Jones ML, Martoni CJ, Di Pietro E, Simon RR, Prakash S. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial. Regul Toxicol Pharmacol 2012; 63(2): 313-320.##24.	Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 2004; 54(5): 1469-1476.##25.	Costa M, Stämpfli H, Allen Vercoe E, Weese J. Development of the faecal microbiota in foals. Equine Vet J 2016; 48(6): 681-688.##26.	Derrien M, Van Baarlen P, Hooiveld G, Norin E, Müller M, de Vos WM. Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. Front Microbiol 2011; 2: 166.##27.	Miele L, Giorgio V, Alberelli MA, De Candia E, Gasbarrini A, Grieco A. Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk. Curr Cardiol Rep 2015; 17(12): 1-7.##28.	Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461(7268): 1282-1286.##29.	Collado MC, Laitinen K, Salminen S, Isolauri E. Maternal weight and excessive weight gain during pregnancy modify the immunomodulatory potential of breast milk. Pediatr Res 2012; 72(1): 77-85.##30.	Ottman NA. Host immunostimulation and substrate utilization of the gut symbiont Akkermansia muciniphila. Wageningen: Wageningen University 2015.##31.	Druart C, Plovier H, Van Hul M, Brient A, Phipps KR, de Vos WM, et al. Toxicological safety evaluation of pasteurized Akkermansia muciniphila. J Appl Toxicol 2020; 1-15.##32.	Marvasti FE, Moshiri A, Taghavi MS, Riazi S, Taati M, Sadati SF, et al. The First Report of Differences in Gut Microbiota Composition between Obese and Normal Weight Iranian Subjects. Iranian Biomedical Journal 2020; 24(3): 148-154.##33.	Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microbial Pathog 2017; 106: 171-181.##34.	Reunanen J, Kainulainen V, Huuskonen L, Ottman N, Belzer C, Huhtinen H, et al. Akkermansia muciniphila Adheres to Enterocytes and Strengthens the Integrity of the Epithelial Cell Layer. Appl Environ Microbiol 2015; 81(11): 3655-3662.##35.	Fändriks L. Roles of the gut in the metabolic syndrome: an overview. J Intern Med 2017; 281(4): 319-336.##36.	Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PloS One 2011; 6(10): e25792.##37.	Siljander H, Honkanen J, Knip M. Microbiome and type 1 diabetes. EBioMedicine 2019; 46: 512-521.##38.	Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, et al. Mucolytic Bacteria With Increased Prevalence in IBD Mucosa AugmentIn VitroUtilization of Mucin by Other Bacteria. Am J Gastroenterol 2010; 105(11): 2420-2428.##39.	Schneeberger M, Everard A, Gómez-Valadés AG, Matamoros S, Ramírez S, Delzenne NM, et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep 2015; 5: 16643.##40.	Gadery Z, Mobassery M, Ostadrahimy AR. Evaluation of Akkermansia muciniphila bacteria in obese and overweight type 2 diabetic patients treated with insulin or oral hypoglycemic agents comparing with healthy subjects. Med J Tabriz Uni Med Sciences Health Services 2020; 42(3): 303-318.##41.	Neef A, Sanz Y. Future for probiotic science in functional food and dietary supplement development. Curr Opin Clin Nutr Metab Care 2013; 16(6): 679-687.##42.	van Baarlen P, Wells JM, Kleerebezem M. Regulation of intestinal homeostasis and immunity with probiotic lactobacilli. Trends Immunol 2013; 34(5): 208-215.##43.	Greer RL, Dong X, Moraes ACF, Zielke RA, Fernandes GR, Peremyslova E, et al. Akkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism. Nat Commun 2016; 7(1): 1-13.##44.	Zhao S, Liu W, Wang J, Shi J, Sun Y, Wang W, et al. Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice. J Mol Endocrinol 2017; 58(1): 1-14.##45.	Ashrafian F, Shahryari A, Behrouzi A, Moradi HR, Lari A, Hadifar S, et al. Akkermansia muciniphila-derived extracellular vesicles as a mucosal delivery vector for amelioration of obesity in mice. Front Microbiol 2019; 10: 2155.##46.	Wu F, Guo X, Zhang M, Ou Z, Wu D, Deng L, et al. An Akkermansia muciniphila subtype alleviates high-fat diet-induced metabolic disorders and inhibits the neurodegenerative process in mice. Anaerobe 2020; 61: 102138.##47.	Yang M, Bose S, Lim S, Seo J, Shin J, Lee D, et al. Beneficial Effects of Newly Isolated Akkermansia muciniphila Strains from the Human Gut on Obesity and Metabolic Dysregulation. Microorganisms 2020; 8(9): 1413.##48.	Shin J, Noh J-R, Chang D-H, Kim Y-H, Kim MH, Lee ES, et al. Elucidation of Akkermansia muciniphila probiotic traits driven by mucin depletion. Front Microbiol 2019; 10: 1137.##49.	Sakai T, Taki T, Nakamoto A, Shuto E, Tsutsumi R, Toshimitsu T, et al. Lactobacillus plantarum OLL2712 regulates glucose metabolism in C57BL/6 mice fed a high-fat diet. J Nutr Sci Vitaminol (Tokyo) 2013; 59(2): 144-147.##50.	Peng GC, Hsu CH. The efficacy and safety of heat killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house dust mite. Pediatr Allergy Immunol 2005; 16(5): 433-438.##51.	Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, et al. A purified mem4brane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 2017; 23(1): 107-113.##52.	Zhang L, Carmody RN, Kalariya HM, Duran RM, Moskal K, Poulev A, et al. Grape proanthocyanidin-induced intestinal bloom of Akkermansia muciniphila is dependent on its baseline abundance and precedes activation of host genes related to metabolic health. J Nutr Biochem 2018; 56: 142-151.##53.	Lawenius L, Scheffler JM, Gustafsson KL, Henning P, Nilsson KH, Colldén H, et al. Pasteurized Akkermansia muciniphila protects from fat mass gain but not from bone loss. Am J Physiol Endocrinol Metab 2020; 318(4): E480-E491.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>تأثیر میکروبیوتای روده بر پاسخ به واکسن ها</TitleF>
		<TitleE>Impact of the Gut Microbiota on Vaccine Responses</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>عدم پاسخ&#8204;دهی یا پاسخ&#8204;دهی ضعیف به واکسن&#8204;ها به عنوان چالش برانگیزترین مسئله در تولید واکسن محسوب می&#8204;شود، و چندین مطالعه برای یافتن دلایل بالقوه آن صورت گرفته است. از آن&#8204;جا که میکروبیوم روده نقشی اساسی در تنظیم و توسعه سیستم ایمنی دارد، به&#8204;نظر می&#8204;رسد ترکیب و تنوع میکروبیوتا در افراد مختلف و از سوی دیگر برهم خوردن تعادل جمعیت میکروبی روده (Dysbiosis)، می&#8204;تواند به عنوان اثرگذارترین فاکتورها بر روی واکنش&#8204;های سیستم ایمنی بدن در پاسخ به واکسن&#8204;های مختلف درنظر گرفته شود. در این مطالعه مروری، مطالعات مربوط به روابط بین میکروبیوم روده و پاسخ ایمنی به واکسن&#8204;ها بررسی شده است.
تاکنون مشخص شده است که فراوانی نسبی بالاتر فایلوم&#8204;های Actinobacteria و Firmicutes می&#8204;تواند پاسخ ایمنی موثرتری را نسبت به واکسن&#8204;ها القاء نماید. درمقابل، فراوانی نسبی بالاتر Proteobacteria و Bacteroidetes در پاسخ&#8204;های ایمنی ضعیف به واکسن&#8204;ها، گزارش شده است. با توجه به تعامل قوی مابین توسعه سیستم ایمنی بدن و ترکیب میکروبیوتا در طول زندگی، تعیین زمان دقیق آزمایش و استفاده از دقیق&#8204;ترین متدها در مطالعات، از جمله تعیین توالی کل ژنوم و تعیین توالی نسل بعد (Next generation sequencing)، از اهمیت ویژه&#8204;ای برخوردار است. با این حال، تفسیر نتایج این نوع مطالعات، به تفاوت&#8204;ها در طراحی مطالعه مانند انتخاب معیارهای ورود وخروج داوطلبان به مطالعه، زمان نمونه&#8204;گیری براساس زمان واکسیناسیون و متدهایی که برای بررسی در هر مطالعه بکار گرفته می&#8204;شوند، بستگی دارد.
این ملاحظات می&#8204;توانند به نتایجی قابل اتکاءتر و درکی بهتر از تقابل بین میکروبیوتا و پاسخ ایمنی به واکسن&#8204;ها منجر شود، که به نوبه خود به بهبود کارایی واکسن&#8204;ها منتهی خواهد شد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Non-responsiveness or poor responsiveness to vaccines are challenging issues in vaccine development, and efforts have been made to find out the potential reasons for these conditions. Intestinal microbiome plays a key role in regulating and development of immune system and the composition and diversity of microbiota in different individuals on the one hand, and the imbalance of intestinal microbial population (Dysbiosis) on the other hand, could be considered as the most effective factors on the human immune system&#8217;s response to vaccines. Herein, we reviewed studies on the relationships between gut microbiome and immune response to vaccines. It is known that higher relative abundance of Actinobacteria and Firmicutes could induce more effective immune response to vaccines. In contrast, higher relative frequencies of Proteobacteria and Bacteroidetes are reported in weak immune response to vaccines. There is a strong interaction between the development of immune system and the composition of microbiota throughout life, therefore, it is important to determine the best times for examinations and using the most accurate methods, including sequencing the entire genome and Next Generation Sequencing (NGS). However, interpretation of the results of these researches depends on study designs, inclusion/exclusion criteria, timing of sampling according to the time of vaccination, and the methods used in each study. These considerations could lead to more reliable results and provide better understanding on the crosstalk between microbiota and immune response to vaccines, which will consequently improve vaccine efficacy.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>84</FPAGE>
			<TPAGE>102</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/242020/11/212020/10/30
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/8/9
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/62020/12/92021/01/10
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/10/21
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>سحر</Name>
				<MidName></MidName>
				<Family>آذری</Family>
				<NameE>Sahar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Azari</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری تخصصی میکروب شناسی، دانشگاه آزاد اسلامی واحد علوم و تحقیقات، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>sa.aeruginosa@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>داور</Name>
				<MidName></MidName>
				<Family>سیادت</Family>
				<NameE>Seyed Davar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Siadat</FamilyE>
				<Organizations>
				<Organization>استاد، گروه تحقیقات سل و بیماری های ریوی، انستیتوپاستور ایران، تهران، ایران . مرکز تحقیقات میکروب شناسی، انستیتوپاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>d.siadat@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>پونه</Name>
				<MidName></MidName>
				<Family>رحیمی</Family>
				<NameE>Pooneh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Rahimi</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه هپاتیت و ایدز، انستیتوپاستور ایران، تهران، ایران . مرکز تحقیقات واکسن های ویروسی، انستیتوپاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>pooneh5376@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سارا</Name>
				<MidName></MidName>
				<Family>احمدی بادی</Family>
				<NameE>Sara</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ahmadi Badi</FamilyE>
				<Organizations>
				<Organization>مرکز تحقیقات میکروب شناسی، انستیتوپاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>sarahmadi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمدرضا</Name>
				<MidName></MidName>
				<Family>آقا صادقی</Family>
				<NameE>MohammadReza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Aghasadeghi</FamilyE>
				<Organizations>
				<Organization>استاد، گروه هپاتیت و ایدز، انستیتوپاستور ایران، تهران، ایران.مرکز تحقیقات واکسن های ویروسی، انستیتوپاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mrasadeghi@pasteur.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>گلناز</Name>
				<MidName></MidName>
				<Family>بهرامعلی</Family>
				<NameE>Golnaz</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Bahramali</FamilyE>
				<Organizations>
				<Organization>استادیار، بخش هپاتیت و ایدز، انستیتوپاستور ایران، تهران، ایران.مرکز تحقیقات واکسن های ویروسی، انستیتوپاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>gbahramali@gmail.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>vaccine</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>response</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>dysbiosis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>واکسن</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پاسخ</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>دیس بیوزیس</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Turnbaugh PJ, Ley R E, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome projects. Nature 2007; 449: 804-810.##2.	Kho Z Y, Lal SK. The human gut microbiome—a potential controller of wellness and disease. Front Microbiol 2018; 9: 1835.##3.	Ettehad Marvasti F, Moshiri A, Taghavi MS, Riazi S, Taati M, Sadati SF, et al. The first report of differences in gut microbiota composition between obese and normal weight iranian subjects. Iran Biomed J 2019; 24(3): 148-154.##4.	Ejtahed HS, Tito RY, Siadat SD, Hasani-Ranjbar Sh, Hoseini-Tavassol Z, Rymenans L, et al. Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women: a randomized double-blind clinical trial. Eur J Endocrinol 2019; 180: 165-176.##5.	Hooks KB, O’Malley MA. Dysbiosis and its discontents. MBIO 2017; 8(5): 1492-1417.##6.	Tamburini S, Shen N, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Natr Med 2016; 22: 713-722.##7.	Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. Nutr Rev 2012; 70(Suppl 1): S38-S44.##8.	Matamoros S, Gras-Leguen C, Le Vacon F, Potel G, de La Cochetiere MF. Development of intestinal microbiota in infants and its impact on health. Trends Microbiol 2013; 21(4): 167-173.##9.	Hugon P, Dufour JC, Colson P, Fournier PE, Sallah K, Raoult D. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis 2015; 15(10): 1211-1219.##10.	Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017; 474(11): 1823-1836.##11.	Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol 2005; 11(8): 1131-1140.##12.	Virgin HW. The virome in mammalian physiology and disease. Cell 2014; 157(1): 142-150.##13.	Dalmasso M, Hill C, Ross RP. Exploiting gut bacteriophages for human health. Trends Microbiol 2014; 22(7): 399-405.##14.	Duerkop BA, Hooper LV. Resident viruses and their interactions with the immune system. Nat Immunol 2013; 14(1): 654-659.##15.	Zimmermann P, Curtis N. The influence of the intestinal microbiome on vaccine responses. Vaccine 2018; 36(30): 4433-4439.##16.	Jamieson AM. Influence of the microbiome on response to vaccination. Hum Vaccin Immunother 2015; 11: 2329-2331.##17.	Lynn MA, Tumes DJ, Choo JM, Sribnaia A, Blake SJ, Leong LEX, et al. Early-life antibiotic-driven dysbiosis leads to dysregulated vaccine immune responses in mice. Cell Host Microbe 2018; 23(5): 653-660 e5.##18.	Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, Iwasaki A. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci 2011; 108(13): 5354-53549.##19.	den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013; 54(9): 2325-2340.##20.	Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-450.##21.	Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013; 39(2): 372-385.##22.	Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010; 139(6): 1844-1854.##23.	Huda MN, Lewis Z, Kalanetra KM, Rashid M, Ahmad SM, Raqib R, et al. Stool microbiota and vaccine responses of infants. Pediatrics 2014; 134(2): e362-e372.##24.	Pabst O, Hornef M. Gut microbiota: a natural adjuvant for vaccination. Immunity 2014; 41(3): 349-351.##25.	Brotman RM, Shardell MD, Gajer P, Tracy JK, Zenilman JM, Ravel J, et al. Interplay Between the Temporal Dynamics of the Vaginal Microbiota and Human Papillomavirus Detection. J Infect Dis 2014; 210(11): 1723-1733.##26.	Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease.Cell Microbiol 2014; 16(7): 1024-1033.##27.	Kowarsky M, Camunas-Soler J, Kertesz M, De Vlaminck I, Koh W, Pan W, et al. Numerous uncharacterized and highly divergent microbes which colonize humans are revealed by circulating cell-free DNA. PNAS 2017; 114(36): 9623-9628.##28.	Bjorksten B. Diverse microbial exposure- Consequences for vaccine development. Vaccine 2012; 30(29): 4336-40.##29.	Huttenhower C, Gevers D, Knight R, Abubucker S, Badger J, Chinwalla AT, et al. The Human Microbiome Project (HMP) Structure, function and diversity of the healthy human microbiome. Nature 2012; 486(7402): 207-214.##30.	Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426–437.##31.	Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016; 14: e1002533.##32.	Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science 2016; 352(6285): 539-544.##33.	Nguyen QN, Himes JE, Martinez DR, Permar SR. The Impact of the Gut Microbiota on Humoral Immunity to Pathogens and Vaccination in Early Infancy. PLoS Pathog 2016; 12(12): e1005997.##34.	Kim YG. Microbiota Influences Vaccine and Mucosal Adjuvant Efficacy. Immune Netw 2017; 17(1): 20-24.##35.	Parker EPK, Kampmann B, Kang G, Grassly NC. Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis. J Infect Dis 2014; 210(6): 853-864.##36.	Kaplan JL, Shi HN, Walker WA. The role of microbes in developmental immunologic programming. Pediatr Res 2011; 69: 465-472.##37.	Hattori M, Taylor TD. The Human Intestinal Microbiome: A New Frontier of Human Biology. DNA Res 2009; 16(1): 1-12.##38.	Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012; 489: 231-241.##39.	Lynn DJ, and Pulendran B. The potential of the microbiota to influence vaccine responses. J Leukoc Biol 2018; 103(2): 225-231.##40.	Nyangahu DD, Plumlee C, Wendoh J, Urdahl KB, Jaspan H. Impact Of Gut Microbiota On Vaccine Response In Hiv Exposed Infants.J Immunol 2019; 202(Suppl,1): 72.##41.	Lazar V, Ditu L-M, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, et al. Aspects of Gut Microbiota and Immune System Interactions in Infectious Diseases, Immunopathology, and Cancer. Front Immunol 2018; 9: 1830.##42.	Ciabattini A, Olivieri R, Lazzeri E, Medaglini D. Role of the Microbiota in the Modulation of Vaccine Immune Responses. Front Microbiol 2019; 10: 1-14.##43.	Oh JZ, Ravindran R, Chassaing B, Carvalho FA, Maddur MS, Bower M, et al. TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity 2014; 41(3): 478-492.##44.	Belizário JE, Napolitano M. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front Microbiol 2015; 6: 1050.##45.	Whittle E, Leonard MO, Harrison R, Gant TW, Tonge DP. Multi-method characterization of the human circulating microbiome. Front Microbiol 2018; 9: 3266.##46.	Round JL, Mazmanian SK. Inducible Foxp3‌ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci (PNAS) 2010; 107(27): 12204-12209.##47.	Lamas B, Richard ML, Leducq V, Pham HP, Michel ML Da Costa G, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 2016; 22: 598-605.##48.	Belkaid Y, Harrison OJ. Homeostatic Immunity and the Microbiota. Immunity 2017; 46(4): 562-576.##49.	Karst SM. The influence of commensal bacteria on infection with enteric viruses. Nat Rev Microb 2016; 14(4): 197-204.##50.	Wesemann DR. Microbes and B cell development. Adv Immunol 2015; 125(1): 155-178.##51.	Severson KM, Mallozzi M, Driks A, Knight KL. B cell development in GALT: role of bacterial superantigen-like molecules. J Immunol 2010; 184(12): 6782-6789.##52.	Zeng MY, Cisalpino D, Varadarajan S, Hellman J, Warren HS, Cascalho M, et al. Gut Microbiota-Induced Immunoglobulin G Controls Systemic Infection by Symbiotic Bacteria and Pathogens. Immunity 2016; 44(3): 647-658.##53.	Haynes BF, Shaw GM, Korber B, Kelsoe G, Sodroski J, Hahn BH, et al. HIV-Host Interactions: Implications for Vaccine Design. Cell Host Microbe 2016; 19(3): 292-303.##54.	Williams WB, Liao H-X, Moody MA, Kepler TB, Alam SM, Gao F, et al. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science 2015; 349(6249): aab1253.##55.	Rahimi P, Vahabpour RA, Aghasadeghi MR, Sadat SM, Howaizi N, Mostafavi E, et al. Neutralizing antibody response after intramuscular purified vero cell rabies vaccination (PVRV) in Iranian patients with specific medical conditions. PloS one 2015; 10(10): e0139171.##56.	SjoÈgren YM, Tomicic S, Lundberg A, BoÈttcher MF, BjoÈrksteÂn B, Sverremark-EkstroÈm E, et al. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. Clin Exp Allergy 2009; 39(12):1842-1851.##57.	Rahimi P, Tabatabaie H, Gouya MM, Zahraie M, Mahmudi M, Ziaie A, et al. Characterization of mutations in the VP1 region of Sabin strain type 1 polioviruses isolated from vaccine-associated paralytic poliomyelitis cases in Iran. J Clin Virol 2007; 39(4): 304-307.##58.	Rahimi P, Tabatabaie H, Gouya MM, Mahmudi M, Musavi T, SamimiRad K, et al. Direct identification of non-polio enteroviruses in residual paralysis cases by analysis of VP1 sequences. J Clin Virol 2009; 45(2): 139-141.##59.	Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project. Nature 2019; 569(7758): 641-648.##60.	Pettengill MA, van Haren SD, Li N, Dowling DJ, Bergelson I, Jans J, et al. Distinct TLR-mediated cytokine production and immunoglobulin secretion in human newborn naïve B cells. Innate Immun 2016; 22(6): 433-443.##61.	Mullie C, Yazourh A, Thibault H, Odou MF, Singer E, Kalach N, et al. Increased poliovirus- specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: a randomized, double-blind, placebocontrolled trial. Pediatr Res 2004; 56(5): 791-795.##62.	Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010; 8: 129.##63.	Seekatz AM, Panda A, Rasko DA, Toapanta FR, Eloe-Fadrosh EA, Khan AQ, et al. Differential response of the cynomolgus macaque gut microbiota to Shigella infection. PLoS One 2013; 8(6): e64212.##64.	Eloe-Fadrosh EA, McArthur MA, Seekatz AM, Drabek EF, Rasko DA, Sztein MB, Fraser CM. Impact of oral typhoid vaccination on the human gut microbiota and correlations with S. Typhi-specific immunological responses. PLoS One 2013; 8(4): e62026.##65.	Harris V, Armah G, Fuentes S, Korpela K, De Vos W. The infant gut microbiome correlates significantly with rotavirus vaccine response in rural Ghana. J Infect Dis 2016; 215(1): 34-41.##66.	Harris VC, Armah G, Fuentes S, Korpela K E, Parashar U, Victor JC, et al. Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. J Infect Dis 2017; 215(1): 34-41.##67.	Parker EPK, Praharaj I, Zekavati A, Lazarus RP, Giri S, Operario DJ, et al. Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in south India. Vaccine 2018; 36(2): 264-272.##68.	Harris V, Ali A, Fuentes S, Korpela K, Kazi M, Tate J, et al. Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan. Gut Microbes 2018; 9(2): 93-101.##69.	Lynn MA, Tumes DJ, Choo JM, Sribnaia A, Blake SJ, Leong LEX, et al. Early-life antibiotic-driven dysbiosis leads to dysregulated vaccine immune responses in mice. Cell Host Microbe 2018; 23: 653-660.e5.##70.	Badi SA, Moshiri A, Marvasti FE, Mojtahedzadeh M, Kazemi V, Siadat SD. Extraction and Evaluation of Outer Membrane Vesicles from Two Important GutMicrobiotaMembers, Bacteroides fragilis and Bacteroides thetaiotaomicron. Cell J 2020; 22(3): 344-349.##71.	Ashrafian F, Behrouzi A, Shahriary A, Ahmadi Badi S, Davari M, Khatami S, et al. Comparative study of effect of Akkermansia muciniphila and its extracellular vesicles on toll-like receptors and tight junction. Gastroenterol Hepatol Bed Bench 2019; 12(2): 163-168##72.	Rabiei N, Badi SA, Marvasti FE, Sattari TN, Vaziri F, Siadat SD. Induction effects of Faecalibacterium prausnitzii and its extracellular vesicles on toll-like receptor signaling pathway gene expression and cytokine level in human intestinal epithelial cells. Cytokine 2019; 121: 154718.##73.	Moosavi SM, Akhavan Sepahi A, Mousavi SF, Vaziri F, Siadat SD. The effect of Faecalibacterium prausnitzii and its extracellular vesicles on the permeability of intestinal epithelial cells and expression of PPARs and ANGPTL4 in the Caco-2 cell culture model. J Diabetes Metab Disord 2020. Available at: https://link.springer.com/article/10.1007/s40200-020-00605-1.##74.	Lauener RP, Birchler T, Adamski J, Braun-Fahrländer C, Bufe A, Herz U, etal. Expression of CD14 and Toll-like receptor 2 in farmers’ and non-farmers’ children. Lancet 2002; 360(9331): 465-466.##75.	Smolen KK, Ruck CE, Fortuno ES, Ho K, Dimitriu P, Mohn WW, et al. Pattern recognition receptor-mediated cytokine response in infants across 4 continents. J Allergy Clin Immunol 2014; 133(3): 818-826.e4.##76.	Kim D, Kim Y, Seo S, Kim D, Kamada N, Prescott D, et al. Nod2-mediated recognition of the microbiota is critical for mucosal adjuvant activity of cholera toxin. Nat Med 2016; 22(5): 524-530.##77.	Fujimura KE, and Lynch SV. Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. Cell Host Microbe 2015; 17(5): 592-602.##78.	Panzer AR, and Lynch SV. Influence and effect of the human microbiome in allergy and asthma. Curr Opin Rheumatol 2015; 27(4): 373-380.##79.	Coit P, and Sawalha AH. The human microbiome in rheumatic autoimmune diseases: a comprehensive review. Clin Immunol 2016; 170: 70-79.##80.	Mangin I, Suau A, Gotteland M, Brunser O, Pochart P. Amoxicillin treatment modifies the composition of Bifidobacterium species in infant intestinal microbiota. Anaerobe 2010; 16(4):433-438.##81.	Adlerberth I, Strachan DP, Matricardi PM, Ahrné S, Orfei L, Aberg N, et al. Gut microbiota and development of atopic eczema in 3 European birth cohorts. J Allergy Clin Immunol 2007; 120(2): 343-350.##82.	Backhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 2015;17(5):690–703.##83.	Fallani M, Young D, Scott J, Norin E, Amarri S, Adam R, et al. Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics. J Pediatr Gastroenterol Nutr 2010; 51(1): 77-84.##84.	Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006; 118(2): 511-521.##85.	Dominguez-Bello MG, Costello E K, Contreras M, Magris M, Hidalgo, G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 2010; 107(26): 11971-11975.##86.	Martin R, Makino H, Cetinyurek Yavuz A, Ben-Amor K, Roelofs M, Ishikawa E,et al . Early-life events, including mode of delivery and type of feeding, siblings and gender, shape the developing gut microbiota. PLoS One 2016; 11(6): e0158498.##87.	Azad MB, Konya T, Maughan H, Guttman DS, Field CJ, Chari RS, et al. Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months. CMAJ 2013; 185(5): 385-394.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>میکروبیوتای دستگاه گوارش و سیروز وابسته به 
ویروس های هپاتیت B و C مزمن</TitleF>
		<TitleE>Gut Microbiota and Chronic 
Hepatitis B and C Viruses-Induced Cirrhosis</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>ویروس&#8204;های هپاتیت B و C از جمله مهم&#8204;ترین مشکلات بهداشت عمومی هستند. این ویروس&#8204;ها به صورت مزمن می&#8204;توانند منجر به بیماری&#8204;های کبدی مانند فیبروز، سیروز و هپاتوسلولارکارسینوما شوند و &#160;اغلب باعث&#160; افزایش مرگ و میر در این&#160; بیماران می&#8204;گردند. بر طبق مطالعات انجام شده،کبد تا حدود زیادی تحت تأثیر تغییرات میکروبیوتای دستگاه گوارش و آسیب&#8204;های سیستم ایمنی ناشی از وقوع التهاب به علت هپاتیت&#8204;های ویروسی می&#8204;باشد. اخیرا پیشرفت&#8204;های چشمگیری در شناسایی میکروبیوتای دستگاه گوارش در بیماران دارای سیروز مربوط به هپاتیت&#8204;های ویروسی و استفاده از آن در پیش&#8204;بینی و درمان آن ها حاصل شده است. پروفایل&#8204;های باکتریایی منحصر به فردی در بیماران سیروتیک وابسته به هپاتیت&#8204;های ویروسی دیده شده است که شامل افزایشStreptococcus ، Prevotella، Staphylococcacea و Enterococcus و همچنین کاهش Ruminococcus و Clostridium می&#8204;باشد. هدف از این مطالعه مروری، بررسی و بحث در مورد پروفایل میکروبیوتای دستگاه گوارش در بیماران مبتلا به عفونت مزمن هپاتیت B، C و نقش آنان در پیشرفت سیروز است.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Hepatitis B and C viruses are major public health problems. These viruses can chronically lead to liver disease such as fibrosis, cirrhosis, and hepatocellular carcinoma, which often increase mortality in these patients. According to previous studies, the liver is highly affected by changes in the microbiota of gastrointestinal tract and immune system damage caused by inflammation due to viral hepatitis. Significant advances have been made in identifying gastrointestinal microbiota in cirrhotic patients associated with viral hepatitis and its use in their prognosis and treatment in recent years. Unique bacterial profiles are observed in cirrhotic patients associated with viral hepatitis, including increased numbers of Streptococcus, Prevotella, Staphylococcus, and Enterococcus, as well as decreased numbers of Clostridium and Ruminococcus. The purpose of this review was to summarize and discuss the gastrointestinal microbiota profile in patients with chronic hepatitis B and C and its role in the progression of cirrhosis.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>103</FPAGE>
			<TPAGE>112</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/242020/11/212020/10/302020/11/20
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/8/30
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/62020/12/92021/01/102021/01/6
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/10/17
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>پریسا</Name>
				<MidName></MidName>
				<Family>ترکمن زاده اسدی</Family>
				<NameE>Parisa</NameE>
				<MidNameE></MidNameE>
				<FamilyE>torkamanzadeh asadabadi</FamilyE>
				<Organizations>
				<Organization>دانشجوی کارشناسی ارشد بیوتکنولوژِی، دانشکده علوم زیستی، دانشگاه آزاد تهران شمال، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>par.torkamanzadeh@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمد مهدی</Name>
				<MidName></MidName>
				<Family>سوری</Family>
				<NameE>Mohamad mehdi</NameE>
				<MidNameE></MidNameE>
				<FamilyE>suri</FamilyE>
				<Organizations>
				<Organization>دانشجوی کارشناسی ارشد بیوتکنولوژِی، دانشکده علوم زیستی، دانشگاه آزاد تهران شمال، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mehdi.sori8969@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سید داور</Name>
				<MidName></MidName>
				<Family>سیادت</Family>
				<NameE>Seyed Davar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Siadat</FamilyE>
				<Organizations>
				<Organization>استاد، گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>d.siadat@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمدرضا</Name>
				<MidName></MidName>
				<Family>آقا صادقی</Family>
				<NameE>MohammadReza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Aghasadeghi</FamilyE>
				<Organizations>
				<Organization>استاد، گروه هپاتیت و ایدز، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mr_sadeqi@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>پونه</Name>
				<MidName></MidName>
				<Family>رحیمی</Family>
				<NameE>Pooneh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Rahimi</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه هپاتیت و ایدز، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>pooneh5376@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سارا</Name>
				<MidName></MidName>
				<Family>احمدی بادی</Family>
				<NameE>Sara</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ahmadi Badi</FamilyE>
				<Organizations>
				<Organization>دکترای میکروبیولوژی، گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی،انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>sarahmadi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمد</Name>
				<MidName></MidName>
				<Family>ظاهری بیرگانی</Family>
				<NameE>Mohamad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>zaheri birgani</FamilyE>
				<Organizations>
				<Organization>دانشجوی کارشناسی ارشد بیوتکنولوژِی، دانشکده علوم زیستی، دانشگاه آزاد تهران شمال، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Amzb11@protonmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>عطیه</Name>
				<MidName></MidName>
				<Family>مطهری</Family>
				<NameE>Atiyyeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Motahhary</FamilyE>
				<Organizations>
				<Organization>کارشناسی ارشد بیوتکنولوژی، دانشکده علوم زیستی، دانشگاه آزاد واحد ارومیه، ارومیه.ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Azinmotahary@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>گلناز</Name>
				<MidName></MidName>
				<Family>بهرامعلی</Family>
				<NameE>Golnaz</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Bahramali</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه هپاتیت و ایدز، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>gbahramali@gmail.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>hepatitis B</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>hepatitis C</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>guts microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>cirrhosis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>dysbiosis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>هپاتیت B</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>هپاتیت C</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتا دستگاه گوارش</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سیروز</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>دیس بیوزیز</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Hézode C. Pan genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high and low income regions. J viral hepat 2017; 24(2): 92-101.##2.	World Health Organization (WHO). Global report on access to hepatitis C treatment. Focus on overcoming barriers. 2016, World Health Organization. Available at: https://apps.who. int/iris/handle/10665.##3.	World Health Organization (WHO). Global hepatitis report, 2017. World Health Organization.##4.	Beckebaum S, Malagó M, Dirsch O, Cicinnati VR, Trippler M, Lampertico P, et al. Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. Clin Transplant 2003; 17(6): 554-559.##5.	Castelnau C, Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alpha 2b in chronic hepatitis delta: relevance of quantitative RT PCR for follow up. Hepatology 2006; 44(3): 728-735.##6.	Liang Y, Shilagard T, Xiao SY, Snyder N, Lau D, Cicalese L, et al. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 2009; 137(4):1448-1458.##7.	Hernandez-Gea V, Fridman S. Pathogenesis of liver fibrosis. Ann Rev Pathol 2011; 6: 425-456.##8.	Bartolomé J, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Quiroga JA, Palacios R, et al. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 2007; 81(14): 7710-7715.##9.	Shrivastav S, Ray R, Ray RB. MicroRNAs: role in hepatitis C virus pathogenesis. Gen Dis 2015; 2(1): 35-45.##10.	Boullier S, Tanguy M, Kadaoui KH, Caubet C, Sansonetti P, Corthésy B, et al. Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits. J Immunol 2009; 183(9): 5879-5885.##11.	Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361(9356): 512-519.##12.	Hartmann P, Chen WC, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Frontiers Physiol 2012; 3: 402.##13.	Fouts DE, Torralba M, Nelson MK, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 2012; 56(6):1283-1292.##14.	Kang Y, Cai Y.Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy. J Hosp Infect 2017; 96(4): 342-348.##15.	Sehgal R, Bedi O, Trehanpati N. Role of microbiota in pathogenesis and management of viral hepatitis. Front Cell Infect Microbiol 2020; 10: 341.##16.	Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Spurnic AR, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci 2019; 20(2): 395.##17.	Xu D, Huang Y, Wang J. Gut microbiota modulate the immune effect against hepatitis B virus infection. Eur J Clin Microbiol Infect Dis 2015; 34(11): 2139-2147.##18.	Jiang, J.-W., et al., Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis. Hepatobiliary Pancreat Dis Int 2019; 18(1): 19-27.##19.	Poeta M, Pierri L, Vajro P. Gut–liver axis derangement in non-alcoholic fatty liver disease. Children 2017; 4(8): 66.##20.	Haque TR, Barritt IV AS. Intestinal microbiota in liver disease. Best Pract Res Clin Gastroenterol 2016; 30(1): 133-142.##21.	Emidio S, Forlino M, Lupo Ma, Rasetti C, Fava G, Abenavoli L, De Santis A, et al. Gut microbiota and alcoholic liver disease. Rev Recent Clin trials 2016; 11(3): 213-219.##22.	Lu H, Wu Z, Xu W, Yang J, Chen J, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Microb Ecol 2011; 61(3): 693-703.##23.	Wang J, Wang Y, Zhang X, Liu J, Zhang Q, Zhao Y, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Frontiers in microbiology, 2017; 8: 2222.##24.	Ren Z, Jiang LA. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 2019; 68(6): 1014-1023.##25.	Wang Y, Gao X, Ghozlane A, Hu H, Li X, Xiao Y. Characteristics of faecal microbiota in paediatric Crohn’s disease and their dynamic changes during infliximab therapy. J Crohns Colitis 2018; 12(3): 337-346.##26.	Huang Y, Li SC, Hu J, Ruan HB, Guo HM, Zhang H, et al. Gut microbiota profiling in Han Chinese with type 1 diabetes. Diabetes Res Clin Pract 2018; 141: 256-263.##27.	Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513(7516): 59-64.##28.	Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57(2): 601-609.##29.	Jun DW, Kim KT,Lee OU,Chae JD, Son BK, Kim SH, et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Digest Dis Sci 2010; 55(5): 1465-1471.##30.	Yang X-A, Lv F, Wang R, Chang Y, Zhao Y, Cui X, et al. Potential role of intestinal microflora in disease progression among patients with different stages of Hepatitis B. Gut pathogens 2020; 12(1): 1-15.##31.	Wei X, Yan X, Zou D, Yang Z, Wang X, Liu W, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol 2013; 13(1): 1-8.##32.	Wu Z-W, Lu H-F, Wu J, Zuo J, Chen P, Shen JF, et al. Assessment of the fecal lactobacilli population in patients with hepatitis B virus-related decompensated cirrhosis and hepatitis B cirrhosis treated with liver transplant. Microbial Ecol 2012; 63(4): 929-937.##33.	Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol 2006; 45(5): 744-757.##34.	Chassaing B, Etienne Mesmin L, Geirtz A. Microbiota liver axis in hepatic disease. Hepatol 2014; 59(1): 328-339.##35.	Woodhouse C, Patel VC, Singanayagam DL, Shawcross. The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Alimentary Pharmacol Therap 2018; 47(2): 192-202.##36.	Llorente C, Schnabl B. The gut microbiota and liver disease. Cellular Molecul Gastroenterol Hepatol 2015; 1(3): 275-284.##37.	Xu M, Wang B, Fu Y, Chen Y, Yang F, Lu H, et al. Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease. Microb Ecol 2012; 63(2): 304-313.##38.	Chen Y, Ji F, Guo J,Shi D, Fang D, Li L. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Scintif Rep 2016; 6(1): 1-9.##39.	Zeng Y, Chen S, Fu Y, Wu W, Chen T, Chen J, et al. Gut microbiota dysbiosis in patients with hepatitis B virus–induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J Viral Hepat 2020; 27(2): 143-155.##40.	Fukui H. Gut microbiota and host reaction in liver diseases. Microorganisms 2015; 3(4): 759-791.##41.	Bajaj JS, Strling RK, Betrapally NS, Nixon DE, Daita K, Heuman DM, et al. HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. Aliment Pharmacol Therapeut 2016; 44(6): 638-643.##42.	Mahmoud Aly AM, Adel AR, El-Gendy AO, Essam T, Aziz RK. Gut microbiome alterations in patients with stage 4 hepatitis C. Gut pathogens 2016; 8(1): 42.##43.	Preveden T, Scarpellini E, Milic N, Luzza F, Abenavoli L. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2017; 11(9): 813-819.##44.	Wan ML, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Sur Nutr 2018; 7(1): 11-20.##45.	Compare D, ccocli P, Rocco A, Nardone OM, de Maria S, Carteni M, et al. Gut–liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22(6): 471-476.##46.	Chen Y, Yang F, Lu H, Wang B, Chen Y, Li D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011; 54(2): 562-572.##47.	Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, et al. Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis 2018; 67(6): 869-877.##48.	Heidrich B, Vital M, Plumeier I, Doscher N, Kahi S, Kirschner J, et al. Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. Liver Int 2018; 38(1): 50-58.##49.	Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60(5): 940-947.##50.	Bajaj JS, Ridion J, Hylemon PB, Heuman DM, Thacker LR, Smith S, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointestinal Liver Physiol 2012; 302(1): G168-G175.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>نقش میکروبیوتای روده در اختلالات شناختی</TitleF>
		<TitleE>The Role of Intestinal Microbiota in Cognitive Disorders</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>&#160;اختلالات شناختی یکی از معضلات مهم در بحث سلامت عمومی سالمندان در سراسر دنیا به شمار می&#8204;آید. نقص در ذخیره سازی و یادآوری اطلاعات جدید، اختلال در حافظه کوتاه مدت و سایر مشکلات شناختی از علائم معمول اختلالات شناختی است که متاسفانه تاکنون درمان قطعی مشخصی برای آن یافت نشده است. مطالعات اخیر نشان دهنده ارتباط بین میکروبیوتای روده و بسیاری از اختلالات شناختی از طریق مسیری با عنوان محور میکروبیوتا- روده- مغز است. تصور می&#8204;شود که از این مسیر میکروبیوتای روده قادر است بر رفتار، عملکرد مغز و اعمال شناختی در دوران پیری اثرگذار باشد. در این مطالعه مروری به بررسی مکانیسم&#8204;های اثر زمینه&#8204;ای ارتباط دهنده میکروبیوتای روده و اختلالات شناختی و اثرات مداخله با پروبیوتیک&#8204;ها بر عملکرد شناختی پرداخته شده است.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>&#160;Cognitive disorders are one of the major public health issues in older population worldwide. Problems in forming and storing new memories, short-term memory impairment, and other cognitive problems are common symptoms of cognitive disorders that have no definite treatment yet. Recent studies have shown an association between gut microbiota and cognitive impairments described as microbiota-gut-brain axis. It seems that gut microbiota is able to influence behavior, brain system, and cognitive functions through this pathway in old age. In this review, the underlying mechanisms of the effect of gut microbiota on cognitive disorders and the role of dietetic intervention with probiotics in cognitive function are discussed.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>113</FPAGE>
			<TPAGE>124</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/242020/11/212020/10/302020/11/202020/10/7
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/7/16
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/62020/12/92021/01/102021/01/62020/12/6
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/16
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>پونه</Name>
				<MidName></MidName>
				<Family>انگورانی</Family>
				<NameE>Pooneh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Angoorani</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد تغذیه، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>poone4444@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>شیرین</Name>
				<MidName></MidName>
				<Family>حسنی رنجیر</Family>
				<NameE>Shirin</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hasani-Ranjbar</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>shirinhasanir@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>احمدرضا</Name>
				<MidName></MidName>
				<Family>سروش</Family>
				<NameE>Ahmad-Reza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Soroush</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>soroush1344@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سید داور</Name>
				<MidName></MidName>
				<Family>سیادت</Family>
				<NameE>Seyed Davar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Siadat</FamilyE>
				<Organizations>
				<Organization>استاد، گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>d.siadat@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>هانیه السادات</Name>
				<MidName></MidName>
				<Family>اجتهد</Family>
				<NameE>Hanieh-Sadat</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ejtahed</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haniejtahed@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فرشاد</Name>
				<MidName></MidName>
				<Family>شریفی</Family>
				<NameE>Farshad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sharifi</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات سلامت سالمندان، پژوهشکده علوم جمعیتی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>farshad.sharifi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سید مسعود</Name>
				<MidName></MidName>
				<Family>ارزاقی</Family>
				<NameE>Seyed Masoud</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Arzaghi</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات سلامت سالمندان، پژوهشکده علوم جمعیتی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>dr.arzaghi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>حسین</Name>
				<MidName></MidName>
				<Family>فخرزاده</Family>
				<NameE>Hossein</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Fakhrzadeh</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات سلامت سالمندان، پژوهشکده علوم جمعیتی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>fakhrzad@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>باقر</Name>
				<MidName></MidName>
				<Family>لاریجانی</Family>
				<NameE>Bagher</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Larijani</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>larijanib@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>cognitive disorders</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>probiotics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiota-gut-brain axis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>اختلالات شناختی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پروبیوتیک</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>محور میکروبیوتا-روده-مغز</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Berryhill ME, Peterson D, Jones K, Tanoue R. Cognitive Disorders. In: Ramachandran VS, (ed). Encyclopedia of Human Behavior. Second Edition. San Diego: Academic Press; 2012. P. 536-542. ##2.	WHO. Alzheimer Disease and Other Dementias. Available at: www.who.int/medicines/areas/ priority_medicines/BP6_11Alzheimer.pdf. Accessed November 15, 2019.##3.	WHO. Dementia: Fact Sheet. Available at: https://www.who.int/newsroom/fact-sheets/ detail/dementia. Accessed November 15, 2019.##4.	Ejtahed HS, Angoorani P, Soroush AR, Siadat SD, Shirzad N, Hasani-Ranjbar S, et al. Our Little Friends with Big Roles: Alterations of the Gut Microbiota in Thyroid Disorders. Endocrine, Metab immune Disord Drug Targets 2020; 20(3): 344-350.##5.	Ejtahed HS, Soroush AR, Angoorani P, Larijani B, Hasani-Ranjbar S. Gut Microbiota as a Target in the Pathogenesis of Metabolic Disorders: A New Approach to Novel Therapeutic Agents. Horm Metab Res 2016; 48(6): 349-358.##6.	Ejtahed H-S, Angoorani P, Hasani-Ranjbar S, Siadat S-D, Ghasemi N, Larijani B, et al. Adaptation of human gut microbiota to bariatric surgeries in morbidly obese patients: A systematic review. Microb Pathog 2018; 116: 13-21.##7.	Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 2021; 19(1): 1-17.##8.	Gareau MG. Microbiota-gut-brain axis and cognitive function.  Microbial endocrinology: The microbiota-gut-brain axis in health and disease: Springer; 2014: 357-371.##9.	Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nature Reviews Microbiology 2012; 10(11):735-742.##10.	Neunlist M, Van Landeghem L, Mahé MM, Derkinderen P, Des Varannes SB, Rolli-Derkinderen M. The digestive neuronal–glial–epithelial unit: a new actor in gut health and disease. Nat Rev Gastroenterol Hepatol 2013; 10(2): 90-100.##11.	Matteoli G, Boeckxstaens GE. The vagal innervation of the gut and immune homeostasis. Gut 2013; 62(8): 1214-1222.##12.	Petra AI, Panagiotidou S, Hatziagelaki E, Stewart JM, Conti P, Theoharides TC. Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther 2015; 37(5): 984-995.##13.	Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain–gut–enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6(5): 306-314.##14.	Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang X, et al. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology 2010; 139(6): 2102-2112. e1.##15.	Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, et al. Postnatal microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response in mice. J Physiol 2004; 558(1): 263-275.##16.	De Kloet ER, Derijk R. Signaling pathways in brain involved in predisposition and pathogenesis of stress‐related disease: Genetic and kinetic factors affecting the MR/GR balance. Ann N Y Acad Sci 2004; 1032(1): 14-34.##17.	Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem 2002; 9(5): 224-237.##18.	Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annual Review Neuroscience 2001; 24(1): 677-736.##19.	Kumar A. Long-term potentiation at CA3–CA1 hippocampal synapses with special emphasis on aging, disease, and stress. Front Ag Neurosci 2011; 3: 7.##20.	Pang PT, Lu B. Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: role of secreted proteins tPA and BDNF. Ageing Research Reviews 2004; 3(4): 407-430.##21.	Franco-Robles E, López MG. Agavins increase neurotrophic factors and decrease oxidative stress in the brains of high-fat diet-induced obese mice. Molecules 2016; 21(8): 998.##22.	Pineda-Rodriguez B, Toscano-Tejeida D, García–Vences E, Rodriguez-Barrera R, Flores-Romero A, Castellanos-Canales D, et al. Anterior chamber associated immune deviation used as a neuroprotective strategy in rats with spinal cord injury. Plos One 2017; 12(11): e0188506.##23.	Kim HJ, Leeds P, Chuang DM. The HDAC inhibitor,sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem 2009; 110(4): 1226-1240.##24.	Canani RB, Di Costanzo M, Leone L. The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. Clinical Epigenetics 2012; 4(1): 1-7.##25.	Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, Kodde A, et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clinical Nutrition 2009; 28(1): 88-93.##26.	Aguilar EC, dos Santos LC, Leonel AJ, de Oliveira JS, Santos EA, Navia-Pelaez JM, etal. Oral butyrate reduces oxidative stress in atherosclerotic lesion sites by a mechanism involving NADPH oxidase down-regulation in endothelial cells. The Journal of Nutritional Biochemistry 2016; 34: 99-105.##27.	Romo-Araiza A, Gutiérrez-Salmeán G, Galván EJ, Hernández-Frausto M, Herrera-López G, Romo-Parra H, etal. Probiotics and prebiotics as a therapeutic strategy to improve memory in a model of middle-aged rats. Front Aging Neurosci 2018; 10: 416.##28.	Caracciolo B, Xu W, Collins S, Fratiglioni L. Cognitive decline, dietary factors and gut–brain interactions. Mechanisms of Ageing and Development 2014; 136-137: 59-69.##29.	Brüssow H. Microbiota and healthy ageing: observational and nutritional intervention studies. Microbial Biotechnology 2013; 6(4): 326-334.##30.	Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, etal. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011; 141(2): 599-609. e1.##31.	Leung K, Thuret S. Gut microbiota: a modulator of brain plasticity and cognitive function in ageing. Healthcare 2015; 3(4): 898-916.##32.	Savignac HM, Corona G, Mills H, Chen L, Spencer JP, Tzortzis G, et al. Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-D-aspartate receptor subunits and D-serine. Neurochem Int 2013; 63(8): 756-764.##33.	Huang Y, Li Y, Huang Q, Cui Z, Yu D, Rajput IR, et al. Effect of orally administered Enterococcus faecium EF1 on intestinal cytokines and chemokines production of suckling piglets. Pak Vet J 2012; 32: 81-84.##34.	Thayer JF, Sternberg EM. Neural concomitants of immunity—Focus on the vagus nerve. Neuroimage 2009; 47(3): 908-910.##35.	Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences 2011; 108(38): 16050-16055.##36.	Bercik P, Park A, Sinclair D, Khoshdel A, Lu J, Huang X, et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut–brain communication. Neurogastroenterology &#38; Motility 2011; 23(12): 1132-1139.##37.	Forsythe P, Bienenstock J. Immunomodulation by commensal and probiotic bacteria. Immunological investigations 2010; 39(4-5): 429-448.##38.	Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neurosc 2008; 9(1): 46-56.##39.	Mosher KI, Wyss-Coray T. Go with your gut: microbiota meet microglia. Nature Neuroscience 2015; 18(7): 930-931.##40.	Erny D, de Angelis ALH, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 2015; 18(7): 965-977.##41.	Ni J, Shen T-CD, Chen EZ, Bittinger K, Bailey A, Roggiani M, et al. A role for bacterial urease in gut dysbiosis and Crohn’s disease. Sci Transl Med 2017; 9(416).##42.	Harry GJ. Microglia during development and aging. Pharmacol Ther 2013; 139(3): 313-326.##43.	Iadecola C. Dangerous leaks: blood-brain barrier woes in the aging hippocampus. Neuron 2015; 85(2): 231-233.##44.	Den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud D-J, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013; 54(9): 2325-2340.##45.	Stilling RM, Dinan TG, Cryan JF. Microbial genes, brain &#38; behaviour–epigenetic regulation of the gut–brain axis. Genes Brain and Behav 2014; 13(1): 69-86.##46.	Al-Lahham Sa'ad H, Peppelenbosch MP, Roelofsen H, Vonk RJ, Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta 2010; 1801(11): 1175-1183.##47.	Rossignol D, Frye R. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Molecular Psychiatry 2012; 17(3): 290-314.##48.	Coskun P, Wyrembak J, Schriner SE, Chen H-W, Marciniack C, LaFerla F, et al. A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta 2012; 1820(5): 553-564.##49.	Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol in Health Dis 2015; 26(1): 26050.##50.	Talani G, Biggio F, Mostallino M, Locci V, Porcedda C, Boi L, et al. Treatment with gut bifidobacteria improves hippocampal plasticity and cognitive behavior in adult healthy rats. Neuropharmacology 2020; 165: 107909.##51.	Luna RA, Foster JA. Gut brain axis: diet microbiota interactions and implications for modulation of anxiety and depression. Curr Opin Biotechnol 2015; 32: 35-41.##52.	Pistollato F, Iglesias RC, Ruiz R, Aparicio S, Crespo J, Lopez LD, et al. Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer’s disease: A focus on human studies. Pharmacol Res 2018; 131: 32-43.##53.	Dominguez LJ, Barbagallo M, Muñoz-Garcia M, Godos J, Martinez-Gonzalez MA. Dietary patterns and cognitive decline: key features for prevention. Curr Pharm Des 2019; 25(22): 2428-2442.##54.	Tangney CC, Li H, Wang Y, Barnes L, Schneider JA, Bennett DA, et al. Relation of DASH-and Mediterranean-like dietary patterns to cognitive decline in older persons. Neurology 2014; 83(16): 1410-1416.##55.	Hildebrandt MA, Hoffmann C, Sherrill–Mix SA, Keilbaugh SA, Hamady M, Chen YY, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009; 137(5): 1716-1724.##56.	Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Science Translational Medicine 2009; 1(6): 6ra14-6ra14.##57.	Li Q, Lauber CL, Czarnecki-Maulden G, Pan Y, Hannah SS. Effects of the dietary protein and carbohydrate ratio on gut microbiomes in dogs of different body conditions. MBio 2017; 8(1): e01703.##58.	Zhu S, Jiang Y, Xu K, Cui M, Ye W, Zhao G, et al. The progress of gut microbiome research related to brain disorders. Journal of Neuroinflammation 2020; 17(1): 25.##59.	Murphy T, Dias GP, Thuret S. Effects of diet on brain plasticity in animal and human studies: mind the gap. Neural Plasticity 2014; 2014(2): 563160.##60.	Pitsikas N, Algeri S. Deterioration of spatial and nonspatial reference and working memory in aged rats: protective effect of life-long calorie restriction. Neurobiology of Aging 1992; 13(3): 369-373.##61.	Gu Y, Scarmeas N. Dietary patterns in Alzheimer's disease and cognitive aging. Current Alzheimer Research 2011; 8(5): 510-519.##62.	Witte A, Fobker M, Gellner R, Knecht S, Flöel A. Caloric restriction improves memory in elderly humans. Proceedings of the National Academy of Sciences 2009; 106(4): 1255-1260.##63.	Singh R, Dinesh L, Kumar S, Sharma S, Kataria H, Kaur M, et al. Late-onset intermittent fasting dietary restriction as a potential intervention to retard age-associated brain function impairments in male rats. Age 2012; 34(4): 917-933.##64.	Luchtman DW, Song C. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology 2013; 64: 550-565.##65.	Cutuli D, De Bartolo P, Caporali P, Laricchiuta D, Foti F, Ronci M, etal. n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. Front Aging Neurosci 2014; 6: 220.##66.	Kelly L, Grehan B, Della Chiesa A, O'Mara SM, Downer E, Sahyoun G, et al. The polyunsaturated fatty acids, EPA and DPA exert a protective effect in the hippocampus of the aged rat. Neurobiol Aging 2011; 32(12): 2318. e1-e15.##67.	Patel SP, Sullivan PG, Lyttle TS, Rabchevsky AG. Acetyl‐l‐carnitine ameliorates mitochondrial dysfunction following contusion spinal cord injury. Journal of Neurochemistry 2010; 114(1): 291-301.##68.	Jones LL, McDonald DA, Borum PR. Acylcarnitines: role in brain. Progress in Lipid Research 2010; 49(1): 61-75.##69.	Logan AC, Katzman M. Major depressive disorder: probiotics may be an adjuvant therapy. Medical Hypotheses 2005; 64(3): 533-538.##70.	Łoniewski I, Misera A, Skonieczna-Żydecka K, Kaczmarczyk M, Kaźmierczak-Siedlecka K, Misiak B, et al. Major Depressive Disorder and gut microbiota–Association not causation. A scoping review. Prog Neuro-Psychopharmacol Biol Psychiatry 2020: 110111.##71.	Savignac H, Tramullas M, Kiely B, Dinan T, Cryan J. Bifidobacteria modulate cognitive processes in an anxious mouse strain. Behavioural Brain Research 2015; 287: 59-72.##72.	Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. British Journal of Nutrition 2011; 105(5): 755-764.##73.	Wall R, Marques TM, O’Sullivan O, Ross RP, Shanahan F, Quigley EM, et al. Contrasting effects of Bifidobacterium breve NCIMB 702258 and Bifidobacterium breve DPC 6330 on the composition of murine brain fatty acids and gut microbiota. Am J Clin Nutr 2012; 95(5): 1278-1287.##74.	Distrutti E, O’Reilly J-A, McDonald C, Cipriani S, Renga B, Lynch MA, et al. Modulation of intestinal microbiota by the probiotic VSL# 3 resets brain gene expression and ameliorates the age-related deficit in LTP. PloS one 2014; 9(9): e106503.##75.	Kaur H, Golovko S, Golovko MY, Singh S, Darland DC, Combs CK. Effects of Probiotic Supplementation on Short Chain Fatty Acids in the App NL-GF Mouse Model of Alzheimer’s Disease. J Alzheimer's Dis 2020(Preprint): 1-20.##76.	Davari S, Talaei SA, Alaei H, Salami A. Probiotics treatment improves diabetes-induced impairment of synaptic activity and cognitive function: behavioral and electrophysiological proofs for microbiome–gut–brain axis. Neuroscience 2013; 240: 287-296.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>مزایای پروبیوتیک‌های غیر فعال و غیر زنده بر سلامت</TitleF>
		<TitleE>Beneficial Effects of Inactive and Non-Viable Probiotics on Health</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>&#160;براساس تعریف بیان شده توسط سازمان بهداشت جهانی، پروبیوتیک&#8204;ها در صورتی که به صورت زنده مورد 
استفاده قرار گیرند اثرات سلامتی بخش بر میزبان دارند. با این حال در سال&#8204;های اخیر فواید بسیاری در اثر استفاده از سلول&#8204;های غیر فعال و غیر زنده میکروب&#8204;ها و یا متابولیت&#8204;های آن&#8204;ها مشاهده شده است. بنابراین به نظر می&#8204;رسد که می&#8204;توان پروبیوتیک&#8204;ها را سلول یا عصاره سلول میکروب زنده، غیر فعال و یا حتی غیرزند&#8204;ه&#8204;ای معرفی کرد که دارای اثرات سلامتی بخش بر میزبان هستند. بر این اساس پروبیوتیک&#8204;ها به 3 دسته پروبیوتیک&#8204;های حقیقی، شبه پروبیوتیک&#8204;ها و روح پروبیوتیک&#8204;ها تقسیم&#8204;بندی می&#8204;شوند. این مطالعه به مرور اثرات و مکانیسم عملکرد سلامتی بخش سلول&#8204;های غیرفعال و غیرزنده میکروبی بر میزبان پرداخته است. هم&#8204;چنین در این مطالعه واژگان پیشنهادی جدید براساس ماهیت سلول یا ماده اثر بخش به گونه ای که تمامی جنبه&#8204;های سلول میکروبی (زنده، غیر زنده، غیر فعال و عصاره سلولی) را در برگیرد شرح داده شده است.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>&#160;According to the World Health Organization, viable probiotics could have health effects. However, in recent years, many benefits have been observed through application of inactive and non-viable cells of microbes or their metabolites. Therefore, probiotics could be defined as viable, inactive, or non-viable microbial cells or cell extracts that have beneficial health effects on the host. Based on the proposed terminology, probiotics are divided into three categories: real probiotics, pseudo-probiotics, and ghost probiotics. This article reviewed the beneficial effects and underlying mechanisms of inactive and non-viable microbial cells on the host. Also in this article, new proposed terms are described based on the nature of the cell or active ingredient so that it could cover all aspects of the microbial cell (viable, non-viable, inactive, and cell extract).</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>125</FPAGE>
			<TPAGE>139</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/242020/11/212020/10/302020/11/202020/10/72020/09/29
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/7/8
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/62020/12/92021/01/102021/01/62020/12/62020/12/6
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/16
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>فاطمه</Name>
				<MidName></MidName>
				<Family>زنده بودی</Family>
				<NameE>Fatemeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Zendeboodi</FamilyE>
				<Organizations>
				<Organization>دکتری علوم و صنایع غذایی، کمیته تحقیقات دانشجویی، انستیتو تحقیقات تغذیه ای و صنایع غذایی کشور، دانشکده علوم تغذیه و صنایع غذایی، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>fzendeboodi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>هانیه السادات</Name>
				<MidName></MidName>
				<Family>اجتهد</Family>
				<NameE>Hanieh-Sadat</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ejtahed</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران    مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haniejtahed@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>محمد مهدی</Name>
				<MidName></MidName>
				<Family>قلیان</Family>
				<NameE>Mohammad Mahdi</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Gholian</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری علوم و صنایع غذایی، گروه تبدیل و نگهداری مواد غذایی، پژوهشکده کشمش و انگور، دانشگاه ملایر، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mohammadmahdi.gholian@stu.malayeru.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>امیر محمد</Name>
				<MidName></MidName>
				<Family>مرتضویان</Family>
				<NameE>Amir Mohammad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mortazavian</FamilyE>
				<Organizations>
				<Organization>استاد، انستیتو تحقیقات تغذیه ای و صنایع غذایی کشور، دانشکده علوم تغذیه و صنایع غذایی، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mortzvn@sbmu.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سارا</Name>
				<MidName></MidName>
				<Family>سهراب وندی</Family>
				<NameE>Sara</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Sohrabvandi</FamilyE>
				<Organizations>
				<Organization>دانشیار، انستیتو تحقیقات تغذیه ای و صنایع غذایی کشور، دانشکده علوم تغذیه و صنایع غذایی، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Sohrabv@sbmu.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>نسیم</Name>
				<MidName></MidName>
				<Family>خورشیدیان</Family>
				<NameE>Nasim</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Khorshidian</FamilyE>
				<Organizations>
				<Organization>استادیار،گروه علوم و صنایع غذایی، دانشکده تغذیه و علوم غذایی آرادان، مرکز تحقیقات سلامت غذایی (نمک)، دانشگاه علوم پزشکی سمنان، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>nkhorshidian@semums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>رضا</Name>
				<MidName></MidName>
				<Family>محمدی</Family>
				<NameE>Reza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mohammadi</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه علوم و صنایع غذایی، دانشکده تغذیه و علوم غذایی، دانشگاه علوم پزشکی کرمانشاه، کرمانشاه، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>r.mohammadi@kums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>probiotics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>parabiotics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>non-viable cell</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>ghost probiotics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>pseudo-probiotics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پروبیوتیک</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پارابیوتیک</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سلول غیر زنده</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>روح پروبیوتیک</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>شبه پروبیوتیک</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Yan. F. Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002; 277(52): 50959-50965.##2.	Norouzbeigi S, Vahid-Dastjerdi L, Yekta R, Sohrabvandi S, Zendeboodi F, Mortazavian AM. Celiac therapy by administration of probiotics in food products: a review. Curr Opin Food Sci 2020; 32: 58-66.##3.	Gérard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens 2014; 3(1): 14-24.##4.	Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012; 2012: 902917.##5.	Gill H, Rutherfurd K. Viability and dose–response studies on the effects of the immunoenhancing lactic acid bacterium Lactobacillus rhamnosus in mice. Br J Nutr 2001; 86(2): 285-289.##6.	Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol 2013; 6(1): 39-51.##7.	Misra S, Mohanty D. Psychobiotics: A new approach for treating mental illness? Crit Rev Food Sci Nutr 2019; 59(8): 1230-1236.##8.	Sarkar A, Lehto SM, Harty S, Dinan TG, Cryan JF, Burnet PW. Psychobiotics and the manipulation of bacteria–gut–brain signals. Trends Neurosci 2016; 39(11): 763-781.##9.	Bermúdez-Humarán LG, Salinas E, Ortiz GG, Ramirez-Jirano LJ, Morales JA, Bitzer-Quintero OK. From probiotics to psychobiotics: live beneficial bacteria which act on the Brain-Gut axis. Nutrients 2019; 11(4): 890.##10.	Cheng LH, Liu YW, Wu CC, Wang S, Tsai YC. Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders. J Food Drug Anal 2019; 27(3): 632-648. ##11.	Collins FL, Rios-Arce ND, Schepper JD, Parameswaran N, McCabe LR. The potential of probiotics as a therapy for osteoporosis. Microbiol Spectr 2017; 5(4): 10. ##12.	Fuller R. Probiotics in man and animals. J Appl Microbiol 1989; 66(5): 365-378. ##13.	Haveenar R, In't Veld JH. Probiotics: A general view In: Wood BJB, (eds). The lactic acid bacteria in health and disease. Boston Springer; 1992. p. 151-152. ##14.	Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11(8): 506-514.##15.	Blagodatskaya E, Kuzyakov Y. Active microorganisms in soil: Critical review of estimation criteria and approaches. Soil Biol Biochem 2013; 67: 192-211.##16.	Adams CA. The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev 2010; 23(1): 37-46.##17.	Aguilar-Toalá J, Garcia-Varela R, Garcia H, Mata-Haro V, González-Córdova A, Vallejo-Cordoba B, et al. Postbiotics: An evolving term within the functional foods field. Trends Food Sci Technol 2018; 75: 105-114.##18.	Collado M, Vinderola G, Salminen S. Postbiotics: facts and open questions. A position paper on the need for a consensus definition. Benef Microbes 2019; 10(7): 711-719.##19.	de Almada CN, Almada CN, Martinez RC, Sant'Ana AS. Paraprobiotics: evidences on their ability to modify biological responses, inactivation methods and perspectives on their application in foods. Trends Food Sci Technol 2016; 58: 96-114. ##20.	Blinkova L, Martirosyan DM, Pakhomov Y, Dmitrieva O, Vaughan R, Altshuler M. Nonculturable forms of bacteria in lyophilized probiotic preparations. Funct Food Health Dis 2014; 4(2): 66-76. ##21.	Lahtinen SJ, Gueimonde M, Ouwehand AC, Reinikainen JP, Salminen SJ. Comparison of four methods to enumerate probiotic bifidobacteria in a fermented food product. Food Microbiol 2006; 23(6): 571-577.##22.	Mohammadi R, Sohrabvandi S, Mohammad Mortazavian A. The starter culture characteristics of probiotic microorganisms in fermented milks. Eng Life Sci 2012; 12(4): 399-409.##23.	Zendeboodi F, Khorshidian N, Mortazavian AM, da Cruz AG. Probiotic: Conceptualization from a new approach. Curr Opin Food Sci 2020;32:103-123##24.	Soares MB, Martinez RC, Pereira EP, Balthazar CF, Cruz AG, Ranadheera CS, et al. The resistance of Bacillus, Bifidobacterium, and Lactobacillus strains with claimed probiotic properties in different food matrices exposed to simulated gastrointestinal tract conditions. Food Res Int 2019; 125: 108542.##25.	Marcial-Coba MS, Pjaca AS, Andersen CJ, Knøchel S, Nielsen DS. Assessment during storage and simulated gastric passage. LWT 2019; 99: 197-201.##26.	Abriouel H, Franz CM, Omar NB, Gálvez A. Diversity and applications of Bacillus bacteriocins. FEMS Microbiol Rev 2011; 35(1): 201-232.##27.	Kosaka T, Maeda T, Nakada Y, Yukawa M, Tanaka S. Effect of Bacillus subtilis spore administration on activation of macrophages and natural killer cells in mice. Vet Microbiol 1998; 60(2-4): 215-225.##28.	Fiorini G, Cimminiello C, Chianese R, Visconti G, Cova D, Uberti T, et al. Bacillus subtilis selectively stimulates the synthesis ##of membrane bound and secreted IgA. Chemioterapia 1985; 4(4): 310-312.##29.	Marseglia GL, Tosca M, Cirillo I, Licari A, Leone M, Marseglia A, et al. Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study. Ther Clin Risk Manag 2007; 3(1): 13.##30.	Urdaci M, Pinchuk I. Antimicrobial activity of Bacillus probiotics In: Horizon Bioscience, Ed. Bacterial spore formers–Probiotics and emerging applications Norfolk, UK; 2004. p. 171-182.##31.	Urdaci MC, Bressollier P, Pinchuk I. Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities. J Clin Gastroenterol 2004; 38: S86-S90.##32.	Duc LH, Hong HA, Barbosa TM, Henriques AO, Cutting SM. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol 2004; 70(4): 2161-2171.##33.	Marrec L. Coagulin, a bacteriocin like inhibitory substance produced by Bacillus coagulans I4. J Appl Microbiol 1998; 85(1): 42-50.##34.	Ozawa K, YABU-UCHI K, Yamanaka K, Yamashita Y, Ueba K, Miwatani T. Antagonistic effects of Bacillus natto and Streptococcus faecalis on growth of Candida albicans. Microbiol Immunol 1979; 23(12): 1147-1156.##35.	Nagai S, Okimura K, Kaizawa N, Ohki K, Kanatomo S. Study on surfactin, a cyclic depsipeptide. II. Synthesis of surfactin B2 produced by Bacillus natto KMD 2311. Chem Pharm Bull 1996; 44(1): 5-10.##36.	Hosoi T, Ametani A, Kiuchi K, Kaminogawa S. Changes in fecal microflora induced by intubation of mice with Bacillus subtilis (natto) spores are dependent upon dietary components. Can J Microbiol 1999; 45(1): 59-66.##37.	Hosoi T, Ametani A, Kiuchi K, Kaminogawa S. Improved growth and viability of lactobacilli in the presence of Bacillus subtilis (natto), catalase, or subtilisin. Can J Microbiol 2000; 46(10): 892-897.##38.	Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy. Int J Mol Sci 2020; 21(3): 1136.##39.	Barbut F, Meynard JL. Managing antibiotic associated diarrhoea: Probiotics may help in prevention. BMJ 2002; 324(7350): 1345-1346.##40.	Plomer M, Perez M, Greifenberg DM. Effect of Bacillus clausii Capsules in Reducing Adverse Effects Associated with Helicobacter pylori Eradication Therapy: A Randomized, Double-Blind, Controlled Trial. Infect Dis Ther 2020; 9(4): 867-878.##41.	Maruta K, Miyazaki H, Masuda S, Takahashi M, Marubashi T, Tadano Y, et al. Exclusion of intestinal pathogens by continuous feeding with Bacillus subtilis C-3102 and its influence on intestinal microflora in broilers. Anim Feed Sci Technol 1996; 67(3): 273-280.##42.	Tejada-Simon MV, Pestka JJ. Proinflammatory Cytokine and Nitric Oxide Induction in Murine Macrophages by Cell Wall and Cytoplasmic Extracts of Lacticacid bacteria. J Food Prot 1999; 62(12): 1435-1444.##43.	Ishikawa H, Kutsukake E, Fukui T, Sato I, Shirai T, Kurihara T, et al. Oral administration of heat-killed Lactobacillus plantarum strain b240 protected mice against Salmonella enterica Serovar Typhimurium. Biosci Biotechnol Biochem 2010; 74(7): 1338-1342.##44.	Nakamura F, Ishida Y, Sawada D, Ashida N, Sugawara T, Sakai M, et al. Fragmented lactic Acid bacterial cells activate peroxisome proliferator-activated receptors and ameliorate Dyslipidemia in obese mice. J Agric Food Chem 2016; 64(12): 2549-2559.##45.	Nakamura S, Kuda T, An C, Kanno T, Takahashi H, Kimura B. Inhibitory effects of Leuconostoc mesenteroides 1RM3 isolated from narezushi, a fermented fish with rice, on Listeria monocytogenes infection to Caco-2 cells and A/J mice. Anaerobe 2012; 18(1): 19-24.##46.	Zeng J, Jiang J, Zhu W, Chu Y. Heat-killed yogurt-containing lactic acid bacteria prevent cytokine-induced barrier disruption in human intestinal Caco-2 cells. Ann Microbiol 2016; 66(1): 171-178.##47.	Orlando A, Refolo M, Messa C, Amati L, Lavermicocca P, Guerra V, et al. Antiproliferative and proapoptotic effects of viable or heat-killed Lactobacillus paracasei IMPC2. 1 and Lactobacillus rhamnosus GG in HGC-27 gastric and DLD-1 colon cell lines. Nutr Cancer 2012; 64(7): 1103-1111.##48.	Shinkai S, Toba M, Saito T, Sato I, Tsubouchi M, Taira K, et al. Immunoprotective effects of oral intake of heat-killed Lactobacillus pentosus strain b240 in elderly adults: a randomised, double-blind, placebo-controlled trial. Br J Nutr 2013; 109(10): 1856-1865.##49.	Zhu L, Shimada T, Chen R, Lu M, Zhang Q, Lu W, et al. Effects of lysed Enterococcus faecalis FK-23 on experimental allergic rhinitis in a murine model. J Biomed Res 2012; 26(3): 226-234.##50.	Segawa S, Wakita Y, Hirata H, Watari J. Oral administration of heat-killed Lactobacillus brevis SBC8803 ameliorates alcoholic liver disease in ethanol-containing diet-fed C57BL/6N mice. Int J Food Microbiol 2008; 128(2): 371-377.##51.	Tsilingiri K, Rescigno M. Postbiotics: what else? Benef Microbes 2012; 4(1): 101-107.##52.	Cicenia A, Santangelo F, Gambardella L, Pallotta L, Iebba V, Scirocco A, et al. Protective role of postbiotic mediators secreted by Lactobacillus rhamnosus GG versus lipopolysaccharide-induced damage in human colonic smooth muscle cells. J Clin Gastroenterol 2016; 50: S140-S144.##53.	Amaretti A, Di Nunzio M, Pompei A, Raimondi S, Rossi M, Bordoni A. Antioxidant properties of potentially probiotic bacteria: in vitro and in vivo activities. Appl Microbiol Biotechnol 2013; 97(2): 809-817.##54.	Shin HS, Park SY, Lee DK, Kim SA, An HM, Kim JR, et al. Hypocholesterolemic effect of sonication-killed Bifidobacterium longum isolated from healthy adult Koreans in high cholesterol fed rats. Arch Pharm Res 2010; 33(9): 1425-1431.##55.	.Tiptiri-Kourpeti A, Spyridopoulou K, Santarmaki V, Aindelis G, Tompoulidou E, Lamprianidou EE, et al. Lactobacillus casei exerts anti-proliferative effects accompanied by apoptotic cell death and up-regulation of TRAIL in colon carcinoma cells. PloS One 2016; 11(2): e0147960.##56.	Li W, Ji J, Chen X, Jiang M, Rui X, Dong M. Structural elucidation and antioxidant activities of exopolysaccharides from Lactobacillus helveticus MB2-1. Carbohydr Polym 2014; 102: 351-359.##57.	Izuddin WI, Loh TC, Samsudin AA, Foo HL. In vitro study of postbiotics from Lactobacillus plantarum RG14 on rumen fermentation and microbial population. R Bras Zootec 2018; 47: e20170255.##58.	Kim HG, Lee SY, Kim NR, Lee HY, Ko MY, Jung BJ, et al. Lactobacillus plantarum lipoteichoic acid down-regulated Shigella flexneri peptidoglycan-induced inflammation. Mol Immunol 2011; 48(4): 382-391.##59.	Ogawa A, Kadooka Y, Kato K, Shirouchi B, Sato M. Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects. Lipids Health Dis 2014; 13(1): 13-36.##60.	Khorshidian N, Yousefi Asli M, Hosseini H, Shadnoush M, Mortazavian AM. Potential Anticarcinogenic Effects of Lactic Acid Bacteria and Probiotics in Detoxification of Process-Induced Food Toxicants. Int J Cancer Prev 2016; 9(5): e7920.##61.	Nowak A, Paliwoda A, Błasiak J. Anti-proliferative, pro-apoptotic and anti-oxidative activity of Lactobacillus and Bifidobacterium strains: A review of mechanisms and therapeutic perspectives. Crit Rev Food Sci Nutr 2019; 59(21): 3456-3467.##62.	Zhang S, Liu L, Su Y, Li H, Sun Q, Liang X, et al. Antioxidative activity of lactic acid bacteria in yogurt. Afr J Microbiol Res 2011; 5(29): 5194-5201.##63.	Saqib S, Akram A, Halim SA, Tassaduq R. Sources of β-galactosidase and its applications in food industry. 3 Biotech 2017; 7(1): 79.##64.	T averniti V, Guglielmetti S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr 2011; 6(3): 261-274.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>تعاملات رژیم غذایی-میکروبیوتا: رویکردی نوین به تغذیه فرد محور</TitleF>
		<TitleE>Diet-Microbiota Interactions: 
A New Approach to Personalized Nutrition</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>&#160;تغذیه فرد محور، رویکرد نوینی در علوم پزشکی می&#8204;باشد که براساس پروفایل ژنتیکی، نیازهای فردی، شرایط زندگی فرد و متناسب با وضعیت سلامتی و بیماری&#8204;های زمینه&#8204;ای آنان است. مطالعات نشان داده&#8204;اند که تنها تفاوت&#8204;های ژنتیکی افراد توجیه&#8204;کننده پاسخ&#8204;های متفاوت افراد نسبت به درمان&#8204;های دارویی و رژیم&#8204;های تجویزی نمی&#8204;تواند باشد و عوامل مهم دیگری از جمله میکروبیوتای روده در این امر دخیل اند. بدن انسان میزبان اکوسیستمی فعال و پویا تشکیل شده از تعداد بسیار زیادی میکرواورگانیسم می&#8204;باشد که ژنومی در حدود ده برابر ژنوم انسانی را تشکیل می&#8204;دهند و با بدن انسان از طریق متابولیت&#8204;های ترشحی از جمله اسیدهای چرب کوتاه زنجیر و اسیدهای صفراوی ثانویه و محصولات حاصل از تخمیر مانند کینورنین، اندول و مشتقات اندولی، تریپتوفان، سروتونین، هسیتامین و دوپامین تعامل دارند. وزن و میزان متابولیسم بدن و وضعیت سلامت و بیماری فرد در نتیجه ی این تعاملات شکل می&#8204;گیرد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>&#160;Personalized nutrition is a new approach in medical sciences that is based on genetic profile, individual needs, and environmental conditions considering health status and chronic diseases of every person. Studies have shown that genetic differences cannot solely justify various responses to medications and diets, and other important factors including gut microbiota are also involved. Human body hosts an active and dynamic ecosystem composed of a large number of microorganisms consisting of genes about ten times more than the human genome. Gut microbiota interacts with the human body through releasing metabolites such as short-chain fatty acids and secondary bile acids and fermentation products such as kynurenine, indoles and indole derivatives, tryptophan, serotonin, histamine, and dopamine. Body weight, metabolic rate, and health and diseases are formed as a result of these interactions.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>140</FPAGE>
			<TPAGE>151</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/242020/11/212020/10/302020/11/202020/10/72020/09/292020/10/26
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/8/5
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/62020/12/92021/01/102021/01/62020/12/62020/12/62020/12/16
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/26
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>هانیه</Name>
				<MidName></MidName>
				<Family>مالمیر</Family>
				<NameE>Hanieh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Malmir</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد تغذیه، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشکده علوم تغذیه و رژیم شناسی، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>hanieh.malmir@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>شیرین</Name>
				<MidName></MidName>
				<Family>حسنی رنجبر</Family>
				<NameE>Shirin</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hasani-Ranjbar</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>shirinhasanir@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>احمد رضا</Name>
				<MidName></MidName>
				<Family>سروش</Family>
				<NameE>Ahmad-Reza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Soroush</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>sorosham@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>ماندانا</Name>
				<MidName></MidName>
				<Family>حسن زاد</Family>
				<NameE>Mandana</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hasanzad</FamilyE>
				<Organizations>
				<Organization>دانشیار، مرکز تحقیقات پزشکی فردی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران  و  مرکز تحقیقات ژنومیکس پزشکی، دانشگاه آزاد اسلامی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>mandanahasanzad@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>احمد</Name>
				<MidName></MidName>
				<Family>اسماعیل زاده</Family>
				<NameE>Ahmad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Esmaillzadeh</FamilyE>
				<Organizations>
				<Organization>استاد، گروه تغذیه جامعه، دانشکده علوم تغذیه و رژیم شناسی، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>a.esmaillzadeh@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>هانیه السادات</Name>
				<MidName></MidName>
				<Family>اجتهد</Family>
				<NameE>Hanieh-Sadat</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ejtahed</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات علوم غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران , مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haniejtahed@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>باقر</Name>
				<MidName></MidName>
				<Family>لاریجانی</Family>
				<NameE>Bagher</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Larijani</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات علوم غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران و</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>emrc@sina.tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>personalized nutrition</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>diet</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>تغذیه فرد محور</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>رژیم غذایی</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Frédérich M, Pirotte B, Fillet M, de Tullio P. Metabolomics as a Challenging Approach for Medicinal Chemistry and Personalized Medicine. J Med Chem 2016; 59(19): 8649-8666.##2.	Egnew TR. Suffering, Meaning, and Healing: Challenges of Contemporary Medicine. Ann Fam Med 2009; 7(2): 170-175.##3.	Cutter GR, Liu Y. Personalized medicine: The return of the house call? Neurol Clin Pract 2012; 2(4): 343-351.##4.	Ozomaro U, Wahlestedt C, Nemeroff CB. Personalized medicine in psychiatry: problems and promises. BMC Medicine 2013; 11(1): 132.##5.	Lu Y-F, Goldstein DB, Angrist M, Cavalleri G. Personalized medicine and human genetic diversity. Cold Spring Harb Perspect Med 2014; 4(9): a008581.##6.	Wu L, Candille SI, Choi Y, Xie D, Jiang L, Li Pook Than J, et al. Variation and genetic control of protein abundance in humans. Nature 2013; 499(7456): 79-82.##7.	Battle A, Mostafavi S, Zhu X, Potash JB, Weissman MM, McCormick C, et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Res 2014; 24(1): 14-24.##8.	Cenik C, Cenik ES, Byeon GW, Grubert F, Candille SI, Spacek D, et al. Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation across humans. Genome Res 2015; 25(11): 1610-1621.##9.	History of the Human Genome Project 2020 [cited 2020 2020]. Available from: https://web.ornl.gov/sci/techresources/Human_Genome/publicat/hgn/hgnarch.shtml.##10.	Turnbaugh PJ, Ley RE, Hamady M, Fraser Liggett CM, Knight R, Gordon JI. The Human Microbiome Project. Nature 2007; 449(7164): 804-810.##11.	Ordovas JM, Corella D. Nutritional genomics. Annual review of genomics and human genetics. 2004; 5: 71-118.##12.	Smits SA, Leach J, Sonnenburg ED, Gonzalez CG, Lichtman JS, Reid G, et al. Seasonal cycling in the gut microbiome of the Hadza hunter-gatherers of Tanzania. Science 2017; 357(6353): 802.##13.	Davenport ER, Mizrahi-Man O, Michelini K, Barreiro LB, Ober C, Gilad Y. Seasonal Variation in Human Gut Microbiome Composition. PLOS ONE 2014; 9(3): e90731.##14.	Obregon Tito AJ, Tito RY, Metcalf J, Sankaranarayanan K, Clemente JC, Ursell LK, et al. Subsistence strategies in traditional societies distinguish gut microbiomes. Nature Communications 2015; 6(1): 6505.##15.	Kim S, Jazwinski SM. The Gut Microbiota and Healthy Aging: A Mini-Review. Gerontology 2018; 64(6): 513-520.##16.	Brooks AW, Priya S, Blekhman R, Bordenstein SR. Gut microbiota diversity across ethnicities in the United States. PLoS Biol 2018; 16(12): e2006842.##17.	Sun L, Zhang X, Zhang Y, Zheng K, Xiang Q, Chen N, et al. Antibiotic-Induced Disruption of Gut Microbiota Alters Local Metabolomes and Immune Responses. Front Cell Infect Microbiol 2019; 9(99).##18.	Wu S, Zeng Z, Fu Z. Effects of environmental pollutants on gut microbiota. Environmental Pollution 2017; 222: 1-9.##19.	Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis 2015; 26: 26050.##20.	Drago L, Toscano M, Rodighiero V, De Vecchi E, Mogna G. Cultivable and Pyrosequenced Fecal Microflora in Centenarians and Young Subjects. J Clin Gastroenterol 2012; 46(Suppl): S81-S84.##21.	Kolodziejczyk AA, Zheng D, Elinav E. Diet–microbiota interactions and personalized nutrition. Nat Rev Microbiol 2019; 17(12): 742-753.##22.	Zhang C, Zhang M, Pang X, Zhao Y, Wang L, Zhao L. Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. ISME J 2012; 6(10): 1848-1857.##23.	Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009; 137(5): 1716-1724.e1-2.##24.	Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008; 3(4): 213-223.##25.	Parks BW, Nam E, Org E, Kostem E, Norheim F, Hui ST, et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab 2013; 17(1): 141-152.##26.	Lai M, Chandrasekera PC, Barnard ND. You are what you eat, or are you? The challenges of translating high-fat-fed rodents to human obesity and diabetes. Nutr Diabetes 2014; 4(9): e135.##27.	Mokkala K, Houttu N, Cansev T, Laitinen K. Interactions of dietary fat with the gut microbiota: Evaluation of mechanisms and metabolic consequences. Clin Nutr 2020; 39(4): 994-1018.##28.	Watson H, Mitra S, Croden FC, Taylor M, Wood HM, Perry SL, et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Randomized Controlled Trial 2018; 67(11): 1974-1983.##29.	Xu B, Christudas S, Devaraj R. Different impacts of plant proteins and animal proteins on human health through altering gut microbiotaant proteins and animal proteins on human health through altering gut microbiota. Functional Foods in Health and Disease 2020; 10(5).##30.	Świątecka D, Narbad A, Ridgway KP, Kostyra H. The study on the impact of glycated pea proteins on human intestinal bacteria. Int J Food Microbiol 2011; 145(1): 267-272.##31.	Bouhnik Y, Raskine L, Simoneau G, Vicaut E, Neut C, Flourié B, et al. The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am J Clin Nutr 2004; 80(6): 1658-1664.##32.	De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010; 107(33): 14691-14696.##33.	Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 2011; 5(2): 220-230.##34.	Martínez I, Kim J, Duffy PR, Schlegel VL, Walter J. Resistant Starches Types 2 and 4 Have Differential Effects on the Composition of the Fecal Microbiota in Human Subjects. PLOS ONE 2010; 5(11): e15046.##35.	Davis LMG, Martínez I, Walter J, Goin C, Hutkins RW. Barcoded Pyrosequencing Reveals That Consumption of Galactooligosaccharides Results in a Highly Specific Bifidogenic Response in Humans. PLOS ONE 2011; 6(9): e25200.##36.	Korpela K, Flint HJ, Johnstone AM, Lappi J, Poutanen K, Dewulf E, et al. Gut Microbiota Signatures Predict Host and Microbiota Responses to Dietary Interventions in Obese Individuals. PLOS ONE 2014; 9(3): e90702.##37.	Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al. Dietary intervention impact on gut microbial gene richness. Nature 2013; 500(7464): 585-588.##38.	Christensen L, Vuholm S, Roager HM, Nielsen D, Krych L, Kristensen M, et al. Prevotella Abundance Predicts Weight Loss Success in Healthy, Overweight Adults Consuming a Whole-Grain Diet Ad Libitum: A Post Hoc Analysis of a 6-Wk Randomized Controlled Trial. J Nutr 2019; 149(12): 2174-2181.##39.	Leshem A, Segal E, Elinav E. The Gut Microbiome and Individual-Specific Responses to Diet. MSystems 2020; 5(5): e00665-e00620.## 40.	Ruiz Ojeda FJ, Plaza Díaz J, Sáez Lara MJ, Gil A. Effects of Sweeteners on the Gut Microbiota: A Review of Experimental Studies and Clinical Trials. Advances in Nutrition 2019; 10(suppl_1): S31-S48.##41.	Umu ÖCO, Rudi K, Diep DB. Modulation of the gut microbiota by prebiotic fibres and bacteriocins. Microb Ecol Health Dis 2017; 28(1): 1348886.##42.	Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi SJ, et al. Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. Foods 2019; 8(3): 92.##43.	Sanders M, Merenstein D, Merrifield C, Hutkins R. Probiotics for human use. Nutrition Bulletin 2018; 43(3): 212-225.##44.	Martin B, Schwab E. Symbiosis: &#34;Living together&#34; in Chaos. Studies in History of Biology 2012; 4(4): 7-25.##45.	Singh RK, Chang HW, Yan D, Lee KM, Ucmak D, Wong K, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med 2017; 15(1): 73.##46.	Xu Y, Wang N, Tan H-Y, Li S, Zhang C, Feng Y. Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems. Front Microbiol 2020; 11: 219.##47.	Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 2016; 65(3): 426-436.##48.	Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment ##Pharmacol Ther 2015; 42(4): 418-427.##49.	Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. Gut Microbes 2012; 3(4): 289-306.##50.	Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol 2019; 10(277).##51.	Clarke SF, Murphy EF, Nilaweera K, Ross PR, Shanahan F, O'Toole PW, et al. The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes 2012; 3(3): 186-202.##52.	Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013; 34(1): 39-58.##53.	Ford H, Frost G. Glycaemic index, appetite and body weight. The Proceedings of the Nutrition Society 2010; 69(2): 199-203.##54.	Delzenne NM, Neyrinck AM, Cani PD. Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. Microbial Cell Fact 2011; 10(Suppl 1): S10.##55.	Pompei A, Cordisco L, Amaretti A, Zanoni S, Raimondi S, Matteuzzi D, et al. Administration of folate-producing bifidobacteria enhances folate status in Wistar rats. Journal of Nutrition 2007; 137(12): 2742-2746.##56.	Masuda M, Ide M, Utsumi H, Niiro T, Shimamura Y, Murata M. Production Potency of Folate, Vitamin B12, and Thiamine by Lactic Acid Bacteria Isolated from Japanese Pickles. Bioscience, Biotechnology, and Biochemistry 2012; 76(11): 2061-2067.##57.	Schurgers LJ, Joosen IA, Laufer EM, Chatrou ML, Herfs M, Winkens MH, et al. Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One 2012; 7(8): e43229.##58.	Laiño JE, Leblanc JG, Savoy de Giori G. Production of natural folates by lactic acid bacteria starter cultures isolated from artisanal Argentinean yogurts. Can J Microbiol 2012; 58(5): 581-588.##59.	Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr 2018; 57(1): 1-24.##60.	Weaver CM, Martin BR, Nakatsu CH, Armstrong AP, Clavijo A, McCabe LD, et al. Galactooligosaccharides improve mineral absorption and bone properties in growing rats through gut fermentation. J Agric Food Chem 2011; 59(12): 6501-6510.##61.	Sun J. Dietary vitamin D, vitamin D receptor, and microbiome. Curr Opin Clin Nutr Metab Care 2018; 21(6): 471-474.##62.	Wongdee K, Rodrat M, Teerapornpuntakit J, Krishnamra N, Charoenphandhu N. Factors inhibiting intestinal calcium absorption: hormones and luminal factors that prevent excessive calcium uptake. J Physiol Sci 2019; 69(5): 683-696.##63.	Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiological Reviews 2001; 81(3): 1031-1064.##64.	Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987; 28(10): 1221-1227.##65.	den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud D-J, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013; 54(9): 2325-2340.##66.	Markowiak-Kopeć P, Śliżewska K. The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome. Nutrients 2020; 12(4): 1107.##67.	Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol 2020.##68.	Jackson MI, Jewell DE. Balance of saccharolysis and proteolysis underpins improvements in stool quality induced by adding a fiber bundle containing bound polyphenols to either hydrolyzed meat or grain-rich foods. Gut Microbes 2019; 10(3): 298-320.##69.	Ramírez Pérez O, Cruz Ramón V, Chinchilla López P, Méndez Sánchez N. The Role of the Gut Microbiota in Bile Acid Metabolism. Ann Hepatol 2017; 16(suppl 1:s3-105): S15-S20.##70.	Dawson PA, Karpen SJ. Intestinal transport and metabolism of bile acids. J Lipid Res 2015; 56(6): 1085-1099.##71.	Abbasi IHR, Abbasi F, Wang L, Abd El Hack ME, Swelum AA, Hao R, et al. Folate promotes S-adenosyl methionine reactions and the microbial methylation cycle and boosts ruminants production and reproduction. AMB Express 2018; 8(1): 65.##72.	Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19(5): 576-585.##73.	Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, DuGar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472 (7341): 57-63.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>وزیکول‌های خارج سلولی حاصل از میکروبیوتای دستگاه گوارش:
رویکرد جدید مطالعات بالینی</TitleF>
		<TitleE>Extracellular Vesicles Derived from Gastrointestinal Microbiota: A New Approach to Clinical Studies</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>وزیکول&#8204;های خارج سلولی که به طور طبیعی از انواع سلول&#8204;ها از جمله باکتری&#8204;ها آزاد می&#8204;شوند، با انتقال انواع مواد زیستی، آنزیم&#8204;ها، فاکتورهای ویرولانس و تنظیم&#8204;کننده ایمنی و نقش در کلونیزاسیون و راه اندازی مسیرهای سیگنالینگ در میکروبیولوژی پزشکی از اهمیت ویژه ای برخوردارهستند. این وزیکول&#8204;ها در دستگاه گوارش نیز با ترشح از باکتری&#8204;های همزیست یا همان میکروبیوتا با مکانیسم&#8204;های متنوعی بر روی بدن میزبان اثر گذاشته و باعث تغییرات سیستماتیک، متابولیکی و فیزیولوژیکی بسیاری می&#8204;شود. امروزه&#160; نقش این وزیکول&#8204;ها در حفظ هموستاز دستگاه گوارش توسط میکروبیوتا و همچنین پاتوژنز و تشخیص بیماری&#8204;های مرتبط نظیر چاقی، دیابت، سرطان&#8204;ها، بیماری التهابی روده، اختلالات ذهنی و برخی بیماری&#8204;های عفونی به اثبات رسیده است. استفاده موثر از این ویژگی می&#8204;تواند با تعدیل میکروبیوتا و متابولیت&#8204;های آن و همچنین در قالب وزیکول&#8204;های خارج سلولی حاصل از پروبیوتیک&#8204;ها امکان&#8204;پذیر باشد. بنابراین مطالعه این وزیکول&#8204;ها در راستای مطالعات میکروبیوتا و پروبیوتیک&#8204;های نسل بعد رویکرد جدیدی در مطالعات بالینی ارائه می&#8204;دهد. مطالعه مروری به بررسی چگونگی تاثیر وزیکول&#8204;های خارج سلولی حاصل از میکروبیوتا بر سلامت بدن و بروز بیماری&#8204;ها پرداخته است.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Extracellular vesicles, naturally released from all cell types including bacteria, are of great importance in medical microbiology due to transporting a variety of biomaterials, enzymes, and virulence factors, regulating immunity, and having roles in colonization and initiation of signaling pathways. These vesicles are also secreted from microbiota in the gastrointestinal tract and affect the host through various mechanisms by causing many systematic, metabolic, and physiological changes. Nowadays, the role of these vesicles is proven in maintaining gastrointestinal homeostasis, the pathogenesis, and diagnosis of related diseases such as obesity, diabetes, cancer, inflammatory bowel disease, mental disorders, and infectious diseases. Effective use of these characteristics could be possible by modulating the microbiota and its metabolites and using extracellular vesicles derived from probiotics. Therefore, the study of these vesicles as microbiota-derived products and next generation probiotics offers a new approach in clinical studies. The present study investigates how the microbiota-derived extracellular vesicles affect the host&#39;s health and play underlying roles in various diseases.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>152</FPAGE>
			<TPAGE>168</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/242020/11/212020/10/302020/11/202020/10/72020/09/292020/10/262020/11/8
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/8/18
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/62020/12/92021/01/102021/01/62020/12/62020/12/62020/12/162020/12/9
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/19
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>زهرا</Name>
				<MidName></MidName>
				<Family>حسینی توسل</Family>
				<NameE>Zahra</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hoseini Tavassol</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکترای بیوتکنولوژی پزشکی، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران . گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی (MRC)، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>zhtavassol@Gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فاطمه</Name>
				<MidName></MidName>
				<Family>اتحاد مروستی</Family>
				<NameE>Fatemeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ettehad Marvasti</FamilyE>
				<Organizations>
				<Organization>کارشناس ارشد میکروبیولوژی، بخش سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی (MRC)، انستیتو پاستور ایران ، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>elli.ettehad@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>شیرین</Name>
				<MidName></MidName>
				<Family>حسنی رنجبر</Family>
				<NameE>Shirin</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hasani-Ranjbar</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>shirinhasanir@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>هانیه سادات</Name>
				<MidName></MidName>
				<Family>اجتهد</Family>
				<NameE>Hanieh-Sadat</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ejtahed</FamilyE>
				<Organizations>
				<Organization>استادیار،  مرکز تحقیقات علوم غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران و مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haniejtahed@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سید داور</Name>
				<MidName></MidName>
				<Family>سیادت</Family>
				<NameE>Seyed Davar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Siadat</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران.گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی (MRC)، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>d.siadat@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>باقر</Name>
				<MidName></MidName>
				<Family>لاریجانی</Family>
				<NameE>Bagher</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Larijani</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>Larijanib@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>extracellular vesicles</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>next generation probiotics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>وزیکول های خارج سلولی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>پروبیوتیک‌های نسل جدید</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Pascale A, Marchesi N, Marelli C, Coppola A, Luzi L, Govoni S, et al. Microbiota and metabolic diseases. Endocrine 2018; 61(3): 357-371.##2.	Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med 2016; 8(1): 1-12.##3.	Ejtahed HS, Tito RY, Siadat SD, Hasani Ranjbar S, Hoseini Tavassol Z, Rymenans L, et al. Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women: a randomized double-blind clinical trial. Eur J Endocrinol 2019; 180(3): 165-176.##4.	Ejtahed HS, Hoseini Tavassol Z, Khatami S, Zangeneh M, Behrouzi A, Badi SA, et al. Main gut bacterial composition differs between patients with type 1 and type 2 diabetes and non-diabetic adults. J Diabet Metab Disord 2020; 19(1): 1-7.##5.	Woting A, Blaut M. The intestinal microbiota in metabolic disease. Nutrients 2016; 8(4): 202.##6.	Clavel T, Desmarchelier C, Haller D, Gérard P, Rohn S, Lepage P, et al. Intestinal microbiota in metabolic diseases: from bacterial community structure and functions to species of pathophysiological relevance. Gut Microbes 2014; 5(4): 544-551.##7.	Satokari R. Modulation of gut microbiota for health by current and next-generation probiotics. Nutrients 2019; 11(8): 1921.##8.	Molina-Tijeras JA, Gálvez J, Rodríguez-Cabezas ME. The immunomodulatory properties of extracellular vesicles derived from probiotics: a novel approach for the management of gastrointestinal diseases. Nutrients 2019; 11(5): 1038.##9.	Zendeboodi F, Khorshidian N, Mortazavian AM, da Cruz AG. Probiotic: Conceptualization from a new approach. Curr Opin Food Sci 2020.##10.	Huang-Doran I, Zhang CY, Vidal-Puig A. Extracellular vesicles: novel mediators of cell communication in metabolic disease. Trends Endocrinol Metab 2017; 28(1): 3-18.##11.	Muraca M, Putignani L, Fierabracci A, Teti A, Perilongo G. Gut microbiota-derived outer membrane vesicles: under-recognized major players in health and disease? Discov Med 2015; 19(106): 343-348.##12.	Anderson HC, Mulhall D, Garimella R. Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis. Lab Invest 2010; 90(11): 1549-1557.##13.	Konoshenko MY, Lekchnov EA, Vlassov AV, Laktionov PP. Isolation of extracellular vesicles: general methodologies and latest trends. BioMed Res Int 2018; 2018.##14.	Cecil JD, Sirisaengtaksin N, O'Brien-Simpson NM, Krachler AM. Outer membrane vesicle host cell interactions. Microbiol Spectr 2019; 7(1): 10.##15.	Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9(8): 581-593.##16.	Deatherage BL, Cookson BT. Membrane vesicle release in bacteria, eukaryotes, and archaea: a conserved yet underappreciated aspect of microbial life. Infect Immun 2012; 80(6): 1948-1957.##17.	Lee EY, Choi DY, Kim DK, Kim JW, Park JO, Kim S, et al. Gram positive bacteria produce membrane vesicles: proteomics based characterization of Staphylococcus aureus derived membrane vesicles. Proteomics 2009; 9(24): 5425-5436.##18.	Kulp A, Kuehn MJ. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol 2010; 64: 163-184.##19.	Kuehn MJ, Kesty NC. Bacterial outer membrane vesicles and the host–pathogen interaction. Genes Dev 2005; 19(22): 2645-2655.##20.	Liu Y, Defourny KA, Smid EJ, Abee T. Gram-positive bacterial extracellular vesicles and their impact on health and disease. Front Microbiol 2018; 9: 1502.##21.	Haurat MF, Elhenawy W, Feldman MF. Prokaryotic membrane vesicles: new insights on biogenesis and biological roles. Biol Chem 2015; 396(2): 95-109.##22.	Schertzer JW, Whiteley M. A bilayer-couple model of bacterial outer membrane vesicle biogenesis. M Bio 2012; 3(2): e00297-11.##23.	Jiang Y, Kong Q, Roland KL, Curtiss III R. Membrane vesicles of Clostridium perfringens type A strains induce innate and adaptive immunity. Int J Med Microbiol 2014; 304(3-4): 431-443.##24.	MacDonald IA, Kuehn MJ. Offense and defense: microbial membrane vesicles play both ways. Res Microbiol 2012; 163(9-10): 607-618.##25.	Prados-Rosales R, Weinrick BC, Piqué DG, Jacobs WR, Casadevall A, Rodriguez GM. Role for Mycobacterium tuberculosis membrane vesicles in iron acquisition. J Bacterio 2014; 196(6): 1250-1256.##26.	Kulkarni HM, Jagannadham MV. Biogenesis and multifaceted roles of outer membrane vesicles from Gram-negative bacteria. Microbiology 2014; 160(10): 2109-2121.##27.	Klimentová J, Stulík J. Methods of isolation and purification of outer membrane vesicles from gram-negative bacteria. Microbiol Res 2015; 170: 1-9.##28.	Behrouzi A, Mazaheri H, Falsafi S, Hoseini Tavassol Z, Moshiri A, Siadat SD. Intestinal effect of the probiotic Escherichia coli strain Nissle 1917 and its OMV. J Diabet Metab Disord 2020; 19(1): 597-604.##29.	Chang X, Wang S-L, Zhao S-B, Shi Y-H, Pan P, Gu L, et al. Extracellular Vesicles with Possible Roles in Gut Intestinal Tract Homeostasis and IBD. Mediators Inflamm 2020; 2020.##30.	Saggioro A. Leaky gut, microbiota, and cancer: an incoming hypothesis. J Clin Gastroenterol 2014; 48(suppl 1): S62-S66.##31.	Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke J-D, Serino M, et al. Intestinal permeability–a new target for disease prevention and therapy. BMC gastroenterol 2014; 14(1): 189.##32.	Ling Z, Dayong C, Denggao Y, Yiting W, Liaoqiong F, Zhibiao W. Escherichia Coli Outer Membrane Vesicles Induced DNA Double-Strand Breaks in Intestinal Epithelial Caco-2 Cells. Med Sci Monit Basic Res 2019; 25: 45-52.##33.	Behrouzi A, Ashrafian F, Mazaheri H, Lari A, Nouri M, Riazi Rad F, et al. The importance of interaction between MicroRNAs and gut microbiota in several pathways. Microb Pathog 2020; 144: 104200.##34.	Carvalho AL, Fonseca S, Miquel-Clopés A, Cross K, Kok K-S, Wegmann U, et al. Bioengineering commensal bacteria-derived outer membrane vesicles for delivery of biologics to the gastrointestinal and respiratory tract. J Extracell Vesicles 2019; 8(1): 1632100.##35.	MirJafari Tafti ZS, Moshiri A, Ettahad Marvasti F, Tarashi S, Sadati Khalili SF, Motahhary A, et al. The effect of saturated and unsaturated fatty acids on the production of outer membrane vesicles from Bacteroides fragilis and Bacteroides thetaiotaomicron. Gastroenterol Hepatol Bed Bench 2019; 12(2): 155-162.##36.	Shen Y, Torchia MLG, Lawson GW, Karp CL, Ashwell JD, Mazmanian SK. Outer membrane vesicles of a human commensal mediate immune regulation and disease protection. Cell Host Microbe 2012; 12(4): 509-520.##37.	Maerz JK, Steimle A, Lange A, Bender A, Fehrenbacher B, Frick JS. Outer membrane vesicles blebbing contributes to B. vulgatus mpk-mediated immune response silencing. Gut Microbes 2018; 9(1): 1-12.##38.	Zakharzhevskaya NB, Vanyushkina AA, Altukhov IA, Shavarda AL, Butenko IO, Rakitina DV, et al. Outer membrane vesicles secreted by pathogenic and nonpathogenic Bacteroides fragilis represent different metabolic activities. Sci Rep 2017; 7(1): 1-16.##39.	Kang C-S, Ban M, Choi E-J, Moon H-G, Jeon J-S, Kim D-K, et al. Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PloS one 2013; 8(10): e76520.##40.	van Bergenhenegouwen J, Kraneveld AD, Rutten L, Kettelarij N, Garssen J, Vos AP. Extracellular vesicles modulate host-microbe responses by altering TLR2 activity and phagocytosis. PloS one 2014; 9(2): e89121.##41.	Patten DA, Hussein E, Davies SP, Humphreys PN, Collett A. Commensal-derived OMVs elicit a mild proinflammatory response in intestinal epithelial cells. Microbiology 2017; 163(5): 702-711.##42.	Alvarez C-S, Badia J, Bosch M, Giménez R, Baldomà L. Outer membrane vesicles and soluble factors released by probiotic Escherichia coli Nissle 1917 and commensal ECOR63 enhance barrier function by regulating expression of tight junction proteins in intestinal epithelial cells. Front Microbiol 2016; 7: 1981.##43.	Cañas M-A, Fábrega M-J, Giménez R, Badia J, Baldomà L. Outer membrane vesicles from probiotic and commensal Escherichia coli activate NOD1-mediated immune responses in intestinal epithelial cells. Front Microbiol 2018; 9: 498.##44.	Behzadi E, Hosseini HM, Fooladi AAI. The inhibitory impacts of Lactobacillus rhamnosus GG-derived extracellular vesicles on the growth of hepatic cancer cells. Microb Pathog 2017; 110: 1-6.##45.	Domínguez Rubio AP, Martínez JH, Martínez Casillas DC, Coluccio Leskow F, Piuri M, Pérez OE. Lactobacillus casei BL23 produces microvesicles carrying proteins that have been associated with its probiotic effect. Front Microbiol 2017; 8: 1783.##46.	Li M, Lee K, Hsu M, Nau G, Mylonakis E, Ramratnam B. Lactobacillus-derived extracellular vesicles enhance host immune responses against vancomycin-resistant enterococci. BMC microbiol 2017; 17(1): 66.##47.	Yonezawa H, Osaki T, Woo T, Kurata S, Zaman C, Hojo F, et al. Analysis of outer membrane vesicle protein involved in biofilm formation of Helicobacter pylori. Anaerobe 2011; 17(6): 388-390.##48.	Ismail S, Hampton MB, Keenan JI. Helicobacter pylori outer membrane vesicles modulate proliferation and interleukin-8 production by gastric epithelial cells. Infect Immun 2003; 71(10): 5670-5675.##49.	Chatterjee D, Chaudhuri K. Association of cholera toxin with Vibrio cholerae outer membrane vesicles which are internalized by human intestinal epithelial cells. FEBS Lett 2011; 585(9): 1357-1362.##50.	Mondal A, Tapader R, Chatterjee NS, Ghosh A, Sinha R, Koley H, et al. Cytotoxic and inflammatory responses induced by outer membrane vesicle-associated biologically active proteases from Vibrio cholerae. Infect Immun 2016; 84(5): 1478-1490.##51.	Bielaszewska M, Marejková M, Bauwens A, Kunsmann-Prokscha L, Mellmann A, Karch H. Enterohemorrhagic Escherichia coli O157 outer membrane vesicles induce interleukin 8 production in human intestinal epithelial cells by signaling via Toll-like receptors TLR4 and TLR5 and activation of the nuclear factor NF-κB. Int J Med Microbiol 2018; 308(7): 882-889.##52.	Nicholas A, Jeon H, Selasi GN, Na SH, Kwon HI, Kim YJ, et al. Clostridium difficile-derived membrane vesicles induce the expression of pro-inflammatory cytokine genes and cytotoxicity in colonic epithelial cells in vitro. Microb Pathog 2017; 107: 6-11.##53.	Elmi A, Nasher F, Jagatia H, Gundogdu O, Bajaj Elliott M, Wren B, et al. Campylobacter jejuni outer membrane vesicle associated proteolytic activity promotes bacterial invasion by mediating cleavage of intestinal epithelial cell E cadherin and occludin. Cell Microbiol 2016; 18(4): 561-572.##54.	Ashrafian F, Shahryari A, Behrouzi A, Moradi HR, Lari A, Hadifar S, et al. Akkermansia muciniphila-derived extracellular vesicles as a mucosal delivery vector for amelioration of obesity in mice. Front Microbiol 2019; 10: 2155.##55.	Moosavi SM, Sepahi AA, Mousavi SF, Vaziri F, Siadat SD. The effect of Faecalibacterium prausnitzii and its extracellular vesicles on the permeability of intestinal epithelial cells and expression of PPARs and ANGPTL4 in the Caco-2 cell culture model. J Diabetes Metab Disord 2020: 1-9.##56.	Macia L, Nanan R, Hosseini-Beheshti E, Grau GE. Host-and Microbiota-Derived Extracellular Vesicles, Immune Function, and Disease Development. Int J Mol Sci 2019; 21(1): 107.##57.	Chelakkot C, Choi Y, Kim D-K, Park HT, Ghim J, Kwon Y, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp Mol Med 2018; 50(2): e450-e.##58.	Choi Y, Kwon Y, Kim D-K, Jeon J, Jang SC, Wang T, et al. Gut microbe-derived extracellular vesicles induce insulin resistance, thereby impairing glucose metabolism in skeletal muscle. Sci Rep 2015;5:15878##59.	Peterson SN, Bradley LM, Ze’ev AR. The gut microbiome: An unexpected player in cancer immunity. Curr Opin Neurobiol 2020; 62: 48-52.##60.	Chronopoulos A, Kalluri R. Emerging role of bacterial extracellular vesicles in cancer. Oncogene 2020; 39: 6951-6960.##61.	Kim OY, Park HT, Dinh NTH, Choi SJ, Lee J, Kim JH, et al. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat Comm 2017; 8(1): 626.##62.	Gujrati V, Kim S, Kim S-H, Min JJ, Choy HE, Kim SC, et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano 2014; 8(2): 1525-1537.##63.	Wei S-C, Wei W, Peng W-J, Liu Z, Cai Z-Y, Zhao B. Metabolic Alterations in the Outer Membrane Vesicles of Patients with Alzheimer’s Disease: An LC-MS/MS-based Metabolomics Analysis. Curr Alzheimer Res 2019; 16(13): 1183-1195.##64.	Singhrao SK, Olsen I. Are Porphyromonas gingivalis Outer Membrane Vesicles Microbullets for Sporadic Alzheimer’s Disease Manifestation? J Alzheimer's Dis Rep 2018; 2(1): 219-228.##65.	Kaparakis-Liaskos M, Ferrero RL. Immune modulation by bacterial outer membrane vesicles. Nat Rev Immunol 2015; 15(6): 375-387.##66.	Shin T, Kim E, McDowell A, Kim Y. Impact of gut microbiota extracellular vesicles on inflammatory and metabolic disease. J Clin Nutr Food Sci 2019; 2(3): 68-78.##67.	Seo MK, Park EJ, Ko SY, Choi EW, Kim S. Therapeutic effects of kefir grain Lactobacillus-derived extracellular vesicles in mice with 2, 4, 6-trinitrobenzene sulfonic acid-induced inflammatory bowel disease. J Dairy Sci 2018; 101(10): 8662-8671.##68.	Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy 2020; 16(1): 38-51.##69.	O’Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol 2017; 2(5): 1-6.##70.	Fábrega MJ, Aguilera L, Giménez R, Varela E, Alexandra Canas M, Antolín M, et al. Activation of immune and defense responses in the intestinal mucosa by outer membrane vesicles of commensal and probiotic Escherichia coli strains. Front Microbiol 2016; 7: 705.##71.	Fábrega M-J, Rodríguez-Nogales A, Garrido-Mesa J, Algieri F, Badía J, Giménez R, et al. Intestinal anti-inflammatory effects of outer membrane vesicles from Escherichia coli Nissle 1917 in DSS-experimental colitis in mice. Front Microbiol 2017; 8: 1274.##72.	Chu H, Khosravi A, Kusumawardhani IP, Kwon AH, Vasconcelos AC, Cunha LD, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science 2016; 352(6289): 1116-1120.##73.	Badi SA, Khatami S, Irani HS, Siadat SD. Induction effects of Bacteroides fragilis derived outer membrane vesicles on toll like receptor 2, toll like receptor 4 genes expression and cytokines concentration in human intestinal epithelial cells. Cell J 2019; 21(1): 57-61.##74.	Caruana JC, Walper SA. Bacterial Membrane Vesicles as Mediators of Microbe–Microbe and Microbe–Host Community Interactions. Front Microbiol 2020; 11:4 32.##75.	Al Nedawi K, Mian MF, Hossain N, Karimi K, Mao YK, Forsythe P, et al. Gut commensal microvesicles reproduce parent bacterial signals to host immune and enteric nervous systems. FASEB J 2015; 29(2): 684-695.##76.	Kim J-H, Jeun E-J, Hong C-P, Kim S-H, Jang MS, Lee E-J, et al. Extracellular vesicle–derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression. J Allergy Clin Immunol 2016; 137(2): 507-516.##77.	López P, González-Rodríguez I, Sánchez B, Gueimonde M, Margolles A, Suárez A. Treg-inducing membrane vesicles from Bifidobacterium bifidum LMG13195 as potential adjuvants in immunotherapy. Vaccine 2012; 30(5): 825-829.##78.	Chang C-J, Lin T-L, Tsai Y-L, Wu T-R, Lai W-F, Lu C-C, et al. Next generation probiotics in disease amelioration. Journal ##of Food and Drug Analysis 2019; 27(3): ##615-622.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>ارتباط بین میکروبیوتای روده و متابولیسم سروتونین</TitleF>
		<TitleE>Interaction between Intestinal Microbiota and Serotonin Metabolism</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>میکروبیوتای روده تولید مولکول&#8204;های سیگنالینگ، مانند سروتونین (5-Hydroxytryptamine: 5-HT) را در میزبان تنطیم می&#8204;کنند. سروتونین یک آمین بیوژنیک است که به&#8204;عنوان یک نوروترنسمیتر در روده و مغز حضور دارد. بین میکروبیوتای دستگاه گوارش انسان و سیستم سروتونین تعامل کاملی وجود دارد. میکروبیوتای روده نقش مهمی در مسیرهای سیگنالینگ سروتونین از طریق محور روده- مغز ایفا می&#8204;کند و نقش مهمی در پاتوفیزیولوژی بیماری&#8204;های متابولیکی و فیزیولوژیکی مرتبط با سروتونین دارد. هدف مطالعه حاضر، بررسی ارتباط بین میکروبیوتای روده و نقش آن در تنظیم سطح سروتونین محیطی است. با توجه به عدم پژوهش کافی و تعیین نشدن ارتباط دقیق بین میکروبیوتا و سیستم سروتونین، اهمیت این مطالعه مروری دو چندان است. در مطالعات متعدد تغییر در میکروبیوتای روده ممکن است سبب تعدیل سیگنالینگ سروتونین شود. همچنین هرگونه اختلال در سیستم سروتونین و عدم هومئوستازی در آن می&#8204;تواند در تغییر هومئوستازی میکروبیوتای روده به دیسبیوزیس موثر باشد و در نهایت باعث ایجاد التهاب در روده و اختلالات دستگاه گوارش شود. امروزه با افزایش مطالعات در زمینه &#160;مکانیسم&#8204;های دقیق تعامل بین میکروبیوتای روده و سیستم سروتونین مشخص شده است که بین میکروبیوتای دستگاه گوارش و سطح سروتونین ارتباط وجود دارد. در این راستا مطالعه حاضر نشان داد که میکروبیوتای روده می&#8204;تواند بر سیستم سروتونین در محور روده و مغز تاثیرگذارد. همچنین سیگنالینگ سروتونین در مسیر محور روده- مغز ممکن است در راهکارهای درمانی جدید برای بهبود اختلالات مرتبط با سروتونین در نظر گرفته شود. از این رو، مطالعات بیش&#8204;تری به منظور تعیین دقیق&#8204;تر ارتباط بین میکروبیوتای روده و سیستم سروتونین پیشنهاد می&#8204;شود.
&#160;</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Gut microbiota regulates the production of signaling molecules, such as serotonin or 5-Hydroxytryptamine: 5-HT in the host. Serotonin is a biogenic amine that acts as a neurotransmitter in the gut and brain. There is a perfect interaction between human gastrointestinal microbiota and the serotonin system. The gut microbiota plays an important role in the serotonin signaling pathways through the gut-brain axis. It also has a major role in the pathophysiology of serotonin-related metabolic and physiological diseases. The aim of this review was to investigate the relationship between gut microbiota and their role in regulating peripheral serotonin levels. This study could be highly important since there is paucity of information on the relationship between intestinal microbiota and the serotonin system. Numerous studies have shown that changes in the gut microbiota may modulate serotonin signaling system. Also, any disorder in the serotonin system and lack of homeostasis in this system can be effective in the homeostasis shift of intestinal microbiota to dysbiosis and ultimately play a role in causing inflammation in the intestine and gastrointestinal disorders. Evidence on the exact mechanisms of the interaction between intestinal microbiota and serotonin levels indicates a link between intestinal microbiota and this system. Current review showed that gut microbiota could affect the serotonin system through the gut-brain axis. Serotonin signaling in the gut-brain axis could be considered in new therapies to improve serotonin-related disorders. Therefore, further studies are proposed to more accurately determine the association between the gut microbiota and the serotonin system.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>169</FPAGE>
			<TPAGE>180</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/242020/11/212020/10/302020/11/202020/10/72020/09/292020/10/262020/11/82020/10/19
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/7/28
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/62020/12/92021/01/102021/01/62020/12/62020/12/62020/12/162020/12/92020/12/15
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/25
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>رضوان</Name>
				<MidName></MidName>
				<Family>یعقوب فر</Family>
				<NameE>Rezvan</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Yaghobfar</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکتری تخصصی (Ph.D) باکتری شناسی، گروه مایکوباکتریولوژی و تحقیقات ریوی، مرکز تحقیقات میکروب شناسی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>rezvanyaghobfar@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فرزام</Name>
				<MidName></MidName>
				<Family>وزیری</Family>
				<NameE>Farzam</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Vaziri</FamilyE>
				<Organizations>
				<Organization>دانشیار، گروه مایکوباکتریولوژی و تحقیقات ریوی، مرکز تحقیقات میکروب شناسی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>farzam_vaziri@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سید علی</Name>
				<MidName></MidName>
				<Family>نجومی</Family>
				<NameE>Seyed Ali</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Nojomi</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه مایکوباکتریولوژی و تحقیقات ریوی، مرکز تحقیقات میکروب شناسی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>ali.nojoumi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>ابوالفضل</Name>
				<MidName></MidName>
				<Family>فاتح</Family>
				<NameE>Abolfazl</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Fateh</FamilyE>
				<Organizations>
				<Organization>استادیار، گروه مایکوباکتریولوژی و تحقیقات ریوی، مرکز تحقیقات میکروب شناسی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>afateh2@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>شهره</Name>
				<MidName></MidName>
				<Family>خاتمی</Family>
				<NameE>Shohreh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Khatami</FamilyE>
				<Organizations>
				<Organization>استاد، گروه بیوشیمی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>sh-khatami@pasteur.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سید داور</Name>
				<MidName></MidName>
				<Family>سیادت</Family>
				<NameE>Seyed Davar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Siadat</FamilyE>
				<Organizations>
				<Organization>استاد، گروه مایکوباکتریولوژی و تحقیقات ریوی، مرکز تحقیقات میکروب شناسی، انستیتو پاستور ایران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>d.siadat@gmail.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>serotonin</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiome</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>gut-brain axis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>neurotransmitter</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سروتونین</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوم</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>محور روده- مغز</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>نوروترنسمیتر</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Prescott JF. History and Current use of antimicrobial drugs in veterinary medicine. Antimicrobial Resistance in Bacteria from Livestock and Companion Animals. Aarestrup F, Shen J, Cavaco L Editor. Washington, 2018.##2.	Metchnikoff II. The prolongation of life: optimistic studies. NewYork: Springer; 2004.##3.	O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7(7): 688-693.##4.	Frank DN, Amand ALS, Feldman RA, Boe deker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007; 104(34): 13780-13785.##5.	Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun 2015; 48: 186-194.##6.	Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 2017; 5(1): 10.##7.	Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14(2): 207-215.##8.	Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature 2006; 444(7122): 1022-1023.##9.	Maurice CF, Haiser HJ, Turnbaugh PJ. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013; 152(1-2): 39-50.##10.	Manichanh C, Eck A, Varela E, Roca J, Clemente JC, González A, et al. Anal gas evacuation and colonic microbiota in patients with flatulence: effect of diet. Gut 2014; 63(3): 401-408.##11.	Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013; 2: e01202.##12.	Borre YE, Moloney RD, Clarke G, Dinan TG, Cryan JF. The impact of microbiota on brain and behavior: mechanisms &#38; therapeutic potential. Adv Exp Med Biol 2014; 817: 373-403.##13.	Janssen AW, Kersten S. Potential mediators linking gut bacteria to metabolic health: a critical view. J Physiol 2017; 595(2): 477-487.##14.	Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe−/− mice. Circulation 2016; 133(24): 2434-2446.##15.	Li Q, Zhou J-M. The microbiota–gut–brain axis and its potential therapeutic role in autism spectrum disorder. Neuroscience 2016; 324: 131-139.##16.	Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132(1): 397-414.##17.	Perry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, et al. Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome. Nature 2016; 534(7606):213-217.##18.	Stasi C, Bellini M, Bassotti G, Blandizzi C, Milani S. Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol 2014; 18(7): 613-621.##19.	Kim D-Y, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95(10): 2698.##20.	Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 2003; 3: S25-S34.##21.	Oláh T, Ocsovszki I, Mándi Y, Pusztai R, Bakay M, Balint E. Opposite effects of serotonin and interferon-α on the membrane potential and function of human natural killer cells. In Vitro Cell Dev Biol Anim 2005; 41(5-6): 165-170.##22.	Albertazzi P. Noradrenergic and serotonergic modulation to treat vasomotor symptoms. J Br Menopause Soc 2006; 12(1): 7-11.##23.	Rea K, Dinan TG, Cryan JF. The microbiome: a key regulator of stress and neuroinflammation. Neurobiol Stress 2016; 4: 23-33.##24.	Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, Velasco-Velázquez MA, Garcés-Alvarez ME, Hurtado-Alvarado G, et al. Immunomodulatory effects mediated by serotonin. J Immunol Res 2015; 2015: 354957.##25.	Reigstad CS, Salmonson CE, III JFR, Szurszewski JH, Linden DR, Sonnenburg JL, et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J 2015; 29(4): 1395-1403.##26.	Stasi C, Sadalla S, Milani S. The Relationship Between the Serotonin Metabolism, Gut-Microbiota and the Gut-Brain Axis. Curr Drug Metab 2019; 20(8): 646-655.##27.	Nzakizwanayo J, Dedi C, Standen G, Macfarlane WM, Patel BA, Jones BV. Escherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance. Sci Rep 2015; 5: 17324.##28.	Hata T, Asano Y, Yoshihara K, KimuraTodani T, Miyata N, Zhang XT, et al. Regulation of gut luminal serotonin by commensal microbiota in mice. PLoS One 2017; 12(7): e0180745.##29.	Mandić AD, Woting A, Jaenicke T, Sander A, Sabrowski W, Rolle-Kampcyk U, et al. Clostridium ramosum regulates enterochromaffin cell development and serotonin release. Sci Rep 2019; 9(1): 1177.##30.	Liu W-H, Chuang H-L, Huang Y-T, Wu C-C, Chou G-T, Wang S, et al. Alteration of behavior and monoamine levels attributable to Lactobacillus plantarum PS128 in germ-free mice. Behav Brain Res 2016; 298: 202-209.##31.	Borrelli L, Aceto S, Agnisola C, De Paolo S, Dipineto L, Stilling RM, et al. Probiotic modulation of the microbiota-gut-brain axis and behaviour in zebrafish. Sci Rep 2016; 6: 30046.##32.	Tian P, Wang G, Zhao J, Zhang H, Chen W. Bifidobacterium with the role of 5-hydroxytryptophan synthesis regulation alleviates the symptom of depression and related microbiota dysbiosis. J Nutr Biochem 2019; 66: 43-51.##33.	Li H, Wang P, Huang L, Li P, Zhang D. Effects of regulating gut microbiota on the serotonin metabolism in the chronic unpredictable mild stress rat model. Neurogastroenterol Motil 2019; 31(10): e13677.##34.	Liang S, Wang T, Hu X, Luo J, Li W, Wu X, et al. Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience 2015; 310: 561-577.##35.	Cao YN, Feng LJ, Wang BM, Jiang K, Li S, Xu X, et al. Lactobacillus acidophilus and Bifidobacterium longum supernatants upregulate the serotonin transporter expression in intestinal epithelial cells. Saudi J Gastroenterol 2018; 24(1): 59-66.##36.	Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015; 161(2): 264-276.##37.	Margolis KG, Li Z, Stevanovic K, Saurman V, Israelyan N, Anderson GM, et al. Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function. J Clin Invest 2016; 126(6): 2221-2235.##38.	Walther DJ, Peter J-U, Bashammakh S, Hortnagl H, Voits M, Fink H, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299(5603): 76.##39.	Gross ER, Gershon MD, Margolis KG, Gertsberg ZV, Cowles RA. Neuronal serotonin regulates growth of the intestinal mucosa in mice. Gastroenterology 2012; 143(2): 408-417. e2.##40.	Mawe GM, Hoffman JM. Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013; 10(8): 473.##41.	Jin D-C, Cao H-L, Xu M-Q, Wang S-N, Wang Y-M, Yan F, et al. Regulation of the serotonin transporter in the pathogenesis ##of irritable bowel syndrome. World J Gastroenterol 2016; 22(36): 8137-8148##42.	Tada Y, Ishihara S, Kawashima K, Fukuba N, Sonoyama H, Kusunoki R, et al. Downregulation of serotonin reuptake transporter gene expression in healing colonic mucosa in presence of remaining low grade inflammation in ulcerative colitis. J Gastroenterol Hepatol 2016; 31(8): 1443-1452.##43.	Chen J-X, Pan H, Rothman TP, Wade PR, Gershon MD. Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am J Physiol 1998; 275(3): G433-G448.##44.	Gershon M. serotonin receptors and transporters—roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004; 20(Suppl 7): 3-14.##45.	Costa M, Brookes SJ, Steeled P, Gibbins I, Burcher E, Kandiah C. Neurochemical classification of myenteric neurons in the guinea-pig ileum. Neuroscience 1996; 75(3): 949-967.##46.	McHugh S, Barkus C, Lima J, Glover L, Sharp T, Bannerman D. SERT and uncertainty: serotonin transporter expression influences information processing biases for ambiguous aversive cues in mice. Genes Brain Behav 2015; 14(4): 330-336.##47.	Bian X, Patel B, Dai X, Galligan JJ, Swain G. High mucosal serotonin availability in neonatal guinea pig ileum is associated with low serotonin transporter expression. Gastroenterology 2007; 132(7): 2438-2447.##48.	Wang Y, Ge X, Wang W, Wang T, Cao H, Wang B, et al. Lactobacillus rhamnosus GG supernatant upregulates serotonin transporter expression in intestinal epithelial cells and mice intestinal tissues. Neurogastroenterol Motil 2015; 27(9): 1239-1248.##49.	Blenau W, Baumann A. Serotonin Receptor Technologies. New York: Humana Press; 2015.##50.	MWJ de Bruin N, G Kruse C. 5-HT6 receptor antagonists: potential efficacy for the treatment of cognitive impairment in Schizophrenia. Curr Pharm Des 2015; 21(26): 3739-3759.##51.	Morton RA, Baptista-Hon DT, Hales TG, Lovinger DM. Agonist- and antagonist-induced up-regulation of surface 5-HT3 A receptors. Br J Pharmacol 2015; 172(16): 4066-4077.##52.	Kho ZY, Lal SK. The human gut microbiome–a potential controller of wellness and disease. Front Microbiol 2018; 9: 1835.##53.	Ashrafian F, Shahryari A, Behrouzi A, Moradi HR, Lari A, Hadifar S, et al. Akkermansia muciniphila-derived extracellular vesicles as a mucosal delivery vector for amelioration of obesity in mice. Front Microbiol 2019; 10: 2155.##54.	Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 2018; 68(2): 280-295.##55.	Wall R, Cryan JF, Ross RP, Fitzgerald GF, Dinan TG, Stanton C. Bacterial neuroactive compounds produced by psychobiotics. Adv Exp Med Biol 2014; 817: 221-239.##56.	Özoğul F, Kuley E, Özoğul Y, Özoğul İ. The function of lactic acid bacteria on biogenic amines production by food-borne pathogens in arginine decarboxylase broth. Food Sci Technol Res 2012; 18(6): 795-804.##57.	Shishov V, Kirovskaya T, Kudrin V, Oleskin A. Amine neuromediators, their precursors, and oxidation products in the culture of Escherichia coli K-12. Appl Biochem Microbiol 2009; 45(5): 494-497.##58.	Özoğul F. Production of biogenic amines by Morganella morganii, Klebsiella pneumoniae and Hafnia alvei using a rapid HPLC method. Eur Food Res Technol 2004; 219(5): 465-469.##59.	Sjögren K, Engdahl C, Henning P, Lerner UH, Tremaroli V, Lagerquist MK, et al. The gut microbiota regulates bone mass in mice. J Bone Miner Res 2012; 27(6): 1357-1367.##60.	Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci 2009; 106(10): 3698-3703.##61.	Ge X, Ding C, Zhao W, Xu L, Tian H, Gong J, et al. Antibiotics-induced depletion of mice microbiota induces changes in host serotonin biosynthesis and intestinal motility. J Pathol Transl Med 2017; 15(1): 1-9.##62.	Olivier B, Soudijn W, van Wijngaarden I. Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors. Prog Drug Res 2000; 54: 59-119.##63.	Fukumoto S, Tatewaki M, Yamada T, Fujimiya M, Mantyh C, Voss M, et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 2003; 284(5): R1269-R1276.##64.	Bonnin A, Levitt P. Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain. Neuroscience 2011; 197: 1-7.##65.	De Vadder F, Grasset E, Holm LM, Karsenty G, Macpherson AJ, Olofsson LE, et al. Gut microbiota regulates maturation of the adult enteric nervous system via enteric serotonin networks. Proc Natl Acad Sci U S A 2018; 115(25): 6458-6463.##66.	McLean PG, Borman RA, Lee K. 5-HT in the enteric nervous system: gut function and neuropharmacology. Trends Neurosci 2007; 30(1): 9-13.##67.	Gribble FM, Reimann F. Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu Rev Physiol 2016; 78: 277-299.##68.	Lauritzen KH, Morland C, Puchades M, Holm-Hansen S, Hagelin EM, Lauritzen F, et al. Lactate receptor sites link neurotransmission, neurovascular coupling, and brain energy metabolism. Cereb Cortex 2014; 24(10): 2784-2795.##69.	McAllister MS, Krizanac-Bengez L, Macchia F, Naftalin RJ, Pedley KC, Mayberg MR, et al. Mechanisms of glucose transport at the blood–brain barrier: an in vitro study. Brain Res 2001; 904(1): 20-30.##70.	Mittal R, Debs LH, Patel AP, Nguyen D, Patel K, O'Connor G, et al. Neurotransmitters: The Critical Modulators Regulating Gut–Brain Axis. J Cell Physiol 2017; 232(9): 2359-2372.##71.	Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry 2013; 74(10): 720-726.##72.	Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y, et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006; 55(2): 191-196.##73.	Lyte M. Microbial endocrinology in the microbiome-gut-brain axis: how bacterial production and utilization of neurochemicals influence behavior. PLoS Pathog 2013; 9(11): e1003726.##74.	Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney R, Shanahan F, et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry 2013; 18(6): 666-673.##75.	Mawe GM, Hoffman JM. Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013; 10(8): 473-486.##76.	Liu Y, Zhao J, Guo W. Emotional roles of mono-aminergic neurotransmitters in major depressive disorder and anxiety disorders. Front Psychol 2018; 9: 2201.##77.	Berer K, Mues M, Koutrolos M, Al Rasbi Z, Boziki M, Johner C, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479(7374): 538-541.##78.	Chervonsky AV. Microbiota and autoimmunity. Cold Spring Harb Perspect Biol 2013; 5(3): a007294.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>نقش میکروبیوم روده در سندرم تخمدان پلی کیستیک</TitleF>
		<TitleE>Role of Gut Microbiome in Polycystic Ovary Syndrome</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>&#160;سندرم تخمدان پلی&#8204;کیستیک (PCOS) یک اختلال پیچیده متابولیک و غدد درون ریز است که 13-8 درصد از زنان سنین باروری را در سراسر جهان تحت تأثیر قرار می&#8204;دهد. این اختلال معمولاً با اختلالات قاعدگی، ناباروری، چاقی و مقاومت به انسولین همراه است. اگرچه دلیل اصلی این سندرم ناشناخته است، اما محققان طی چند سال اخیر ارتباط بین تغییرات میکروبیوم روده (دیس بیوزیس) را با بسیاری از انواع بیماری&#8204;های غدد درون ریز نشان داده&#8204;اند. لذا این مقاله مروری با هدف درک بهتر نقش میکروبیوم روده در ایجاد و پیشرفت بیماری سندرم تخمدان پلی کیستیک و مکانیسم&#8204;های زمینه&#8204;ساز این بیماری انجام شده است. براساس جمع&#8204;بندی یافته&#8204;های اخیر در مورد نقش میکروبیوتای روده در بروز این بیماری، هرچند هنوز نمی&#8204;توان با قطعیت در این خصوص نتیجه&#8204;گیری کرد اما شواهدی وجود دارد که نشان می&#8204;دهد با کنترل متابولیک افراد شاید بتوان از بروز PCOS پیشگیری کرد. به منظور ارائه رویکردهای درمانی جدید برای زنان مبتلا به PCOS، روشن شدن مکانیسم&#8204;های احتمالی زمینه&#8204;ای از اهمیت ویژه ای برخوردار است. مطالعات نشان داده&#8204;اند که اصلاح میکروبیوم روده در زنان مبتلا به PCOS، با استفاده از مداخلات پروبیوتیک، پری&#8204;بیوتیک، سین بیوتیک و روش&#8204;های پیوند میکروبیوتای مدفوع، می&#8204;تواند در بهبود بسیاری از علائم این سندرم و جلوگیری از بروز عوارض بیش&#8204;تر موثر باشد. بنابراین توصیه می&#8204;شود در کنار سایر درمان&#8204;های متداول، تعدیل میکروبیوتای روده هم مورد توجه قرار گیرد. البته به تحقیقات و کاوش بیش&#8204;تری در این زمینه در آینده نیاز می&#8204;باشد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>&#160;Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that affects 8-13% of women at reproductive age worldwide. This disorder is usually associated with menstrual disorders, infertility, obesity, and insulin resistance. The underlying cause of this syndrome is unknown, however in recent years, researchers have shown an association between intestinal microbiota alterations )dysbiosis( and many types of endocrine diseases. Therefore, this review article aimed to improve understanding about the role of intestinal microbiome in development and progression of polycystic ovary syndrome and the underlying mechanisms of this disease. Based on recent findings on the role of intestinal microbiota in the development of this disease, metabolic control may help to prevent that, however it is not yet conclusive. Exploring possible underlying mechanisms is of particular importance for providing new treatment approaches in women with polycystic ovary syndrome. Studies showed that modification of intestinal microbiome in women with PCOS using probiotics, prebiotics, synbiotics, and fecal microbiota transplantation could be effective in improving many of the symptoms of this syndrome and preventing further complications. Therefore, gut microbiota modification is recommended to be considered along with other common treatments. Of course, more research is needed in this field.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>181</FPAGE>
			<TPAGE>199</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/242020/11/212020/10/302020/11/202020/10/72020/09/292020/10/262020/11/82020/10/192020/11/20
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/8/30
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/62020/12/92021/01/102021/01/62020/12/62020/12/62020/12/162020/12/92020/12/152020/12/15
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/25
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>ذکرا</Name>
				<MidName></MidName>
				<Family>زاغی</Family>
				<NameE>Zekra</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Zaghi</FamilyE>
				<Organizations>
				<Organization>دانشجوی دکترای میکروبیولوژی، گروه زیست شناسی، دانشگاه آزاد اسلامی، واحد علوم و تحقیقات، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>zaghi1360@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سید داور</Name>
				<MidName></MidName>
				<Family>سیادت</Family>
				<NameE>Seyed-Davar</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Siadat</FamilyE>
				<Organizations>
				<Organization>استاد، گروه سل و تحقیقات ریوی، مرکز تحقیقات میکروبیولوژی، انستیتو پاستور ایران، تهران، ایران   مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>d.siadat@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>هانیه السادات</Name>
				<MidName></MidName>
				<Family>اجتهد</Family>
				<NameE>Hanieh-Sadat</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ejtahed</FamilyE>
				<Organizations>
				<Organization>مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران    استادیار، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haniejtahed@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>نوشین</Name>
				<MidName></MidName>
				<Family>شیرزاد</Family>
				<NameE>Nooshin</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shirzad</FamilyE>
				<Organizations>
				<Organization>دانشیار، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>nshirzad11@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>شیرین</Name>
				<MidName></MidName>
				<Family>حسنی رنجبر</Family>
				<NameE>Shirin</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hasani-Ranjbar</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>shirinhasanir@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>باقر</Name>
				<MidName></MidName>
				<Family>لاریجانی</Family>
				<NameE>Bagher</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Larijani</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>polycystic ovary syndrome</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>gut microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>microbiome</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>dysbiosis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>سندرم تخمدان پلی کیستیک</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتای روده</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوم</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>دیس بیوزیس</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Yılmaz €O, Pala HG, Artunc¸ €Ulk€umen B. Artunc, €Ulk€umen B. Polikistik Over Sendromlu ve Normal Menstrüel Sikluslu Kadınlarda İnsülin Duyarlılığı Düzeylerinin Kıyaslanması. Kafkas J Med Sci 2017; 7(2): 102-106.##2.	Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol 2004; 60(1): 1-17.##3.	Homburg R. Polycystic ovary syndrome. Best Practice &#38; Research Clinical Obstetrics &#38; Gynaecology 2008; 22(2): 261-274.##4.	Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352(12): 1223-1236.##5.	Macut D, Bjekic-Macut J, Rahelic D, Doknic M. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract 2017; 130: 163-170.##6.	Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012; 33(5): 812-841.##7.	Barber TM, Franks S. Genetics of polycystic ovary syndrome. Polycystic Ovary Syndrome 2013; 40: 28-39.##8.	Liu R, Zhang C, Shi Y, Zhang F, Li L, Wang X. Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome. Front Microbiol 2017; 28(8): 324.##9.	Kant R, de Vos WM, Palva A, Satokari R. Immunostimulatory CpG motifs in the genomes of gut bacteria and their role in human health and disease.J Med Microbiol 2014; 63(Pt 2): 293-308.##10.	Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)–a novel theory for the development of Polycystic Ovarian Syndrome. Med Hypotheses 2012; 79(1): 104-112.##11.	Altuntas Y, Batman A. Microbiota and metabolic syndrome. Turk Kardiyol Dern Ars 2017; 45(3): 286-296.##12.	Quigley EM. Basic definitions and concepts: organization of the gut microbiome. Gastroenterol Clin North Am 2017; 46(1): 1-8.##13.	Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016; 14(8): e1002533.##14.	Pascale A, Marchesi N, Marelli C, Coppola A, Luzi L, Govoni S, Giustina A, Gazzaruso C. Microbiota and metabolic diseases. Endocrine 2018; 61(3): 357-371.##15.	Faith JJ, Guruge JL, Charbonneau M et al. The long-term stability of the human gut microbiota. Science 2013; 341(6141): 1237439.##16.	Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489: 220-230.##17.	Rosenbaum M, Knight R, Leibel RL. The gut microbiota in human energy homeostasis and obesity. Trends Endocrinol Metab 2015; 26(9): 493-501.##18.	Vaiserman AM, Koliada AK, Marotta F. Gut microbiota: a player in aging and a target for anti-aging intervention. Ageing Res Rev 2017; 35: 36-45.##19.	Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C.Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 2011; 5: 71-86.##20.	Fallucca F, Porrata C, Fallucca S, Pianesi M. Influence of diet on gut microbiota, inflammation and type 2 diabetes mellitus. First experience with macrobiotic Ma-Pi 2 diet. Diabetes Metab Res Rev 2014; 30(S1): 48-54.##21.	Insenser M, Murri M, Del Campo R, Martinez-Garcia MA, Fernandez-Duran E, Escobar-Morreale HF. Gut microbiota and the polycystic ovary syndrome: influence of sex, sex hormones, and obesity. J Clin Endocrinol Metab 2018; 103(7): 2552-2562.##22.	Torres PJ, Siakowska M, Banaszewska B, Pawelczyk L, Duleba AJ, Kelley ST, et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with Hyperandrogenism. J Clin Endocrinol Metab 2018; 103(4): 1502-1511.##23.	Round JL, Mazmanian SK. The gut microbiome shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9(5): 313-323.##24.	Qi X, Yun C, Sun L, Xia J, Wu Q, Wang Y, et al. Gut microbiota-bile acid interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med 2019; 25(8): 1225-1233.##25.	Zhang J, Sun Z, Jiang S, Bai X, Ma C, Peng Q, et al. Probiotic Bifidobacterium lactis V9 Regulates the Secretion of Sex Hormones in Polycystic Ovary Syndrome Patients through the Gut-Brain Axis. mSystems 2019; 4(2): e00017-e00019.##26.	Zeng B, Zhiwen Lai, Sun Lijin, Zhang Zhongbao, Yang Jianhua, Li Zaixin, et al. Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study. Res Microbiol 2019; 170(1): 43-52.##27.	Kelley ST, Skarra DV, Rivera AJ, Thackray VG. The gut microbiome is altered in a letrozole-induced mouse model of polycystic ovary syndrome. PLoS One 2016; 11(1): e0146509.##28.	Lindheim L, Bashir M, Munzker J, Trummer C, Zachhuber V, Leber B, et al. Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): a pilot study. PLoS One 2017; 12(1): e0168390.##29.	Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol 2018; 182: 27-36.##30.	Hersoug L-G, Møller P. Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obesity Review 2016; 17(4): 297-312.##31.	Kim JJ, Choi YM, Hong MA, Kim MJ, Chae SJ, Kim SM, et al. Serum visfatin levels in non-obese women with polycystic ovary syndrome and matched controls. Obstet Gynecol Sci 2018; 61(2): 253-260.##32.	Vrbikova J, Hill M, Bendlova B, Grimmichova T, Dvorakova K, Vondra K, et al. Incretin levels in polycystic ovary syndrome. Eur J Endocrinol. 2008; 159(2): 121-127.##33.	Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 2015; 11(10): 577-591.##34.	Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27(2): 104-119.##35.	Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016; 7(3): 189-200.##36.	Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrat improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58(7): 1509-1517.##37.	Den Besten G, Lange K, Havinga R, Van Dijik TH, Gerding A, Van Eunen K, et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol 2013; 305(12): G900-G910.##38.	Saad MJ, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology (Bethesda) 2016; 31: 283-293.##39.	Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011; 121(6): 2126-2132.##40.	Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017; 474(11): 1823-1836.##41.	Sayin SI, Wahlström A, Felin J, Jantti S, Ulrich Marschal H, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17: 225-235.##42.	Cullberg G, Hamberger L, Mattsson L, Mobacken H, Samsioe G, et al. Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a lowdose desogestrel–ethinylestradiol combination. Acta Obstet Gynecol Scand 2011; 64(3): 203-207.##43.	Li S, Chu Q, Ma J, Sun Y, Tao T, Huang R, et al. Discovery of novel lipid profiles in PCOS: Do insulin and androgen oppositely regulate bioactive lipid production? J Clin Endocrinol Metab 2017; 102(3): 810-821.##44.	Fujisaka S, Ussar S, Clish C, Devkota S, Drevfuss JM, Sakaguchi M, et al. Antibiotic effects on gut microbiota and metabolism are host dependent. J Clin Invest 2016; 126(12): 4430-4443.##45.	Lotta LA, Scott RA, Sharp SJ, Burgess S, Luan J, Tilin T, et al. Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: a mendelian randomisation analysis. PLoS Med 2016; 13(11): e1002179.##46.	Neis EP, Dejong CH, Rensen SS. The role of microbial amino acid metabolism in host metabolism. Nutrients 2015; 7(4): 2930-2946.##47.	Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BAH, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 2016; 535(7612): 376-381.##48.	Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 2001; 276(41): 38052-38060.##49.	Zhao L, Zhu Z, Lou H, Zhu G, Huang W, Zhang S, et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget 2016; 7(23): 33715-33721.##50.	Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576-585.##51.	Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011; 12: 453-466.##52.	Aydin K, Arusoglu G, Koksal G, Cinar N, Aksoy DY, Yildiz BO, et al. Fasting and post-prandialglucagon like peptide 1 and oral contraception in polycystic ovary syndrome. Clin Endocrinol 2014; 81(4): 588-592.##53.	Basak Ozgen Saydama BOY. Gut-brain Axis and metabolism in polycystic ovary syndrome. Curr Pharm Des 2016; 22(36): 5572-5585.##54.	Chaudhari NK, Nampoothiri LP. Neurotransmitter alteration in a testosterone propionate-induced polycystic ovarian syndrome rat model. Horm Mol Biol Clin Investig 2017; 29(2): 71-77.##55.	Turnbaugh PJ, Ridaura VK, Faith JJ, Rey Fe, Knight R, Gordon J, et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009; 1(6): 6799-6806.##56.	Jakubowicz D, Barnea M, Wainstein J, Froy O. Effects of caloric intake timing on insulin resistance and hyperandrogenism in lean women with polycystic ovary syndrome. Clin Sci (Lond) 2013; 125(9): 423-432.##57.	Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidencebased guidelines. J Acad Nutr Diet 2013; 113(4): 520–545.##58.	Clarke SF, Murphy EF, OʼSullivan O, Lucey AJ, Humphreys M, Hogan A, et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut 2014; 63(12): 1838-1839.##59.	Mika A, Van Treuren W, González A, Herrera J, Knight R, Fleshner M, et al. Exercise is more effective at altering gut microbial composition and producing stable changes in lean mass in juvenile versus adult male F344 rats. PLoS One 2015; 10(5): e125889.##60.	Singh RK, Chang HW, Yan D, Lee KM, Ucmak D, Wong K, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med 2017; 15(1): 73.##61.	Azziz R, Carmina E, Dewailly D, Diamanti Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91(11): 4237-4245.##62.	Zhao W, Ke M. Report of an unusual case with severe fecal impaction responding to medication therapy. J Neurogastroenterol Motil. 2010; 16(2): 199-202.##63.	Kociolek LK, Gerding DN. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol 2016; 13(3): 150-160.##64.	Panchal P, Budree S, Scheeler A, Medina G, Seng M, Wong WF, et al. Scaling safe access to fecal microbiota transplantation: past, present, and future. Curr Gastroenterol Rep 2018; 20(4): 14.##65.	Guo Y, Qi Y, Yang X, Zhao L,Wen S, Liu Y, et al. Association between Polycystic Ovary Syndrome and Gut Microbiota. PLoS One 2016; 11(4): e0153196.##66.	Hotel ACP, Cordoba A. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Prevention 2001; 5(1): 1-10.##67.	Hsieh FC, Lee CL, Chai CY, Chen WT, Chen YL, Wu CS. Oral administration of Lactobacillus reuteri GMNL‑263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. Nutr Metab 2013; 10(1): 35.##68.	Karamali M, Eghbalpour S, Rajabi S, Jamilian M, Bahmani F, Ebrahimi MT, et al. Effects of Probiotic Supplementation on Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women With Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Arch Iran Med 2018; 21: 1-7 (Persian).##69.	Gibson GR, Scott KP, Rastall R, Tuohy K, Hotchkiss A, Ferrandon AD, et al. Dietary prebiotics: current status and new definition. Food Sci Technol Bull Funct Foods 2010; 7: 1-19.##70.	Nilsson AC, Ostman EM, Holst JJ, Bjorck IME. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. J Nutr 2008; 138(4): 732-739.##71.	Urías-Silvas JE, Cani PD, Delmée E, Neyrinck A, Lopez MG, Delzenne N, et al. Physiological effects of dietary fructans extracted from Agave tequilana Gto and Dasylirion spp. Br J Nutr 2008; 99: 254–261.##72.	Zhang Q, Yu H, Xiao X, Hu L, Xin F, ##Yu X. Inulin-type fructan improves diabetic phenotype and gut microbiota profiles in rats. PeerJ 2018; 6: e4446.##73.	Nasri K, Jamilian M, Rahmani E, Bahmani F, Tajabadi Ebrahimi M, Asemi Z. The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, doubleblind, placebo-controlled trial. BMC Endocr Disord 2018; 18(1): 21.##74.	Esmaeilinezhad Z, Babajafari S, Sohrabi Z, Eskandari M-H, Amooee S, Barati-Boldaji R. Effect of synbiotic pomegranate juice on glycemic, sex hormone profile and anthropometric indices in PCOS: a randomized, triple blind, controlled trial. NutrMetab Cardiovasc Dis 2019; 29(2): 201-208 (Persian).##75.	Samimi M, Dadkhah A, Kashani HH, Tajabadi Ebrahimi M, Hosseini ES, Asemi Z. The Effects of synbiotic supplementation on metabolic status in women with polycystic ovary syndrome: a randomized double-blind clinical trial. Probiotics Antimicro Prot 2019; 11: 1355-1361 (Persian).##76.	Etxeberria U, Arias N, Boqué N, Macarulla MT, Portillo MP, Martinez JA, et al. Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in highfat sucrose diet-fed rats. J Nutr Biochem 2015; 26(6): 651-660.##77.	Wang K, Feng X, Chai L, Cao S, Qiu F. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev 2017; 49(2): 139-157.##78.	Zhang X, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, et al. Modulation of gut microbiota byberberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep 2015; 5: 14405.##79.	Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. Int J Endocrinol 2016; 2016: 1849162.##80.	Clements RS, Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr 1980; 33(9): 1954-1967.##81.	Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med 2010; 16(11-12): 543-552.##82.	Wojciechowska A, Osowski A, Jóźwik M, Górecki R, Rynkiewicz A, Wojtkiewicz J. Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS. Int J Mol Sci 2019; 20(22): 5787.##83.	Sobota Grzeszyk A, Kuźmicki M, Szamatowicz J. Myoinositol in the Prevention of Gestational Diabetes Mellitus: Is It Sensible? J Diabetes Res 2019; 2019: 3915253.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>تحلیل تولیدات علمی حوزه میکروبیوتا و کووید-19 : 
یک مطالعه علم سنجی</TitleF>
		<TitleE>Analysis of Scientific Products about Microbiota and 
Covid-19: A Scientometric Study</TitleE>
		<TitleLang_ID>1</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>1</Language_ID>
			<CONTENT>&#160;سابقه و هدف: علایم گوارشی در کنار علایم تنفسی در بیماران کووید-19 ثبت شده و نشان از نقش میکروبیوتا در این بیماری دارد. هدف از انجام این مطالعه علم سنجی، بررسی مقالات چاپ شده در زمینه ارتباط میکروبیوتا و کووید-19 در راستای رسیدن به راهکارهای جدید جهت کنترل همه&#8207;گیری کووید-19 است.
مواد و روش&#8204;ها: در این مطالعه استنادی جستجو در عنوان و چکیده مقالات در فاصله زمانی اول ژانویه تا پانزدهم اکتبر 2020 در پایگاه استنادی اسکوپوس انجام گرفت. پس از استخراج اطلاعات، تمامی مراحل تحلیل داده&#8207;ها به&#8207;وسیله گزینه &#34;تجزیه و تحلیل نتایج&#34;در پایگاه اسکوپوس، نرم&#8207;افزار SPSS و تحلیل شبکه VOSviewer انجام شد.
یافته&#8204;ها: به&#8207;طور کلی 87 مقاله معیار ورود به مطالعه را داشتند. بیش&#8207;ترین تولید علم در ماه جولای (20 مدرک) بود. بیش&#8207;ترین حوزه موضوعی مورد تحقیق به &#34;طب&#34; (66 رکورد) تعلق داشت. بیش&#8207;ترین تولیدات علمی از کشور آمریکا (14/24درصد) و قسمت اعظم وابستگی دانشگاهی به &#8220;Chinese University of Hong Kong&#8221; (54/8 درصد) از کشور چین بود. بیش&#8207;ترین سهم از مقالات (05/8 درصد) در مجله&#8220;Lancet Gastroenterology and Hepatology&#8221; چاپ شده بود. تعداد کل استنادات 401 بار و شاخص H برابر با 9 بود. در شبکه همکاری نویسندگان، نویسنده برتر از چین بود، اما در شبکه همکاری کشورها، اولویت با آمریکا بود. از منطقه خاورمیانه، 6 مقاله توسط کشورهای ایران، قطر، ترکیه و اردن (بیش&#8207;ترین استناد برابر با 5) منتشر شده بود.
استنتاج: تحقیقاتی در راستای شفاف&#8207;سازی نقش میکروبیوتا در عفونت ویروسی کووید-19 صورت گرفته است. ولی نیاز به پژوهش&#8207;های گسترده &#8207;تر می&#8207; باشد.</CONTENT>
			</ABSTRACT>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>&#160; Background and purpose: Gastrointestinal symptoms along with respiratory symptoms recorded in patients with Covid-19 indicate the role of microbiota in this disease. The purpose of this scientometric study was to assess the articles published on the relationship between microbiota and Covid-19 in order to control the pandemic by reaching new strategies.
Materials and methods: Relevant articles were searched in Scopus database by titles and abstracts, published from January 1 to October 15, 2020. Data analysis was performed by analysis tools available in Scopus database, SPSS and VOSviewer network analysis version 1.6.15.
Results: Overall, 87 papers were included. The most productive time was July in which 20 articles were published. The top subject area was medicine (n=66 papers). The first productive country was the USA (24.14%), and the top institute was the Chinese University of Hong Kong (8.54%) in China. The top source was the Lancet Gastroenterology and Hepatology journal that published 8.05% of the articles. Total number of citations were 401 and their H‑index was 9. Top author and top country in the co-authorship network assessment or international collaboration were from China and the USA, respectively. From the Middle East, six articles were published on microbiota and Covid-19 by Iran, Jordan, Qatar, and Turkey and the highest cited article (5 times) was&#160; from Jordan.
Conclusion: Some research has been carried out to investigate the role of microbiota in developing Covid-19. However, further studies are needed to clarify this role.
&#160;</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>200</FPAGE>
			<TPAGE>211</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2021/02/12020/10/312020/11/152020/11/262020/10/312020/10/292020/11/242020/11/212020/10/302020/11/202020/10/72020/09/292020/10/262020/11/82020/10/192020/11/202020/11/2
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1399/8/12
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2021/01/292020/12/62020/12/62021/01/102020/12/62020/12/62020/12/62020/12/92021/01/102021/01/62020/12/62020/12/62020/12/162020/12/92020/12/152020/12/152020/12/6
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1399/9/16
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>هانیه السادات</Name>
				<MidName></MidName>
				<Family>اجتهد</Family>
				<NameE>Hanieh-Sadat</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ejtahed</FamilyE>
				<Organizations>
				<Organization>استادیار،  مرکز تحقیقات علوم غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران  و مرکز تحقیقات چاقی و عادات غذایی، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>haniejtahed@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>وحیده</Name>
				<MidName></MidName>
				<Family>اویسی</Family>
				<NameE>Vahideh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Oveissi</FamilyE>
				<Organizations>
				<Organization>دکترای عمومی داروسازی، دانشکده داروسازی، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>oveva92@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>عذرا</Name>
				<MidName></MidName>
				<Family>طباطبائی ملاذی</Family>
				<NameE>Ozra</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Tabatabaei-Malazy</FamilyE>
				<Organizations>
				<Organization>استادیار، مرکز تحقیقات بیماری های غیر واگیر، پژوهشکده علوم جمعیتی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>tabatabaeiml@sina.tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>سلمان</Name>
				<MidName></MidName>
				<Family>شیروانی راد</Family>
				<NameE>Salman</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Shirvani Rad</FamilyE>
				<Organizations>
				<Organization>دانشجوی پزشکی عمومی، دانشکده پزشکی، دانشگاه آزاد اسلامی، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>salamonca@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>فریده</Name>
				<MidName></MidName>
				<Family>رضی</Family>
				<NameE>Farideh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Razi</FamilyE>
				<Organizations>
				<Organization>دانشیار، مرکز تحقیقات دیابت، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>f-razi@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>باقر</Name>
				<MidName></MidName>
				<Family>لاریجانی</Family>
				<NameE>Bagher</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Larijani</FamilyE>
				<Organizations>
				<Organization>استاد، مرکز تحقیقات غدد و متابولیسم، پژوهشکده علوم بالینی غدد و متابولیسم، دانشگاه علوم پزشکی تهران، تهران، ایران</Organization>
				</Organizations>
				<Countries>
				<Country>ایران</Country>
				</Countries>
				<EMAILS>
				<Email>emrc@tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Covid-19</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>scientometrics</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Scopus</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>میکروبیوتا</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>کووید-19</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>علم سنجی</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>اسکوپوس</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>1.	Shinde T, Hansbro PM, Sohal SS, Dingle P, Eri R, Stanley R. Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives. Microorganisms 2020; 8(6): 921.##2.	Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Transl Res 2020; 226: 57-69.##3.	Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterol 2020; 159(3): 944-955. ##4.	He Y, Wang J, Li F, Shi Y. Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections. Front Microbiol 2020; 11: 1302.##5.	Kalantar-Zadeh K, Ward SA, Kalantar-Zadeh K, El-Omar EM. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles. ACS Nano 2020; 14(5): 5179-5182.##6.	Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, et al. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut 2020; 69(9): 1555-1563.##7.	Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res 2020; 285: 198018.##8.	Cassotta M, Forbes-Hernández TY, Calderón Iglesias R, Ruiz R, Elexpuru Zabaleta M, Giampieri F, et al. Links between Nutrition, Infectious Diseases, and Microbiota: Emerging Technologies and Opportunities for Human-Focused Research. Nutrients 2020; 12(6): 1827.##9.	de Jong SE, Olin A, Pulendran B. The Impact of the Microbiome on Immunity to Vaccination in Humans. Cell Host Microbe 2020; 28(2): 169-179.##10.	Mongeon P, Hus AP. The journal coverage of Web of Science and Scopus: a comparative analysis. Scientometric 2016; 106: 213-228.##11.	Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of Science, Scopus, and Google Scholar for articles published in general medical journals. JAMA 2009; 302: 1092-1096.##12.	Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. [Management of corona virus disease-19 (COVID-19): the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(1): 147-157.##13.	Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. The Lancet Gastroenterol Hepatol 2020; 5(7): 644-645.##14.	Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med 2010; 182(8): 1058-1064.##15.	Zeng J, Wang CT, Zhang FS, Qi F, Wang SF, Ma S, Wu TJ, Tian H, Tian ZT, Zhang SL, Qu Y. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive care Med 2016; 42(6): 1018-1028.##16.	Ceccarelli G, Scagnolari C, Pugliese F, Mastroianni CM, d'Ettorre G. Probiotics and COVID-19. Lancet Gastroenterol Hepatol 2020; 5(8): 721-722.##17.	Akour A. Probiotics and COVID-19: is there any link?. Lett Appl Microbiol 2020; 71(3): 229-234.##18.	Zhao Y, Cao Y, Wang S, Cai K, Xu K. COVID-19 and gastrointestinal symptoms. Br j Surg 2020; 107(10): e382-e383.##19.	Konturek PC, Harsch IA, Neurath MF, Zopf Y. Covid-19-more than respiratory disease: A gastroenterologist’s perspective. J Physiol Pharmacol 2020; 71(2): 1-11.##20.	Ng SC, Chan FKL, Chan PKS. Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification. Lancet Gastroenterol Hepatol 2020; 5(7): 642-643.##21.	Green CA, Quraishi MN, Shabir S, Sharma N, Hansen R, Gaya DR, et al. Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward. Lancet Gastroenterol Hepatol 2020; 5(6): 531.##22.	Ianiro G, Mullish BH, Kelly CR, Sokol H, Kassam Z, Ng S, et al. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol 2020; 5(5): 430-432.##23.	Lancet. COVID-19: a new lens for non-communicable diseases. Lancet 2020; 396 (10252): 649.##24.	Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. Obesity 2020; 28(6): 1005.##25.	Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: a systematic review and meta-analysis. J Med Virol 2020.##26.	Newman ME. The structure of scientific collaboration networks. Proc Natl Acad Sci USA 2001; 98(2): 404-409.##27.	Abbasi-Oshaghi E, Mirzaei F, Khodadadi I. Letter from Iran: Experiences with COVID-19. Respirology 2020; 25(11): 1214-1215. ##28.	Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. Front Immunol 2020; 11: 1582.##29.	Ejtahed HS, Hasani-Ranjbar S, Siadat SD, Larijani B. The most important challenges ahead of microbiome pattern in the post era of the COVID-19 pandemic. J Diabetes Metab Disord 2020; 3: 1-3.##30.	Aktas B, Aslim B. Gut-lung axis and dysbiosis in COVID-19. Turk J Biol 2020; 44(3): 265-272.##31.	Chaari A, Bendriss G, Zakaria D, McVeigh C. Importance of Dietary Changes During the Coronavirus Pandemic: How to Upgrade Your Immune Response. Front Public Health 2020; 8: 476.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>

</ARTICLES>

</JOURNAL>
</XML>
